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ABSTRACT 
Protein-protein interactions (PPIs) are one of the basic mechanisms in cellular biology, 
but also involve in diseases if they are dysregulation.  Disrupting aberrant PPI activities 
is useful in medicinal chemistry.  One approach to inhibit PPIs is to design small 
molecule peptidomimetics bearing side-chain orientations similar to protein ligands, in 
which those mimics might displace or interfere the native PPIs.  Previous research in our 
group developed Exploring Key Orientations (EKO) program that matches Ca-Cb 
coordinates of virtual small molecules to the side-chain vectors of proteins at PPI 
interfaces.  Similar Ca-Cb orientations between mimics and protein ligands indicate that 
small molecules might be suitable to displace protein ligands, i.e. those compounds 
might interfere PPIs.   
We used EKO to deduce small molecules that might disrupt medicinally-relevant PPIs. 
Herein, EKO implicated our designed mimics, hydantoin-oxazoline, triazole-oxazole and 
triazole-oxazoline derivatives, might disrupt Nef•MHC-I•AP1 and NEDD8•NAE 
interactions, in which they are relevant to HIV-1 and cancer diseases respectively.  After 
learning from these projects, we designed hydantoin-piperazine analogues to disrupt 
PCSK9•LDLR interaction that causes hypercholesterolemia disease.  Although the first-
generation hydantoin-piperazine derivatives did not show good PCSK9•LDLR inhibition, 
we modified chemotype structures by cooperating with a docking program, Glide, to 
improve inhibitory potencies.  As a result, we successfully obtained lead compounds that 
significantly disrupt PCSK9•LDLR interaction with the measurable binding affinities. 
Besides these protein targets, we synthesized another minimalist mimic, oxazoline 
piperidine-2,4-dione, that has conformational biases toward helical and sheet-turn-sheet 
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motifs.  This structure potentially has favorable cellular- and oral-permeability calculated 
by QikProp. 
We are also interested in how to design molecules suitable for PPI inhibition.  A concept 
of secondary structure mimicry is widely applied to design molecules that resemble a 
secondary structure at an PPI interface, hence possibly disrupt protein-protein 
interaction.  However, there is no direct study to prove a correlation between secondary 
structure mimicry and interface mimicry.  To respond this issue, we used EKO to match 
several new chemotypes on the ideal secondary structures and PPIs database, and then 
compared the frequencies of secondary structures that chemotypes matched at PPI 
interfaces to the ideal secondary structure biases of each chemotype.  We found that, in 
general, good secondary structure mimics tend to match frequently at PPI interfaces; 
however, they mostly match on non-ideal secondary structure motifs.   
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CHAPTER I 
INTRODUCTION 
1.1 Disrupting Protein-protein Interactions By Small Molecules 
Protein-protein interactions (PPIs) are pivotal to cellular biology.  They are implicated in 
signal transduction, cell-to-cell communication, transcription, replication and membrane 
transportation.  Dysregulation of PPIs can cause neurodegenerative diseases, cancer, 
and other maladies.1  Inhibitors that disrupt aberrant PPIs associated with diseases 
states are potentially useful in medicinal chemistry.  Theoretically, this type of inhibitor 
should have an advantage over enzyme inhibitors, for instance, insofar as they 
selectively bind on protein targets due to the diversity of protein interfaces unlike 
targeting similar catalytic active sites of enzymes; this reduces probability of off-target 
effects.  However, protein interfaces tend not to have well-defined, concave binding sites 
and most are lipophilic, thus hard to ‘drug’ using small molecules.2,3  Even though protein 
interfaces are featureless, they also contain ‘hot-spot’ residues, which are largely 
responsible for driving binding.1,4  Hot spots tend to tightly pack in clusters forming a 
network of interactions, in which can be called ‘hot-regions’.5  Interactions around ‘hot 
regions’ are dominated by side-chain-to-side-chain contacts, which are accounted for 
~80% of all interfacial interactions.6  Thus small molecules that perturb ‘hot-spot’ or ‘hot-
regions’ binding sites are favorable candidates to disrupt PPIs. 
Several methods are currently used to discover PPI inhibitors.  High-throughput 
screening (HTS) is a widespread approach; this suffers low hit rates, weakly potent hits 
and difficulties in removal of false positives because compound collections do not have 
2 
appropriate chemotype.1,7  Fragment-based screening features elaboration of low-affinity 
small molecules that are not likely to disrupt PPIs alone;8 the challenge with this method 
tends to be linking fragments together effectively.  Computer-aided design approaches 
tend to be quite limited9.  Of particular interest is rational design of secondary structure 
mimics10-12 following the hypothesis that if a secondary structure exists at an interface, 
then a mimic that presents side-chains in the same way might displace the protein ligand 
in the PPI.  
A widely applied design principle for designing molecules to inhibit PPIs is the concept of 
secondary structure mimicry.11,12  In applying this method, researchers identify a 
secondary structure at an interface, possibly one known to encompass a hot-spot,13 then 
focus on designing molecules that resemble that secondary structure.  Some 
chemotypes featured in this method are peptidic.  For instance, stapled peptides14-22 
which are essentially cyclic peptides, have been used by many groups to mimic helices 
at interfaces.  However, there are also considerable efforts to use less peptidic 
molecules that do not have polyamide backbones, but do present amino acid side-
chains.23-26  These have come to be known as minimalist secondary structure mimics. 
1.1.1 Minimalist Peptidomimetics 
Minimalist mimics do not have peptidic backbones; instead, they have rigid organic 
cores that can project at least three amino acid side-chains in orientations that resemble 
similar features on select regions of peptides or proteins.  Examples of minimalist mimics 
are shown in Figure 1.1 (putative helix mimics: A,27-29 B,30 C,31-33 D,34,35 E,36 F,37 G,38 and 
H39; sheet mimic, I40).  Much research in this area has been driven by the assumption 
3 
that if a secondary structure is found at a protein-protein interface then a corresponding 
minimalist mimic is a candidate to displace the protein containing that motif from the 
interface.10,11,26  There are, in fact, several instances in which minimalist mimics have 
been proven to disrupt PPIs.40-51  For example, terphenyl-based helical mimetics (B) was 
proved to disrupt p53/HDM2 involving cancerous tumor. 
Figure 1.1  Examples of minimalist mimics A-I. 
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Figure 1.1  Continued. 
According to the description outlined above, several compounds can be claimed as the 
minimalist peptidomimetics.  However, what are the criteria of being good minimalist 
mimics?  In our opinion, there are four characteristics that guide researchers to design 
good minimalist mimics.52 
(i) Syntheses of chemotypes must be facile for most of amino acid side-chains (e.g. 
Arg, Trp, His etc.) 
(ii) Minimalist mimics may not have global minimum energy conformations 
corresponding to the proteins or peptides they resemble, but those 
corresponding conformations should be thermodynamically or kinetically 
accessible at given conditions (e.g. at room temperature or physiological 
temperature).   
(iii) Chemotypes should be rigid to compensate the loss of entropy on docking.   
(iv) Accessible chemotypes project Ca-Cb coordinates that overlay well on the Ca-
Cb of secondary structures or proteins. 
1.1.2 Universal Peptidomimetics 
Secondary structures at PPI interfaces are most often distorted, and many interfaces do 
not involve them at all.  Thus, any mimic that exclusively resembles an ideal secondary 
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structure motif is unlikely to be widely applicable to interfaces containing real secondary 
structures of that kind.  The hidden potential of so-called minimalist mimics is that many 
chemotypes in this class also populate conformations other than the targeted secondary 
structure (Figure 1.2).52-54  We coined the term universal peptidomimics to describe small 
molecules simultaneously populating conformations that resemble more than one 
secondary structure.53  This led us to appreciate that, in some situations, minimalist 
mimics can resemble regions of a PPI interface without resembling any particular 
secondary structure.  Consequently, it is important to directly relate accessible 
conformations of minimalist mimics to PPI interfaces without reference to secondary 
structures.   
 
 
Figure 1.2  An example of a universal peptidomimetic.  Compound 1 can adopt their 
conformations to match on (a) 310-helix, (b) b-strand, (c) a-helix, (d) strand-turn-strand, 
and (e) non-ideal secondary structure at PPI interface.  
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Figure 1.2  Continued. 
 
1.2 Exploring Key Orientation (EKO) as a Method to Identify Small Molecules 
that Disrupt Protein-protein Interaction 
 
1.2.1 Introduction 
 
Minimalist peptidomimetics have to project side-chains vectors similar to the side-chains 
orientations of protein ligands to mimic side-chains interactions between protein 
c d 
e 
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receptors and ligands.  Nevertheless, the ability to obtain good Ca-Cb overlays is 
beyond human perception.  This is because rigid chemotypes can adopt several 
conformations in solution.  Identifying conformations by crystallography may be 
inappropriate since this method reveals only one conformation, and that crystal structure 
may not be a good representative due to the distortion by crystal packing forces.  Dr. 
Burgess’ lab had developed algorithms to systematically overlay side-chains of 
numerous conformations of a chemotype to the side-chains of PPIs or secondary 
structures.  We named this program ‘Exploring Key Orientation (EKO)’.  Figure 1.3 
illustrates steps in this strategy.  This program enumerates simulated preferred 
conformations using quenched molecular dynamics (QMD, described below).  Ca-Cb 
coordinates of conformers are clustered, overlaid on the Ca-Cb coordinates of PPIs or 
secondary structures, and determined how goodness of fit in root mean square deviation 
(RMSD).  Low RMSDs imply the side-chains orientations of preferred conformations 
replicate side-chains orientations of PPIs or secondary structures.  Side-chain vectors 
beyond Ca-Cb (e.g. Cb-Cg) are not considered because those are relatively mobile and 
do not define overall direction.  This program can be applied to search good overlays of 
chemotypes on secondary structures (EKOS), side-chains at PPI interfaces (EKO), and 
single crystals of chemotypes (EKOX). 
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Figure 1.3  Diagram of EKO process. 
 
1.2.2 EKOS 
 
EKOS (Exploring Key Orientations on Secondary structures) facilitates systematic, 
quantitative overlay of minimalist mimic preferred conformations on secondary structures 
(Figure 1.4).54,55  This procedure can be applied to ideal secondary structures, interfacial 
secondary structures (that may be distorted from the ideal), or any protein fragment for 
which there is crystallographic data or reliable PDB coordinates.   
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Figure 1.4  Diagram of EKOS 
 
In EKOS, preferred conformations of the featured minimalist mimic with three methyl 
side chains (representing Ala, Ala, Ala) are determined using a molecular dynamics 
routine.  Quenched molecular dynamics (QMD)56,57  is the protocol used in our work.  In 
QMD, a large number (e.g. 1500) of high temperature conformations for each 
stereoisomer of a chemotype are rapidly (no slow cooling) quenched to give 
conformations lacking bond vibrations (ie at 0 K).  In each case, conformers within 3 
kcal•mol-1 of the lowest energy one identified are described as “preferred”.  These 
preferred conformations are systematically overlaid with each other using an algorithm 
that optimizes fit of side-chain Ca-Cb vectors to generate families of conformers.  Rigid 
chemotypes may converge to only one conformational cluster, whereas hundreds of 
families might be generated from more flexible systems.  A key feature of the families is 
that every member projects side-chains in highly similar directions, since they are 
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clustered on the basis of Ca-Cb vectors.  Families generated in QMD at this stage are 
similar to dynamic Boltzmann distributions of conformational states in solution. 
QMD implemented as described above is deliberately designed to reveal the intrinsic 
conformational biases of a chemotype in the absence of any extrinsic factors.  It is for 
this reason that the calculations are performed using a continuous dielectric medium of 
80 (roughly approximating to water), and not using explicit solvent molecules.  Similarly, 
three methyl substituents are used so that the conformations of the chemotype are not 
biased by interactions between side-chains.   
1.2.3 EKO 
Another data-mining approach (Exploring Key Orientations, EKO) similarly compares 
simulated preferred conformations of minimalist mimics but with sets of three interface 
side-chains in PPIs (Figure 1.5).58  Intrinsic conformational biases of chemotypes are 
critical because if a small molecule tends to project side chains in the same orientations 
as a segment of the protein ligand in a PPI, then that protein receptor can at least 
accommodate, and perhaps even enforce, this conformational bias.   
EKO can be run in two ways; we call these matching and mining, and they are biology- 
and chemistry-centered, respectively (Figure 1.5).  In EKO matching, a single protein-
protein interface is compared with preferred conformations of a series of chemotypes.  
This is biology-centered because the PPI target is decided first, supposing that a 
chemotype can then be found to disrupt it.  This approach is in perfect harmony with 
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common strategies in the pharmaceutical industry in which target selection is the first 
step.   
Figure 1.5  Two modes of EKO: chemistry-centered EKO (mining, top), and biology-
centered EKO (matching, bottom). 
EKO mining compares preferred conformations of one stereoisomer of a chemotype with 
nearly all the PPI interfaces in the PDB (currently >240,000, greater than the number of 
structures in the PDB).  Using queued jobs, eight stereoisomers of a chemotype can be 
compared in this way in about 8 h using a powerful desktop computer with ample disc 
space.  A chemotype that mimics peptide/protein conformations well, in terms of side-
chain orientations, will inevitably overlay on medicinally relevant PPIs.  Researchers in 
N N
OHN
O
O
mining > 240,000 PPI interfaces 
chemistry-
centered 
EKO 
one 
chemotype 
N N
OHN
O
O
matching several chemotypes 
biology-
centered 
EKO 
one PPI 
interface 
CO2HN
R3
N
O
N
R2
HN O
O
R1
N
O
N
NN
R1
R2
R3 N NN
O
O
NH
O
O
R2 R
3
R1
12 
the pharmaceutical industry tend to have less interest in EKO mining than the matching 
routine.  This comes from a valid observation that target selection is such an important 
issue, but perhaps an under-appreciation of how difficult it is to design small molecules 
to impede specific PPIs.  EKO mining has the advantage that using it to identify 
potentially tractable PPIs for a chemotype is a simpler problem than de novo chemotype 
design for a specific PPI.  At a minimum, EKO mining is an idea-generation tool to 
narrow the target selection down to PPIs that are compatible with the minimalist mimics 
that can be made. 
1.2.4 EKOX 
Crystal structures of minimalist mimics are informative, but they only give one snap-shot 
of the dynamic conformational ensemble.  There is no widely used method to evaluate if 
a conformation observed in a single crystal X-ray study is a preferred conformation in a 
dynamic equilibrium, or just an artifact of crystal packing forces.  We believed it was 
desirable to be able to quantify the correspondence between solid-state structures and 
conformations in solution.  However, a common problem in conformational analyses is to 
evaluate the relevance of a solid-state structure to a conformational ensemble in 
solution.  For minimalist mimics, a simple modification of EKOS, EKOX (Exploring Key 
Orientations on X-ray structures) can be used to determine if a solid-state conformation 
from an X-ray structure is present in the simulated conformational ensemble.  EKOX 
facilitates estimates of the energy difference between the simulated solution-state 
conformer closest to the solid-state structure and the lowest energy one overall.   
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Figure 1.6 shows data to illustrate how EKOX can work.  Coordinates for a solid-state 
structure of L-2fff were obtained from single crystal X-ray diffraction.  Preferred solution 
conformers of L-2aaa were generated, and their Ca - Cb coordinates systematically 
compared with the X-ray structure (L-2fff).  Figure 1.6b shows the Ca - Cb coordinates 
of the preferred conformer for L-2aaa in solution matched the X-ray structure of L-2fff 
with an RMSD of 0.09 Å, and that conformer was 0.16 kcal•mol-1 above the lowest 
energy one observed.  Thus, the solid-state structure is a representative of at least one 
populated conformer in solution, and is not an artifact of crystal packing forces. 
Figure 1.6  Illustration of EKOX.  (a) crystal structure of L-2fff.  (b) Comparison of best 
fitted preferred conformers of minimalist mimic L-2aaa (grey) with the X-ray crystal 
structure of L-2fff (gold) to elucidate the match and energy difference. 
N
O
N
NN
L-2fff
PhPh
Ph
a
  
 
14 
 
Figure 1.6  Continued. 
 
1.3 Conclusion 
 
Finding suitable inhibitors to disrupt aberrant PPIs involving diseases is a bottleneck in 
medicinal chemistry.  Unlike conventional well-defined targets like kinases active sites or 
G-protein coupled receptors, protein-protein interfaces tend to be flat, featureless, and 
difficult to target.  Established methods like HTS are not suitable to identify candidates 
within reasonable time, and tend to have high cost overheads.  New methods that help 
accelerate the discovery of PPI inhibitors are potentially valuable.   
 
Rational small molecules design to disrupt PPIs usually concentrates on mimicking 
secondary structures found at protein interfaces.  Researchers attempt to synthesize 
less peptidic molecules bearing side-chain residues; this type of compounds is called 
‘minimalist peptidomimetic’.  Nevertheless, comparing Ca-Cb overlays between 
minimalist mimics and secondary structures is difficult because chemotypes can adopt 
several conformational ensembles in solution.  Previous works in Dr. Burgess’ group 
b 
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developed EKO to systematically overlay Ca-Cb coordinates of simulated preferred 
conformations on the sets of Ca-Cb coordinates of secondary structures or PPI 
interfaces.  This algorithm matches preferred conformations of chemotypes on ideal 
secondary structures (EKOS), non-ideal secondary structures at PPIs interfaces (EKO), 
or a single crystal (EKOX).  All these methods are useful to deduce suitable chemotypes 
to the appropriate protein targets.  These approaches have been proved to find new 
inhibitors that disrupt HIV-1 protease dimerization and perturb antithrombin 
oligomerization.58,59   
My PhD research began by using EKO to search potential inhibitors to disrupt Nef•MHC-
I•AP1 (relevant to HIV) and NEDD8•NAE (for cancer) complexes.  After learning from 
these projects, we moved to another new interesting target PCSK9•LDLR (related to 
hypercholesterolemia).  Incorporating with a docking program to refine structures of 
chemotypes, we found the potential leads that inhibited PCSK9•LDLR interaction.  Our 
interest broadened to study relationship between EKOS and EKO in term of how 
relevant chemotype bias toward ideal secondary structures to the frequency of 
secondary structures found at PPIs.  Finally, we had prepared another minimalist mimic 
that might be useful to disrupt PPIs. 
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CHAPTER II 
INITIAL ATTEMPTS TO USE EKO TO DESIGN INHIBITORS 
FOR TWO NON-IDEAL PROTEIN-PROTEIN INTERACTION 
TARGETS 
2.1 Introduction 
EKO implicates protein targets by determining how closely the side-chains on a scaffold 
align with side-chains at protein interface.  If the fit is good, this indicates the molecule 
may displace the protein ligand and perturb that particular protein-protein interaction. 
This is a hypothesis that needs to be verified experimentally; our group’s long-term 
objective is to understand how widely applicable this approach is.  My initial attempts to 
do this prioritized the PPIs Nef•MHC-I•AP1 (in HIV) and NEDD8•NAE (for cancer).  We 
were unable to find effective small molecules for these in the time available.  That was 
not a failure of the approach but a failure in how we implemented the approach.  This 
chapter is to elaborate on that, and to explain what we learned from this exercise. 
The chemotype designs used for the two targets mentioned above were based on 
oxazoline and oxazole moieties coupled with hydantoin or triazole analogues (mimics 1-
3).  We synthesized compounds implicated by EKO; but those chemotypes were so 
difficult to prepare that it was not possible to obtain sufficient numbers of samples in the 
time available.  That meant, for instance, the optimization to improve the binding 
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interaction was not practical. Consequently, we were unable to find a promising 
compound lead that had sufficient measurable inhibitory activity.   
Another reason we could not find inhibitors disrupting these PPIs because they both had 
large interface surfaces and tight binding complexes that should be problematic for small 
molecules to disrupt.  It could be that EKO would never lead to effective chemotypes for 
these types of target, but we were simply not able to reach a conclusion because of the 
chemotype-synthesis issue.  Nevertheless, the experience gained from these efforts let 
to positive results in the following chapters. 
2.1.1 Oxazolines/oxazoles: Inspired Natural Building Blocks 
Natural products can inspire design of novel chemotypes having biological activities.  In 
marine organisms, oxazoline and oxazole moieties can be in post-translationally 
modified cyclic peptides.60,61  These structures can resist enzymatic degradation, show 
better bioavailability than linear peptides, and enhanced conformational rigidity.  Many 
oxazoline/oxazole-containing natural products are antibacterial, antiviral or antitumor 
agents.61  Consequently, medicinal chemists frequently use derivatives of these 
heterocycles. 
Oxazoline and oxazole scaffolds can be implemented into peptidomimetic designs as 
amide isosteres to prevent proteolysis62, or as privileged pharmacophores.63-65  
Moreover, oxazoline and oxazoles can be synthesized from amino acids enabling 
opportunities to incorporate most of the 19 genetically encoded side-chains.  
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2.1.2 Nef (Negative Regulatory Factor) Protein: A Key Player In HIV 
Human Immunodeficiency Virus (HIV) is a lentivirus that impairs the immune system in 
the host cells by reducing levels of CD4+ helper T cells.66-68  Several enzymes (eg 
reverse transcriptase, integrase or protease) and accessory proteins (eg Nef) have been 
studied intensively to cure or repress HIV infection.69-74  Consequently there are now 
several drugs that target proteins associated with HIV-1.  These pharmaceuticals are 
normally used in combination, as antiretroviral “drug cocktails”.  These drug 
combinations are so effective that they overcome the high rate of mutation in the HIV-
virus.  However, to eliminate the virus altogether requires a strategy to cripple it in the 
latent state.  As a result, developments of new anti-HIV compounds are still crucial to 
care of AIDS patients. 
Although anti-retroviral drug cocktails have been used widely to increase life expectancy 
for infected individuals, the rise of multidrug-resistant strains of HIV-1, and the need to 
overcome latency in search of a cure, underline the need for new antiretroviral drugs that 
have complementary mechanisms to the traditional ones.  Nef inhibitors are good 
candidates because they interfere with the HIV-1 life cycle, and enhance recognition by 
immune system to kill virally infected cells (described below).75  Within past 10 years, 
some inhibitors have been reported to disrupt Nef’s function, either by abolishing kinase 
downstream signaling76-78 or interfering Nef dimerization.79-81  Nevertheless, an inhibitor 
that directly perturb tertiary complex of Nef•MHC-I•AP1 has not been reported to date. 
Such a small molecule that has a different mechanism of action should be considered as 
a complement in the antiretroviral drug cocktail.   
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Nef is a 23- to 35-kDa myristoylated peripheral membrane protein encoded in the HIV 
genome.  This accessory protein enables the HIV virus to evade immune surveillance in 
the host by antagonizing the antiviral activity of cytotoxic T lymphocytes.82  These T cells 
use MHC-I (Major Histocompatibility Complex class I) to recognize viral peptides 
displayed on infected cells.  To avoid detection, Nef reduces the amount of MHC-I 
expression on cytotoxic T cells by complexing with the clathrin adapter protein complex 
1 (AP1) forming a tertiary complex (Nef•MHC-I•AP1) that is internalized by clathrin-
coated vesicles, wherein all components are degraded in the lysosome.83    
The molecular basis of Nef•MHC-I•AP1 had been revealed by Guatelli and Xiong who 
successfully co-crystallized this complex by fusing MHC-I to the N-terminus of Nef and 
forming a single crystal with the µ1 domain of AP1 (Figure 2.1a).84  This crystal structure 
revealed a binding interface of three components of around 2,266 Å2.  The tyrosine-
containing sequence of MHC-I (YSQA) binds the canonical Yxxϕ recognition site of AP1 
(ϕ, bulky hydrophobic residue; x, any amino acids) by fitting Tyr-residues of MHC-I in a 
binding pocket of AP1.85  The small methyl side chain of alanine does not totally fill an 
AP1 pocket hence this complex does not form unless Nef is present to contribute side-
chains that complete the tight association of MHC-I and AP1 (Figure 2.1c).84  Nef uses 
proline-rich PxxP repeats to lock MHC-I onto the side wall of AP1.  The Nef•MHC-I•AP1 
interaction has two strong electrostatic interactions.  First, Nef acidic cluster 62-EEEE-65 
has a long-range electrostatic interaction with lysine and arginine residues of AP1 
(Figure 2.1d).  The second charged interface involves a three-way network from Asp327 
of MHC-I, Asp123 of Nef and a basic patch of AP1 (Arg225, Arg393, Lys396, Arg211 
and Arg246).  Besides those binding forces, Nef C-terminus has an indispensable role to 
form a groove that binds MHC-I and AP1 (Figure 2.1b).  
20 
Figure 2.1  (a) Crystal structure of Nef•MHC-I•AP1 (4EMZ).  (b) MHC-I binding pocket. 
(c) YSQA motif of MHC-I.  (d) Long-range electrostatic interaction 
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Figure 2.1  Continued. 
2.1.3 NEDD8 (neural precursor cell expressed developmentally downregulated protein 
8):NEDD8 ACTIVATING ENZYME (NAE) 
Protein homeostasis by ubiquitination is important to cell function, and dysregulation of 
this process may lead to aberrant cellular activities involving cancer.  The ubiquitin-
d
c
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proteasome system has been validated as a therapeutic target.  Thus the proteasome 
inhibitor, e.g. bortezomib (VELCADE, Millennium Pharmaceuticals Inc.), is used to treat 
multiple myeloma and relapsed mantle cell lymphoma.86  However, this broad spectrum 
of proteasome inhibitor has some undesired off-target side effects.  Therefore, inhibitors 
targeting at certain step, preferably E3 ligase, would selectively stabilize protein 
homeostasis, reduce the toxicity and improve the drug’s therapeutic index.   
Figure 2.2  Ubiquitination and Neddylation pathway.87 
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Ubiquitinylation is regulated by a parallel mechanism involving NEDD8 and 
“neddylation”.  NEDD8 is an 81-amino acid ubiquitin-like protein with a 9 kDa molecular 
mass.  It shares 60% identity and 80% homology with ubiquitin.88,89  This protein 
specifically regulates one category of ubiquitin’s E3 ligases, cullin-RING ligases (CRLs). 
Homeostasis of certain protein substrates associated with tumor development (e.g. a 
tumor suppressor p27) is implicated in this process.86,90  NEDD8 overexpression 
suppresses those substrates, which can lead to cancer development.  Consequently, 
inhibitors targeting neddylation may be useful for antitumor therapy.86,87,91 
NEDD8 and ubiquitin both activate E3 ligases.  NEDD8 is adenylated by E1 NEDD8-
activating enzyme (NAE), then transferred to E1 cysteine side-chain via a thioester 
linker.  Activated NEDD8 is subsequently transferred to the E2 NEDD8-conjugated 
enzyme called UBC12, then to the CRLs.  Conjugation of NEDD8 to these E3 enzyme 
(the CRLs) triggers ubiquitin ligase activity, causing ubiquitin to be transferred to the ε-
amino group of the substrate lysine residues, then polyubiquitination.  In general, the 
process of ubiquitination and neddylation is similar (Figure 2.2).86,87,92   
NAE interacts with NEDD8 via three main interfaces (Figure 2.3a).  First, NEDD8’s 
acidic face forms salt bridges with the APPBP1 domain of NAE (Figure 2.3b).  Second, a 
hydrophobic patch on NEDD8 contacts UBA3’s adenylation domain.  Third, the C-
terminus of NEDD8 penetrates into hydrophobic groove in the UBA3 domain, which 
closes to the ATP binding site (Figure 2.3c).  All three interactions account for ~3350 Å2 
contact surface area.93 
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Figure 2.3  (a) Crystal structure of NEDD8•NAE (1R4N).  (b) NEDD8 acidic face 
interacts with APPBP1.  (c) Hydrophobic patch and C-terminal residues interact with 
UBA3.  Ala72 is highlighted in magenta. 
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Figure 2.3  Continued. 
NEDD8 activation is initiated when its C-terminal loop inserts into the UBA3 hydrophobic 
groove, and the NEDD8 C-terminal glycine interacts ATP to form a NEDD8•AMP adduct. 
The catalytic cysteine of NAE then forms a thioester with NEDD8.  Next, a second 
NEDD8 protein occupies the same hydrophobic groove, which rearranges the NAE 
structure so that it can transthiolate NEDD8 to E2 enzyme (UBC12) initiating the overall 
neddylation process (Scheme 2.1a-c).94-96 
Scheme 2.1  (a-c) Mechanism of NEDD8 activation by NAE.  (d) MLN4924 inhibits 
NEDD8 transthiolation to E2 enzyme. 
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Scheme 2.1  Continued. 
 
Despite the structural similarity between ubiquitin and NEDD8, they selectively interact 
with their own E1 partners.  Specifically, Arg190 of UBA3 acts as a negative gate, which 
prevents an ubiquitin to bind NEDD8’s E1 enzyme due to the steric clash between Arg72 
of ubiquitin and Arg190 from UBA3.  Conversely, the Ala72 of NEDD8 does not provide 
additional interaction with Gln190 of ubiquitin’s E1 enzyme, hence NEDD8 has reduced 
affinity for ubiquitin activating enzyme.97  The selectivity engendered by Ala72 of NEDD8 
can be used to design peptidomimetics targeting NEDD8•NAE rather than ubiquitin•E1 
enzyme.   
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MLN4924 (Millennium Pharmaceuticals) is a first-in-class inhibitor of the NEDD8•NAE 
interaction; it has an IC50 of 4.7 ± 1.5 nM.98  MLN4924, which has a similar structure to 
AMP, fits into the ATP binding site of UBA3 forming a stable acyl sulfonamide bond with 
NEDD8 (Scheme 2.1d).  The covalent MLN4924•NEDD8 adduct inhibits downstream 
neddylation, hence deactivates CRLs activities, including protecting the tumor 
suppressor p27 from degradation.  Currently, MLN4924 has passed phase I clinical 
trials.99  Apart from this well-known inhibitor, the non-covalent leads M22 and ZM223 
(from virtual screening) were predicted to bind at the ATP-binding site of NAE similar to 
MLN4924, and did indeed inhibit the NEDD8•NAE interaction.100,101 
Figure 2.4  Structures of non-covalent compound leads that disrupt NEDD8•NAE 
interaction. 
2.2 Syntheses and Binding of Triazole-oxazole Mimics to Perturb Nef•MHC-
I•AP1 Protein-protein Interaction 
We analyzed compounds 1 and 2 for overlays on the Nef•MHC-I•AP1 interface (PDBID 
= 4EMZ)84 using EKO.  Compound 1 showed several hits < 0.35 Å RMSD (Table B.1) 
and for compound 2 there were two.  Compound 1 overlaid at interface regions that 
appear to be important, including the Nef acidic face, and the sidewall of AP1 that 
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docked with MHC-I.  At this stage, a number of overlays on MHC-I, either between 
Nef•MHC-I or MHC-I•AP1 interactions, were less than expected.  This is because 
consecutive interfacial side-chains on MHC-I must point to Nef and AP1 alternately 
(Figures 2.1b-c), but EKO did not consider any overlays of chemotypes that project their 
side-chains perpendicular or greater to the protein partner.  To solve this issue, we used 
the EKOS routine to evaluate the fit of our chemotypes on the MHC-I peptide in the 
absence of the Nef and AP1 proteins.  This approach is not so rigorous, but we 
hypothesized it might still lead to hits.   
 
Applying EKOS as described above, several overlays of 1 were identified on this MHC-I 
peptide (Table B.1).  Only two overlays for 2 (D-2vee and L-2eev) had an RMSD <0.35 
Å, both were found on the loop at acidic face of Nef (Glu64, Glu65 and Val66; Figure 
2.1d).  However, syntheses of compounds 1 were highly time-consuming (months to get 
one compound) hence only compounds 2 were synthesized for this study.  
 
 
Figure 2.5  Structures of mimic 1-3 
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were used to designate configurations of amino acids.  Lower case one-letter codes are 
used to delineate the amino acid side-chains R1 – R3 and relate them to the closest 
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amino acid; primed letters indicate protected side-chains (eg c’ for the –CH2SCH(C6H5)3 
of Cys and e’ for the –CH2CH2COOC(CH3)3 of Glu). 
D-2vee and L-2eev were prepared from oxazole to triazole as shown in Scheme 2.2.  
This synthesis involved dipeptide thioester formation 4, reduction of the -COSEt 
functionality to aldehydes 5,102 then immediate cyclization to oxazole 6.103  Finally, N-
deprotection, conversion to an azide,104 Cu-mediated triazole formation105 and side-chain 
deprotection, gave the desired compounds 2.  Also, the protected forms, D-2ve’e’ and L-
2ee’v (di-tert-butyl esters) were saved for bioassay.  L-2fff was synthesized as a “partial 
negative control”, insofar as it contains the same core structure but bears side-chains 
that were not implicated in the EKO analyses.  Another compound, L-2fif was also 
prepared.  The purpose of adding this compound was to determine if epimerization at 
the Ile Ca during synthesis.  In the event, epimerization was not observed (NMR) but the 
compound was still screened.   
Scheme 2.2  Syntheses of triazole-oxazole 2. 
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Scheme 2.2  Continued. 
 
Compounds 2 were sent to Dr. Yong Xiong (Department of Molecular Biophysics & 
Biochemistry, Yale University) to test for disruption of the Nef•MHC-1•AP1 complex 
(Alphascreen assay; Figure 2.6).106  Thus, the µ1 domain of AP1 with a His tag was 
attached to Ni-chelate donor beads, then with the fused MHC-I•Nef complex supported 
via a FLAG tag, on anti-FLAG acceptor beads.  Those two bead types are brought close 
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together when AP1•MHC-I•Nef forms.  The donor beads are excited at 680 nm, which 
generate singlet oxygen molecules that can only activate the acceptor beads (to emit 
light at 520-620 nm) when the complex formation draws them into proximity.  Donor and 
acceptor beads without inhibitors give the highest Alphascreen signal, hence this serves 
as a negative control (no disruption).  On the other hand, a blank without any beads (no 
fluorescent signal at 520-620 nm possible), is a positive control.  The inhibitors that can 
interfere with the Nef•MHC-I•AP1 interaction should provide a fluorescent signal higher 
than the negative control, but less than positive control.   
 
 
Figure 2.6  Alphascreen assay.  Ni-chelated donor bead captures His-AP1 protein, and 
anti-FLAG acceptor bead captures MHC-I•Nef-FLAG protein.  The singlet oxygen 
molecules generated from donor beads are transferred to the acceptor beads when 
those come close together.   
 
Six compounds were tested in the Alphascreen assay at 100 µM concentrations.  Two of 
these were from EKO (D-2vee and L-2eev), two were protected-forms of those hits [D-
2ve’e’ and L-2ee’v, e’ = -(CH2)2COOBn], and the two partial negative control (L-2fff and 
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L-2fif).  Unfortunately, there was insignificant disruption; the best result, L-2eev, was 
about 10% inhibition (Figure 2.7).  
 
 
Figure 2.7  Results of an Alphascreen assay.  Proteins at 300 nM were premixed with 
beads (10 µg/mL at final concentration) for 1 h before adding 100 µM inhibitors.  
Fluorescent emissions were measured using an EnVision 3 plate reader.  
 
2.3 Syntheses and Biological Assays of Hydantoin-oxazoline and Triazole-
oxazoline to Perturb The NEDD8•NAE Protein-protein Interaction 
 
NEDD8 inserts its C-terminus into the tunnel of UBA3 to initiate neddylation, so our 
strategy was to occupy that UBA3’s hydrophobic groove with chemotpyes.  Thus, EKO 
hits at the C-terminus of NEDD8 were selected.  Compounds 1 and 3 had three and one 
promising overlays, respectively (Table B.2), all of which impacted the key Ala72 that 
governs selectivity over ubiquitin’s E1 enzyme.  Interestingly, compound 1 gave 
excellent hits (RMSD ≤ 0.30 Å) around this region.   
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Four chemotypes 1, including the partial negative control (LLL-1fff), were synthesized for 
analysis as NEDD8•UBA3 inhibitors (Scheme 2.3).  Cyclization of dipeptides to 
hydantoins 8 was based on several literature procedures.107-109  These hydantoins 8 
could be deprotected at the C-terminus, then coupled with amino alcohols.  Oxazoline 
cyclization was done in two-steps using methanesulfonyl chloride as an activator.  Some 
other conditions had been tested, but failed to obtain desired products (Figure B.1).  
Another two compounds, LLD-1ffs and LDL-1vfc’, were also synthesized, but for other 
purposes which are not discussed in this chapter.   
 Scheme 2.3 Synthesis of hydantoin-oxazoline 1. 
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Scheme 2.3  Continued. 
One triazole-oxazoline mimic, DL-3lal, was synthesized as shown in Scheme 2.4.  An 
azido-dipeptide was prepared by converting the amino to the azido group,104 then 
coupling with an amino alcohol.  4-Methyl-1-pentyne was “clicked” to the azido-dipeptide; 
this particular group was chosen to resemble a leucine side-chain.105  Finally, alcohol 11 
was converted to halide by the Appel reaction,110 then cyclized to an oxazoline.  Overall, 
synthesis of compounds 3 were easier to achieve than for chemotypes 1 and 2. 
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Scheme 2.4  Synthesis of triazole-oxazoline DL-3lal 
All four positive compounds and one partial negative control were sent to Dr. Jennifer 
Carew (Hematologic Malignancy Disease Team, The University of Arizona Cancer 
Center).  These compounds were tested on the human AML cell line (MV4-11), which is 
sensitive to MLN4924 (IC50 ~200 nM)111 by measuring cell viability via an ATPLite 
assay.111,112  ATP is a marker for cell viability because it is present in all metabolically 
active cells but its concentration declines rapidly once at the onset of necrosis or 
apoptosis.  Compounds at 5 different concentrations (up to 10 µM) were incubated with 
MV4-11 cells for 72 h.  Mammalian cell lysis solution was then added to break the cell 
membrane, and substrate solution (luciferase/luciferin) was added.  ATP in the cytosol 
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drives bioluminescence that can be quantitated in a plate reader.  The emitted light is 
proportional to the ATP concentration: stronger light intensity means more viable cells.  
Recall that neddylation is a part of tumor suppressor degradation, so compounds that 
disrupt NEDD8•NAE should reduce cell viability of tumor cells.  The results were shown 
in Figure 2.8.  Surprisingly, LLL-1fff, a partial negative control, reduced cell viability down 
to ~ 65% at 10 µM.  Other compounds, however, did not show any effect on MV4-11 cell 
line.  This is an unexpected result since LLL-1fff does not correspond to any part of the 
interface implicated in EKO.   
 
Figure 2.8  Results of cell viability assay.  Cells treated at various concentrations of 
compounds were determined their viability by ATPLite assay. 
 
2.4 Conclusion 
 
EKO algorithm is designed to assist in the design of inhibitors for PPIs by matching 
chemotypes with interface regions corresponding to the protein ligand.  This approach 
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has been proved to find new inhibitors that disrupt HIV-1 protease dimerization and 
perturb antithrombin oligomerization58,59; nevertheless, this program still needs more 
examples to build up its reliability.  Herein, we chose Nef and NEDD8 proteins to search 
for further validation.  We were attracted to these relatively new targets because of their 
high value in medicinal chemistry.  Based on EKO analyses, compound 1 had 
conformations that overlaid well on interfaces in the Nef•MHC-I•AP1 complex, and three 
hits on the NEDD8•NAE interface.  However, due to the limited time and synthesis 
difficulty, only a small number of compounds were synthesized for NEDD8•NAE target.  
Compounds 2, which had two hits on Nef’s acidic face, were prepared along with two 
partial negative controls, and compound 3 had one hit for NEDD8 target. 
 
The highest inhibition in the Nef Alphascreen assay, L-2eev, was around 10%, which 
was slightly higher than the protected form.  D-2vee, on the other hand, had lower 
inhibition than the protected form.  Overall, compounds 2 had little effect on Nef•MHC-
I•AP1 interaction.  There are possible reasons of these poor inhibitions.  First, Nef•MHC-
I•AP1 complex has large interface (> 2000 Å), in which only one small molecule (< 900 
Å2) may not have enough impact to disrupt protein-protein interaction.  Second, MHC-I 
was fused to C-terminal Nef in this assay, which provided a stronger binding interaction 
than a natural tertiary complex.  Lastly, the main interfacial interaction is at MHC-I 
peptide between Nef and AP1; small molecules mimicking MHC-I should be more 
interesting because they can intervene between Nef and AP1.  With these reasons, the 
combination of acidic face inhibitors and MHC-I mimics may provide a better inhibition 
because they cover larger area of PPI interface than only one inhibitor.   
 
In cell viability assay for NEDD8•NAE target, only partial negative control, LLL-1fff, 
reduced cell viability.  This is an unexpected outcome since Phe side-chain triads do not 
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involve in NEDD8•NAE interaction.  We hypothesized the cell permeability of 
compounds was problematic because they must internalize to disrupt NEDD8•NAE 
interaction. Our collaborator did Western blot assays using cell lysates to test of the 
compounds could disrupt NEDD8•NAE interaction under these conditions, but they did 
not (data not shown).   
What did we learn from this study?  We cannot conclude that EKO did not work in either 
of these cases, because only a few compounds were prepared, and these were not even 
the most desirable ones to test.  This was so because the compounds were so time-
consuming to prepare.  However, the Nef•MHC-I•AP1 interfaces are perhaps too large 
and tightly bound for small molecule disruption.  Consequently, this is what we 
concluded: 
(i)  Chemotype accessibility is critical.  Even if the overlays implicated by EKO at 
a PPI interface are encouraging, progress will be severely constrained if the compounds 
cannot be made easily.  EKO overlays may not be enough to validate potential mimics 
precisely since the program only considers Ca-Cb alignments, but does not examine 
binding energies or steric clashes.  In the latter project we use Glide to refine our 
structure designs, but, again, the analogs must be accessible. 
(ii)  Target selection is critical.  PPIs with large interface surface areas and 
featuring tight complexes will be difficult to inhibit. 
Despite these limitations, we did not give up on Nef•MHC-I•AP1 or NEDD8•NAE.  In fact, 
the study was stopped because we saw a more interesting opportunity: inhibition of 
PCSK9•LDLR using more accessible chemotypes, and this is described in the next two 
chapters. 
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CHAPTER III 
DESIGN OF HYDANTOIN-PIPERAZINE-BASED 
PEPTIDOMIMETICS TO DISRUPT PCSK9•LDLR INTERACTION 
3.1 Introduction 
Heart disease, a leading cause of death, is frequently associated with plaque in the 
arteries causing atherosclerosis, which is attributed by elevated levels of low density 
lipoprotein (LDL) in the blood.  LDLRs (LDL-receptors), on the surface of hepatocytes, 
are responsible for capturing LDL particles, and importing them into the liver for 
destruction.  Thus, LDLR•LDL complexes on the surface of hepatocytes undergo 
clathrin-mediated endocytosis into endosomes wherein the acidic environment triggers 
rearrangement of the LDLR extracellular domain, releasing bound lipoproteins, leaving 
the LDLR to be recycled to the plasma membrane (Figure 3.1a).113  
Removal of LDL particles by hepatocytes is negatively modulated by a chaperone called 
PCSK9114,115 that recognizes plasma membrane LDLR.116  PCSK9 inhibits the 
rearrangement of LDLR in LDLR•LDL complexes, so that the receptor is not recycled to 
the plasma membrane but is instead routed to lysosomes where LDL, LDLR and PCSK9 
are degraded (Figure 3.1b).117-120  Plasma LDL cholesterol levels thus can be decreased 
by inhibiting the PCSK9•LDLR interaction, because that increases the display of LDLR 
on the liver.113,121,122  This effect was discovered after genetic studies had correlated LDL 
levels in some patients with mutations associated with gain or loss of function of 
PCSK9;123,124 two loss of function mutations correlate with significantly reduced risk of 
coronary heart disease.123  Indeed, an individual with no detectable PCSK9, and 
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extremely low LDL levels, was healthy, suggesting suppression of PCSK9 for lipid 
lowering is safe.125  Conversely, individuals with gain-of-function mutations in PCSK9 
have a higher risk of coronary heart disease.123,124  
Figure 3.1  (a) In the absence of PCSK9, LDL particles are degraded in lysosome, 
whereas LDLRs are recycled back to the plasma membrane.  (b) In the presence of 
PCSK9, all components are degraded in lysosomes. 
Multiple clinical studies have shown injectable antibody therapeutics that impede the 
PCSK9•LDLR protein-protein interaction (PPI) significantly decrease circulating LDL 
levels.126  Subsequently, two antibody drugs that disrupt PCSK9•LDLR are FDA 
approved (Repatha from Amgen and Praluent from Sanofi/Regeneron); they appear to 
be tolerated well, with no serious side effects, and are efficacious.127-132 PCSK9•LDLR 
therefore is a validated target for medicinal chemistry.  
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The preferred modality for disruption of PCSK9•LDLR, however, is small molecule drugs, 
not mAbs, on the basis of mode of administration, cost, shelf life, and immunogenic 
response issues.  Thus in 2014 Genentech stated: “Undoubtedly, an orally available 
small molecule inhibitor of PCSK9, due to lower cost and ease of administration, would 
be a highly desirable alternative therapeutic agent.”133  Peptides have been used to 
mimic both components in the PCSK9•LDLR interaction.134-140  However, peptides are 
unlikely to provide therapeutic leads for PCSK9•LDLR because they have poor stabilities 
in plasma.141  There are few reports of non-peptidic small molecules that inhibit the 
PCSK9•LDLR interaction.  Portola Pharmaceuticals have reported 
tetrahydroisoquinolines (Figure 3.2a) that increase LDL-uptake in the liver cells, and 
showed increase of LDLR display on cells.142  Similarly, Park et al reported 2,2-
diphenylpropyl derivatives (Figure 3.2b) that increase LDL-uptake, and the decrease of 
plasma LDL in the wild type mice but not the corresponding PCSK9-knockout mice.143,144  
Nevertheless, both studies did not report any evidence of their compounds disrupting 
PCSK9•LDLR interaction; those compounds may act via different mechanism.  Another 
small molecule reported by Stucchi et al features an oligo N-methyl imidazole (Figure 
3.2c) that can disrupt PCSK9•LDLR based on ELISA assay (IC50 = 11.2 ± 0.2 µM), and 
increase LDL uptake in HepG2 cells (EC50 = 6.04 µM).145  Surprisingly, Stucchi’s 
oligoimidazole structure is amphiphilic and featureless, in which it is hard to imagine how 
this analogue binds on the PCSK9 protein specifically.  Thus, in our view, designing 
small molecules to disrupt PCSK9•LDLR has just begun.  Herein, we developed the 
hydantoin-piperazine 12 (Figure 3.2d) using EKO (as outlined in in chapter I), developed 
solid-phase syntheses to enable parallel syntheses of analogs, and evaluated their 
PCSK9•LDLR inhibition using a commercial TR-FRET binding assay kit.   
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Figure 3.2  Examples of non-peptide small molecules that inhibit PCSK9•LDLR 
interaction; (a) tetrahydroisoquinoline derivative, (b) 2,2-diphenyl propane moiety, and 
(c) imidazole-based peptidomimetic.  (d) Structure of hydantoin-piperazine 12 used in 
this study. 
3.1.1 Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Protein: Low Density 
Lipoprotein Receptor (LDLR) 
PCSK9 is a 692-amino acid glycoprotein that is structurally similar to subtilisin 
proteases.146-148  It uses its catalytic domain to bind to the extracellular EGF-A domain of 
LDLR in a 1:1 complex with a Kd, between 170 and 840 nM (Figure 3.3a).120,149,150  
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Figure 3.3  (a) PCSK9•LDLR(EGF-A) interaction.  (b) Key interactions are highlighted in 
yellow. 
 
Residues 367 - 381 and the EGF-A domain of LDLR (residues 293 – 332) interact via a 
relatively compact interface (ca 520 Å2).  The interface features an antiparallel b-sheet 
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comprised of 377 – 380 of PCSK9 and 308 – 310 of the LDLR EGF-A domain (Figure 
3.3b).  Additionally, Asp238 and Thr377 of PCSK9 form salt bridges to LDLR EGF-A (to 
Asn295 and Asn309 respectively), and residues 153 - 155 of PCSK9 also interact with 
LDLR EGF-A domain.  Particularly, Ser153 H-bonds to LDLR EGF-A Asp299.  Arg194 of 
PCSK9 forms another salt bridge with Asp310 of EGF-A.  In an acidic environment like 
lysosome, His306 of EGF-A is protonated, which forms an extra salt bridge with Asp374 
of PCSK9.  Overall, however, the interface is hydrophobic but surrounded by the polar 
interactions described above.  Key apolar amino acids of PCSK9 at this interface 
include: Ile369, Phe379 and Cys378.  Conversely, on LDLR EGF-A Leu318 is critical.120 
 
3.1.2 Hydantoins In Minimalist Mimic Design 
 
Imidazolidine-2,4-diones, or hydantoins, are pharmaceutically-interesting scaffolds; the 
best well-known hydantoin drugs are phenytoin derivatives (Dilantin®, Epilan®, Cerebyx® 
etc.) which are anticonvulsants.  Several hydantoin-based candidates are now in clinical 
trials for other applications.151  Several publications and reviews have featured the 
syntheses of these five-membered heterocycles.107,151,152  Hydantoin rings have broad 
structural diversity151 because they can be modified at the 1,3,5-positions; moreover, 
spirohydantoins and fused hydantoins can be prepared.  
 
Even though hydantoins are synthetically accessible and widely used in 
pharmaceuticals, there are not many hydantoin-based peptidomimetics.  One publication 
from Hamilton et al described preparations of b-strand mimics based on a 1,3-phenyl-
linked hydantoin scaffold153, and another paper from Albericio et al featured a hydantoin 
ring in a short peptide that fit into an active site of caspase-3.154   
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3.1.3 Piperazine-containing Minimalist Mimics 
Piperazine is one of the most frequent nitrogen heterocycles in U.S. FDA approved 
drugs.  Most of them contain substituents at both the N1 and N4-positions.155  This 
analogue is significant in the medicinal chemistry of a range of different biological 
targets.156  Thus several reports have demonstrated a broad spectrum of pharmaceutical 
activities of this scaffold, including anticancer, antidepressant, antibacterial and 
antimalarial agents.157  This valuable heterocycle has also been incorporated into 
scaffolds designed to resemble a-helices.  König and Maity prepared 1,4-dipiperazino 
benzene chemotypes to resemble i, i+3, i+7 in a peptidic a-helix, like Hamilton’s 
terphenyl helical mimics.36  Two publications by Rebek et al demonstrated the use of 
piperazine to prepare compounds in which the side-chains putatively resemble to i, 
i+3/i+4, i+7 residues on a-helix, and the same group prepared other piperazine-
containing scaffolds to project side-chains in orientations similar to an extended a-helix 
(i, i+4, i+8, i+11).158,159 
3.2 Secondary Structure Analysis of Hydantoin-piperazine Mimic 12 by EKOS 
Eight stereoisomers of hydantoin-piperazine 12 with all methyl side-chains, i.e. those 
that mimic alanine side-chains (12aaa), were evaluated for how similar they project their 
side-chain orientations when compared to the side-chains orientations of ideal 
secondary structures.  Before doing EKOS analyses, hydantoin-piperazine 12aaa was 
subjected to quenched molecular dynamics (QMD)57 to generate simulated preferred 
conformations.  Briefly, a molecule was minimized and then subjected to molecular 
dynamic at high temperature (1000K) for a short period time (1500 ps).  Molecular 
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conformations were recorded every 1 ps (i.e. 1500 conformations) then minimized using 
molecular mechanics.53,160,161  Conformations within 3.0 kcal/mol of the global minimum 
were considered as preferred conformations and used in the EKOS evaluation.  For this 
mimic 12, approximately 400-500 conformers of each stereoisomer have energy within 
3.0 kcal/mol from the lowest conformation, i.e. those are preferred conformers.   
Data from the EKOS analysis described above are presented in Figure 3.4a.  All eight 
isomers have representative conformers that match on sheet-type motifs (strand-turn-
strand, parallel and anti-parallel b-sheet; all below 0.50 Å) better than helical motifs (310-, 
a-, p-helix).  The best overlay is a DLL-12aaa isomer that spans two parallel b-sheets 
with an exceptionally low RMSD (0.26 Å, Figure 3.4b).  In contrast, mimics 12 do not 
overlay well on a 310-helix (Figure 3.4a red bars).  Overall, this chemotype has a bias 
towards sheet-type secondary structure mimicry, although it is not outstanding 
comparing to other exceptional chemotypes in Chapter V.  Although mimic 12 is not 
outstanding in terms of secondary structure mimicry, it matches well on protein-protein 
interfaces, e.g. it has 14 hits on PCSK9•LDLR interface.  How relevant the secondary 
structure mimicry of small molecules to the protein-protein interfaces will be discussed in 
chapter V.  
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Figure 3.4  (a) EKOS matching results of hydantoin-piperazine 12 with ideal secondary 
structures.  (b) Overlay of DLL-12aaa on a parallel b-sheet. 
 
3.3 Potential Hits of Hydantoin-piperazine Mimics Derived From EKO Analyses 
 
Simulated preferred conformers generated from QMD were matched on a PCSK9•LDLR 
crystal structure (PDBID: 3gcx)162 using EKO.58  Ca - Cb coordinates from the side-
chains of hydantoin-piperzaine 12aaa were systematically overlaid on Ca - Cb 
coordinates for the PCSK9•LDLR interface side-chains.  Low root mean square 
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deviations (RMSDs) between the Ca-Cb orientations imply preferred conformations of 
the compound mimics the protein side-chains well.  In this work, we set the RMSD cut 
off at 0.50 Å; overlays below that were considered as “potential hits”.  A summary of the 
hits is shown in Table 3.1.   
EKO found 12 hits on LDLR, and 2 on PCSK9 shown in Table 3.1.  Those hits matched 
on at least one hot spot residue reported in literature150, e.g. Asp299, Asn309 and Leu 
318 of LDLR, and Ile369 and Phe379 of PCSK9 protein.  In this study, we are interested 
in small molecules targeting PCSK9 protein.  This is because small molecules that dock 
on LDLR may internalize into cells together with LDL particles via LDL-uptake pathway, 
or may impede LDL•LDLR interaction.  To avoid this problem, we discarded two mimics 
on PCSK9.  Of the 12 hits on LDLR, eight hits were chosen for further studies based on 
availability of starting materials, e.g. mimics involving D-Asn are costly and not suitable 
to synthesize mimic 12 for the initial screening. 
Several crystal structures of PCSK9•LDLR have been reported149,163,164 but 3gcx was 
selected based on several criteria: (i) proteins were expressed as the full length (for 
PCSK9), or enough to maintain their functionality (LDLR); (ii) they are human proteins; 
(iii) crystal structures were obtained from X-ray diffraction with high resolution (< 3.0 Å); 
and, (iv) they were crystalized in similar physiological environments (pH 7.4).  Another 
crystal structure, 3bps,150 was obtained under almost the same conditions, both 
structures are nearly identical (RMSD = 0.26 Å for all atoms), and EKO analyses showed 
the results from those two crystal structures are almost identical. 
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Table 3.1  Potential LDLR mimics based on scaffold 12, from EKO analyses RMSD ≤ 
0.50 Å. 
Match on Isomer Residues RMSD (Å) 
LDLR 
DDD D299-L298-N301 0.39 
LDD D299-L298-N301 0.41 
LLD C297-N301-D299 0.42* 
DDL D299-L298-N301 0.43 
LLL C297-N301-D299 0.44* 
LDL D299-L298-N301 0.45* 
DLD C297-N301-D299 0.46* 
LLL L298-D299-N301 0.46* 
DLL C297-N301-D299 0.47* 
DDD V307-C308-L318 0.47* 
LLD L298-D299-N301 0.48 
DLL N309-C308-L318 0.50* 
PCSK9 
DLL F379-V380-I369 0.48 
DLD F379-V380-I369 0.48 
*  Selected hits  
 
3.4 Syntheses of Piperazine-based Amino Acids ‘Pip-acids’ 
 
Piperazine-amino acids ‘pip-acid’ 15 is a relatively new building block that is hardly 
represented in the literature,165 but in Dr. Burgess’s group is researching syntheses and 
applications of this fragment.  This unit has some interesting features.  A piperazine ring 
imparts rigidity relative to oligopeptides.  A wide range of pip-acids can be synthesized 
from both natural and non-natural amino acid precursors, hence there are opportunities 
to prepare libraries of pip-acids for drug discovery, e.g. for fragment-based screening.  
Additionally, the piperazine ring is common in pharmaceuticals as described 
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above.156,166,167  Thus piperazine-amino acids are valuable for synthesizing hydantoin-
piperazine molecules (my project), but also as valuable building blocks for other 
applications (Maritess Arancillo in Dr Burgess’ group). 
 
Pip-acids 15 in Scheme 3.1 were prepared from C-protected amino acids and trinosyl 
diethanolamine.  Trinosyl diethnolamine 13 was prepared from commercial 
diethanolamine and 4-nosyl chloride under basic conditions.168  We successfully made 
this material on ~100 g scale, and purified it by precipitation in dichloromethane and 
further recrystallization in THF/MeOH mixture.  Purified trinosyl diethanolamine 13 was 
reacted with C-protected amino acids in refluxing acetonitrile to give the protected 
piperazine-amino acids 14.  We modified a protocol that similarly used aryl amines in the 
literature, so that we could synthesize pip-acids without microwave irradiation.169  
Several different protecting groups on various amino acids are tolerated under the 
conditions we developed.  In the final step, protecting groups at the main-chain 
carboxylic acid were removed by different methods to obtain acid-free pip-acids 15 as 
the building blocks for solid-phase syntheses.  Overall, it is possible to prepare this 
analogue with any kind of amino acids; even the sensitive side-chain of histidine could 
be synthesized by this protocol.  Nevertheless, there are some cases that reactions do 
not proceed smoothly.  For instance, D-Asn-OMe is prone to methylate at amide side-
chain during syntheses, which can be avoided by using a side-chain protecting 
asparagine, e.g. trityl protecting group; however, due to the cost of D-amino acid, we did 
not prepare further.  Another amino acid, L-Trp(Boc)-OMe, lost its Boc group during 
hydrolysis; however, this indole-deprotected product is useful in solid-phase syntheses 
since an indole is less reactive than a primary or secondary amine with respect to amide 
bond formation reactions.  If necessary, Boc-protecting groups can be re-introduced onto 
the indole ring after hydrolysis.  Benzyl-protecting groups cannot be cleaved via 
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hydrogenolysis in syntheses of pip-acids because that would reduce the nosyl-nitro 
group.  Consequently, we used BBr3 to remove benzyl groups without affecting nosyl 
group or the Ca chirality.    
Scheme 3.1  Syntheses of piperazine-amino acids ‘pip-acids’. 
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3.5 Syntheses of Hydantoin-piperazine Mimics 12 via Solid-phase Syntheses 
and TR-FRET Binding Assay 
Throughout this work, acid-labile (tert-butyl or trityl) side-chain protecting groups of 
Fmoc-amino acids were carried through the pip-acid syntheses unless otherwise 
indicated.  Similar to previous chapter, capital letters (D, L) are represented 
configurations of side-chain residues, and lower case one-letter codes are presented the 
amino acid side-chains R1 – R3 with primed letters indicate protected side-chains (eg c’ 
for the –CH2SCH(C6H5)3 of Cys and n’ for the –CH2CONHCH(C6H5)3 of Asn). 
Hydantoin-piperazine mimics 12 were synthesized via solid-phase syntheses (Scheme 
3.2) on 2-chlorotrityl resin to produce C-terminal carboxylates after cleavage.  Loading 
the first pip-acid was achieved under basic solutions using microwave irradiation to 
accelerate the reaction.  Nosyl group was deprotected using mercaptoethanol and DBU, 
and then two cycles of standard coupling/deprotection of Fmoc amino acids were 
performed under microwave irradiation.  After the final Fmoc deprotection, the amino 
group was reacted with p-nitrophenyl chloroformate, then the adduct was treated with 
Hunnig’s base to initiate cyclization to hydantoins.  Finally, the compounds were cleaved 
from resins under mildly acidic conditions to preserve the side-chain protecting groups; 
this facilitated detection during the preparative HPLC relative to the core structure that 
does not contain chromophores.  Purified compounds were deprotected from their acid-
labile protecting groups in a TFA/Et3SiH/H2O cocktail, precipitated, washed several times 
with cold ether to remove byproducts, then lyophilized to obtain the final products as 
powders.  Two compounds, LLL-12ldn and LDL-12dln, were synthesized using benzyl-
protecting aspartate (-CH2COOBn), which were removed via hydrogenolysis with 10% 
Pd on charcoal under H2 atmosphere.   
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Scheme 3.2  Solid-phase syntheses of hydantoin-piperazine peptidomimetic 12. 
All eight compounds were evaluated for their PCSK9•LDLR inhibitions using a TR-FRET 
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nm respectively.  This lanthanide complex has a fluorescent decay longer than 
background fluorescence or light scattering from media, thus the fluorescent intensity 
can be measured after interfering signals have completely decayed.  This LDLR-Eu3+ 
interacts with the protein partner, PCSK9, which has been biotinylated.  Another 
component, an acceptor conjugated with dye, recognizes the biotin on PCSK9 protein.  
This dye, usually an allophycocyanin derivative, can be excited around 620 nm and emit 
fluorescence at 665 nm.  When LDLR and PCSK9 interact together (i.e. a positive 
condition), the europium complex and the acceptor dye come into close proximity, 
resulting the Förster Resonance Energy Transfer (FRET) that gives a fluorescence 
maxima at 665 nm.  If the two proteins do not interact (i.e. a positive outcome if caused 
by a small molecule), the fluorescent intensity of europium is greater at a shorter 
wavelength (620 nm).   
 
In this experiment, we set the sample containing LDLR, PCSK9, dye acceptor and 
vehicle (DMSO) as the negative giving a highest intensity of 665 nm wavelength.  For 
the positive, PCSK9 was excluded, which reduced the intensity at 665 nm but increased 
fluorescence intensity at 620 nm.  Samples containing PCSK9•LDLR inhibitors should 
show a higher intensity at 620 nm than the negative control, but not exceed the positive 
one.  Pep2-8, a 13-residue peptide developed by Genentech,133 was used here as a 
positive control.  We screened all eight inhibitors at 10 µM and 50 µM concentrations 
(Figure 3.5).  The results showed three mimics could inhibit PCSK9•LDLR above 20 % 
at 50 µM comparing to negative control (DDD-12vcl, LLL-12ldn, LDL-12dln); however, 
the deviations were huge, and some tests had irregular inhibition outcome.  For 
instance, DLL-12ncl, DDD-12vcl, DLL-12cnd and DLD-12cnd had fluorescent intensity 
lower than negative control (negative % inhibition).  Moreover, inhibitions of DLL-12cnd 
and LLD-12cnd at 10 µM were slightly better than 50 µM.  All these events raised a 
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question about the quality of this assay.  Nevertheless, the data implied that our small 
molecules might have poor binding affinities toward PCSK9 protein, or that the TR-FRET 
assay had insufficient sensitivity to make any conclusions.  In either case, modification of 
the chemotype is necessary to improve inhibitory potency, and other assays were 
developed, as described in the next chapter.   
Figure 3.5  Compounds 12 were screened for their inhibition using a commercial 
PCSK9•LDLR TR-FRET assay kit (BPS Bioscience).  Compounds 12 and Pep2-8 were 
tested at 10 and 50 µM.   
3.6 Conclusion 
Diseases related to high levels of bad cholesterol, cLDL, are major human threats. 
Traditional drugs lowering total cholesterol in plasma, e.g. statins, are not effective for 
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every patient.  One reason is because statins can promote the excretion of PCSK9 that 
reduces LDL receptors on liver cell surface.170,171  In turn, LDL particles cannot be 
cleared out from the plasma, leading to the plaque formation and subsequently causing 
atherosclerosis.  New drugs targeting PCSK9 might lower LDL plasma concentrations, 
and might be used alone or in combination with statins.  Recently, Repatha and Praluent 
became the first approved mAb drugs targeting PCSK9.  However, the cost and mode of 
administration of these therapeutics have encouraged researchers to develop small 
molecules that impede PCSK9 functionality.   
Hydantoin-piperazine mimic 12 were designed as a novel small molecule to disrupt 
PCSK9•LDLR.  Both hydantoin and piperazine-amino acid give rigidity to 12, and are 
both common substructures in pharmaceutical drugs.  Analysis by EKO revealed many 
hits for the PCSK9•LDLR interaction.  To validate the EKO results, we synthesized pip-
acids 15, and used them to construct hydantoin-piperazine mimics by solid-phase 
syntheses; compounds bearing the side-chains implicated by EKO analyses were 
prepared.  All 8 mimics were screened together with the positive peptide, Pep2-8, using 
a TR-FRET assay kit, but the results were inconclusive; the best three compounds, DDD-
12vcl, LLL-12ldn and LDL-12dln, showed % inhibition greater than 20%, but the 
deviations were huge, even Pep2-8 data showed nearly 20% deviation.  Surprisingly, 
fluorescent intensities of some cases were even lower than the negative control.  It is not 
clear whether these peculiar results are due to the poor activities of mimics, or the assay 
itself is not suitable for small molecules that may have weak binding affinities.  In any 
event, we decided to modify mimics 12 to improve their binding affinity toward PCSK9 by 
using Glide to refine our structures.  This process led to another set of new potential hits 
that, after a series of experiments, show lead compounds to disrupt PCSK9•LDLR 
interaction.  These data are described in the next chapter. 
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CHAPTER IV 
OPTIMIZATION OF HYDANTOIN-PIPERAZINE-BASED MIMICS TO 
IMPROVE INHIBITORY EFFICACY AGAINST PCSK9•LDLR 
INTERACTION 
4.1 Introduction 
In the previous chapter, compounds 12 did not show significant inhibitory activities 
against PCSK9•LDLR interaction in the TR-FRET assay.  We hypothesized compounds 
12 might have weak binding affinities, so our next strategy was to do structural 
modifications.  Consequently, an iterative docking and energy minimization procedure 
was used to virtually modify chemotypes 12 to include additional pharmacophores that 
would increase binding affinities.  Specifically, the preferred conformations of 12 were 
overlaid on LDLR in the 3gcx structure, LDLR was removed, then the chemotypes were 
docked in place using Glide within the Schrodinger package.172-174  This procedure gave 
“baseline energies” for interactions of 12 with PCSK9 to which data from docking 
virtually modified analogs could be compared;175 this procedure was performed in the 
Schrodinger software package using the CombiGlide routine.  Figure 4.1 shows an 
example of docked and minimized structure of 12•PCSK9 generated from the original 
EKO overlay (gold color).  We noticed that there is a conspicuous negatively charged 
cavity in PSCK9, proximal to the C-terminus of 12, but not interacting with it. 
Consequently, we made that cavity a priority in CombiGlide simulations.  Those 
calculations indicated the optimal Arg at the 12 C-terminus fits into that negative cliff on 
PCSK9 leading to compound 16 (silver color), which improved calculated binding energy 
by 2.72 kcal/mol due to the extra H-bonds to Asp367.   
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Figure 4.1  Docking of LDL-12dln (gold) and LDLL-16dlnr (silver) onto PCSK9.  (a) 
Compounds LDL-12dln and LDLL-16dlnr overlay on the LDLR (shown in magenta wire), 
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in which six Ca-Cb atoms of chemotypes and LDLR side-chains (green arrows) are 
compared; RMSD = 1.75 and 1.95 Å for LDL-12dln and LDLL-16dlnr, respectively.  (b) 
Improving binding affinity of LDLL-16dlnr is likely due to the H-bonds of Arg residue to 
the Asp367 of PCSK9 at a negative “cliff face” region as indicated in green lines. 
We refined our eight first-generation hydantoin-piperazine mimics 12 with CombiGlide to 
obtain fifteen second-generation mimics 16 shown in Scheme 4.1 and Scheme 4.2. 
These compounds were tested both in binding and cellular assays, and the results 
indicated the promising lead, LDLL-16dlnr, that had dissociation constant (Kd) at 25 µM 
based on SPR analysis, and showed significant increase of fluorescent-labeled LDL 
uptake in a LDL-uptake assay. 
4.1.1 Glide and Combiglide 
Methods for docking flexible ligands on the rigid 3D receptors, especially from high-
resolution crystal structures, are extensively employed in drug discovery.  Numerous 
programs are available for academic or commercial purposes, in which they have 
similar steps of docking ligands on the receptors.  Programs search the lowest-energy 
conformations of a ligand, and then calculate their binding interactions to the protein 
receptor.  Those interactions are the sum of major binding energies, e.g. van der 
Waals, Coulombic, hydrogen bonds and electrostatic energies.  Those calculated 
energies are processed through docking score algorithms to rank how good each 
chemotype docks on protein receptors.  However, solvent effects, entropic effects and 
side-chain flexibility of protein receptors can perturb the docking calculations leading to 
inaccuracy of results.  Some programs have been calibrated with experiments to 
minimize those issues, e.g. MOE-Dock, GOLD, Glide, FlexX etc.176   
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Glide172,173 (Grid-based Ligand Docking with Energetics) has been designed to perform 
an exhaustive search of the positional, orientational, and conformational space 
available to the ligand.  It produces a set of initial ligand conformations to roughly 
screen on the receptor to search for promising ligand poses.  Selected promising pre-
screen poses are minimized in the field of receptor using the molecular mechanics 
energy function, OPLS-AA (Optimized Potentials for Liquid Simulations-All Atoms) force 
field.175  Lowest-energy poses are subjected to a Monte Carlo calculation to further 
minimize torsional strains.  Finally, the scoring function, GlideScore, calculates binding 
affinity and reports a docking score, which can be used to compare among other 
compounds in database screens.  GlideScore has two standard algorithms; a softer, 
more forgiving, ‘SP’ calculation that minimizes false negatives suitable for a huge 
database, and a harder ‘XP’ function that minimizes false positives for a limited number 
of optimized compounds.174   
 
Virtual combinatorial ligands can be enumerated from the parental ligand using 
CombiGlide.  Fragment libraries are replaced at certain positions on parental ligands to 
generate the virtual combinatorial libraries (for example see Scheme 4.1), and then 
those libraries are docked on protein receptors with Glide to rank the fragments that 
should be incorporated.  For a large virtual combinatorial library, e.g. > 300 enumerated 
ligands, the fast SP calculation is recommended to rank those enumerated ligands 
while minimizing computational cost, and then the small subset (~ top 10-30 ligands 
from the SP ranking) is recalculated using the precise XP calculation to obtain high-
quality ranking results.  This process is useful to deduce a number of potential ligands 
to be synthesized for study. 
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4.2 Design Second Generation Hydantoin-piperazine Mimics with Glide 
 
Molecular dockings of the virtual libraries were performed using Glide in Schrödinger 
package (version 2015-4).172-175  All eight selected hits from the first-generation 
hydantoin-piperazine were used as the templates for optimizations.  First, methyl side-
chains of the hydantoin-piperazine templates were substituted with the side-chain amino 
acids from EKO matchings (Table 3.1) corresponding to the side-chain residues at LDLR 
interface.  Docking of these on PCSK9 would give the baseline energies for the 
interactions between 12 and PCSK9.  Modification at C-terminus was done using 
CombiGlide routine.  In this work, we substituted carboxylic acid with amino-acid 
lactones (Scheme 4.1).  We made our own library by varying R4 with both L- and D- 
genetically-encoding amino acids (except Met, Gly and Pro) and an additional ornithine 
amino acid for the total of 36 virtual fragments.  These virtually modified compounds 16 
were docked on PCSK9 again.  We used OPLS 2005 force field with 20 Å of the grid 
box, and restricted the virtual conformations within 5 Å from the parental poses to 
maintain the original poses obtained from QMD minimization.  We picked the mimics that 
had best docking scores from each template for further study.  In most cases, the 
positive-charge residues, His, Lys or optimally Arg, were the best for R4 position, and 
binding poses were comparable to the original poses from QMD. 
 
Based on our experience preparing compounds 12, cyclization of hydantoin was difficult 
when side-chain R1 was cysteine, and the final product had relatively poor stability.  We 
decided to replace this cysteine residue by screening other amino acid side-chains using 
CombiGlide and Glide routines.  The top results showed glutamine or glutamate 
derivatives gave the best docking score (highest negative Gibbs free energy).  
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Therefore, we substituted Cys on hydantoin with those Glu or Gln (for instance, from 
DLL-12cnd to DLLL-16qndr).  
 
Scheme 4.1  Illustrative process on how to modify mimic 12 to 16. 
 
4.3 Syntheses of Second Generation Hydantoin-piperazine Mimics via Solid-
phase Syntheses 
 
Solid phase syntheses of chemotypes 16 on TentaGel-NH2 resin were developed 
(Scheme 4.2).  Overall syntheses were similar to the first generation described in 
chapter III with some modifications.  Again, lower case one-letter codes depicted the 
amino acid side-chains R1-R4 as described in previous chapter, and side-chain 
protecting groups were acid-labile.  Methionine linker was attached on TentaGel-NH2 as 
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a cleaving group at the end of syntheses.  Amino acids R4 were coupled followed by 
nosyl-protected piperazine fragments 15 under microwave irradiations.  Nosyl-removal 
as indicated in chapter III,177 then two more coupling-deprotection cycles using standard 
N-Fmoc-protected amino acids assembled the structures bearing the R2 and R1 side-
chains.  N-Fmoc groups were removed, and then converted to hydantoins via a two-step 
process.107  Finally, cyanogen bromide was used to cleave the protected chemotypes 16 
from the resin, giving the C-terminal lactone appendix in these structures.  After 
preparative HPLC purification, compounds were treated with the TFA cocktail to 
deprotect acid-labile side-chains, and then lyophilized to obtain desired compounds 16. 
Implementation of Scheme 4.2 gave 15 compounds for screening, but one, LLLD-
16ldnq, was surprisingly vulnerable to degradation in the air, and was not considered 
further.  One of the compounds that was considered, LDLL-16dl(CN)r, is a byproduct 
formed via dehydration of the Asn side-chain in the cyanogen bromide cleavage step. 
Scheme 4.2  Solid phase syntheses of chemotypes 16 and the structure of LDLL-
16dl(CN)r. 
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Scheme 4.2  Continued. 
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Scheme 4.2  Continued. 
4.4 Binding Assays 
All featured second-generation hydantoin-piperazine 16 were tested for their activities to 
disrupt PCSK9•LDLR interaction.  Direct binding experiments were performed by three 
experiments.  Surface plasmon resonance (SPR) was conducted by our collaborator, Dr 
Xiaowen Liang, from the Center for Infectious and Inflammatory Diseases, Institute of 
Biosciences and Technology.  This method featured measurements of direct binding of 
inhibitors to the immobilized PCSK9 on a Biacore sensor chip, which could screen 
several inhibitors in short period and ultimately obtain dissociation constant (Kd).  We 
received PCSK9 protein from Dr. Jay Horton at UT Southwestern Medical Center. 
Another experiment involved quantification of inhibition using a commercial 
PCSK9•LDLR in vitro binding assay kit (MBL Int. Co).  This ELISA assay allowed 
determining direct inhibition of small molecules to the recombinant PCSK9 and EGF-AB 
of LDLR, i.e. this assay proved the specific disruption between those two proteins. 
Photoaffinity labeling was the third experiment to prove that our lead inhibitor bound on 
the PCSK9.  We incubated PCSK9 with the modified lead compound, LDLL-18dlnr, 
irradiated with UV flashlight, and then ‘clicked’ with azide-fluor 488.  This experiment, 
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including the synthesis of labeling fragment 19, was conducted by Bosheng Zhou from 
Dr. Burgess’ lab.   
 
4.4.1 Surface Plasmon Resonance (SPR) 
 
Surface plasmon resonance (SPR) was used to screen 14 compounds indicated in 
Figure 4.2a.  The positive control, Pep2-8, was also used in this study, and throughout 
other experiments.  This 13-residue oligopeptide was reported to bind PCSK9 with Kd 
0.66 ± 0.11 μM.133  One compound, LLLL-16aaar, is a “partial negative control” having 
the same core as the EKO-implicated compounds, but only Ala side-chains and an all-L 
stereochemistry that was not predicted via EKO, i.e. LLLL-16aaar controls for random 
stereochemistry and lacks of functional side-chains.  In the event, three compounds and 
Pep2-8 were selected (on the basis of this initial SPR data and the cellular uptake 
assays described below) for more thorough SPR analyses to determine dissociation 
constant (Figure 4.2b-e): LDLL-16dlnr (Kd 24.8  ± 9.1 μM), DLDD-16nclk (41.2  ± 17.5 
μM), LDLL-16dl(CN)r (35.8 ± 11.4 μM) and Pep2-8 (3.56 ± 0.16 μM).   
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Figure 4.2  (a) Initial SPR screening of 14 compounds at 50 µM and Pep2-8 at 5 µM 
over PCSK9 supported on gold via amine coupling chemistry.  (b-e) Sensorgram profiles 
of LDLL-16dlnr, DLLD-16nclk, LDLL-16dl(CN)r (1, 3, 9, 27 and 54 µM) and Pep2-8 (1, 2, 
4, 8 and 16 µM) respectively. 
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Figure 4.2  Continued. 
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4.4.2 Enzyme-linked Immunosorbent Assay (ELISA) 
 
Seven compounds in the library (again, selected on the basis of the SPR data and the 
cellular assays described below) were subjected to an ELISA assay to obtain additional 
evidence that the small molecules bind PCSK9 (Figure 4.3).  In this assay, EGF-AB 
domain of LDLR was pre-coated in a 96-well plate.  His-tagged PCSK9 and inhibitors 
were incubated together, and then added into the 96-well plate.  Inhibitors binding 
PCSK9 should interfere with PCSK9•LDLR interaction, which in turn reduces the 
intensities at 450 nm after adding His-tag mAb conjugated with HRP and substrate TMB.   
 
Figure 4.3  PCSK9•LDLR ELISA assay of selected compounds and Pep2-8 (50 µM) 
with 50 ng/mL PCSK9.  Results are the averages ± SD of three independent 
experiments.  
 
Error limits in this assay are higher than in the SPR experiments.  These seven 
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LDLR relative to a negative control that contained both proteins with DMSO (represent 
complete interaction).  
4.4.3 Photoaffinity Labeling 
Two derivatives of LDLL-16dlnr, compounds 17 and 18, were prepared to explore if 
binding of these to PCSK9 could be detected via photoaffinity labeling.  Thus, a 
protected LDLL-16dlnr that replaced lactone with b-alanine was prepared on chlorotrityl 
resin, cleaved with the protecting groups in place, and coupled to a photoaffinity 
fragment 19 to obtain 18 (Scheme 4.3).  Meanwhile, compound 17 without labeling 
fragment was used as a competitor to 18. 
Scheme 4.3  Synthesis of compound 17 and 18. 
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Scheme 4.3  Continued. 
Pre-incubation of PCSK9 with 18 and (optionally) with a large excess of the blocking 
ligand 17, irradiation of some wells at 365 nm, copper-mediated click reaction with 
Alexa-488-azide, then SDS-PAGE gave the data shown in Figure 4.4.  A fluorescent 
band corresponding to the molecular mass of labeled PCSK9 (~60 kDa) was observed 
only in the wells that were irradiated in the absence of the blocking ligand 17 (lane 1, 4 
and 7).  
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Figure 4.4  Photoaffinity labeling of human PCSK9 protein with compound 18. 
4.5 Biological Assays 
Apart from binding assays, we examined our inhibitors in cell culture.  Human 
hepatocellular carcinoma (HepG2) was chosen for this study, which was reported to 
have abundant LDLRs on cell surface, and was a standard cell line used in the study of 
PCSK9.121,130,133,162,178  Two featured experiments, LDL-uptake and cell-surface LDLR 
assays, were performed to determine the biological actives of small molecules toward 
live cells.   
Before evaluating our compounds, seven selected compounds shown in Figure 4.3 were 
tested for cytotoxicity using liver cells (HepG2).  All seven of these compounds showed 
no toxicity up to 50 μM.  The compound with the lowest Kd in SPR studies, LDLL-16dlnr, 
was also checked at 100 μM and showed no cytotoxicity even at this concentration 
(Figure D.1).  Another preliminary experiment to the key cellular assays, the water 
solubilities of the featured compounds were measured.  The solubility concentration 
60 kDa-
60 kDa-
in-gel fluorescence (488nm)
CBB-G250
73 
gradients for these materials were linear to beyond 100 μM, i.e. they were soluble at the 
maximum concentration used in the uptake assays below (Figure D.2). 
4.5.1 LDL-uptake Assay 
An established assay for PCSK9•LDLR inhibition features uptake of fluorescently labeled 
LDL nanoparticles (BODIPY-LDL, Invitrogen) by hepatocytes; the cells become 
fluorescent as the particles are absorbed.133  Uptake of the BODIPY-containing particles 
is maximized in the absence of PCSK9, and the cells become fluorescent; conversely, 
adding PCSK9 diminishes that signal.  Addition of PCSK9 and a compound that 
interferes with the PCSK9•LDLR interaction would be expected to give cells that are 
more fluorescent than those to which only PCSK9 was added but less so than cells to 
which none of that protein was present. 
Figure 4.5a shows maximal uptake (calibrated to 100 %; black bar) in the absence of 
PCSK9, while all the other data points correspond to 15 µg/mL of that protein; the 
“negative” corresponds to only PCSK9 added (calibrated to 0 %).  Pep2-8 at 30 µM 
restored the LDL uptake (yellow bar) to within 80 % of its maximal value (black).  Several 
of the featured chemotypes 16 showed promise insofar as they, like Pep2-8, also 
restored fluorescence; the ones marked with a red dagger were selected for further 
assays on the basis of this data and the SPR studies above.  Recall that LLLL-16aaar is 
a “partial control” as described above (same chemotype, just methyl side-chains); it did 
not induce significant BODIPY-LDL uptake. 
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Figure 4.5b shows data derived from repetition of these experiments under identical 
conditions except that three different doses of the test compounds were used.   Overall, 
all the compounds show a dose response, except LLLD-16qndr, DLLL-16qndr, and, as 
expected, the partial control LLLL-16aaar.  Figure 4.5c shows a more extensive dose-
response curve for one of these compounds, LDLL-16dlnr (again, selected on the basis 
of the overall data); this data shows an encouraging correspondence. 
 
It is curious that LDL uptake in the HepG2 cells was significantly enhanced when 100 
µM of compound was used (Figure 4.5c).  This is consistent with the SPR binding data in 
which LDLL-16dlnr showed a longer resident time (15-20 fold slower off-rate) compared 
with Pep2-8 (Table D.1).  More particularly, the longer half-life of the LDLL-
16dlnr•PCSK9 complex became more obvious when higher concentration (100 µM) of 
compound was injected onto the PCSK9-functionalized surface.  One explanation for 
these observations is that there could be a synergistic target site for LDLL-16dlnr that 
only becomes significant at higher compound concentrations. 
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Figure 4.5  Uptake of BODIPY-LDL by hepatocytes.  (a) Initial screen at 50 µM 
concentrations.  (b) Data of select compounds at three different doses.  (c) A more 
extensive dose-response curve of one select lead: LDLL-16dlnr.  All results are 
represented as means ± SD of three independent experiments.  Significant differences 
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between compounds and negative control are determined using student’ t-test (* p ≤ 
0.05, ** p ≤ 0.01). 
 
 
Figure 4.5  Continued. 
 
4.5.2 Cell-surface LDLR Assay 
 
Two assays were attempted to probe if increased uptake of LDL particles correlates with 
increased expression of LDLR.  Our initial attempts to do this featured monitoring LDLR 
levels on treated and untreated hepatocytes using flow cytometry.  HepG2 treated with 
PCSK9 would display the lowest level of LDLR, whereas cells treated with inhibitors or 
without PCSK9 would have higher LDLR levels.  The data obtained (Figure 4.6) 
indicated an increase in LDLR levels upon treatment with the seven hit compounds (as 
shown in Figure 4.5b), but the errors in the measurements were such that the increases 
had borderline statistical significance.   
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Figure 4.6  Percent surface LDLR level on the surface of HepG2 cells.  
 
Consequently, we resorted to a semi-quantitative approach in which the LDLRs on live 
hepatocytes (treated and untreated) were visualized using an LDLR-selective mAb in 
combination with an Alexa Fluor®-labeled secondary mAb.  Figure 4.7a shows 
expression of LDLR in the cells was suppressed when they were treated with PCSK9 
alone.  When cells were treated with the test compounds, then they stained more 
brightly (Figure 4.7b-e) though not as brilliant as the Pep2-8 or positive culture that did 
not incubate with PCSK9 (Figure 4.7f-g).  Figure 4.7h plotted the average corrected total 
cell fluorescence (CTCF) of Figure 4.7a-g by ImageJ software.  All three selected 
compounds (DLDD-16nclk, LDLL-16dlnr, DLLL-16qndr) had average fluorescent 
intensity higher than the partial negative control LLLL-16aaar, which supported the 
observation from LDL-uptake assay.  In the process of fluorescent quantification, we 
manually selected all cells in each image.  These measurements were estimated, so that 
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the error bars were not reported.  Nevertheless, the conclusion was still valid; the 
featured compounds were able to disrupt PCSK9•LDLR interaction.   
Figure 4.7  Fluorescent imaging of HepG2 cells treated with PCSK9 and (a) DMSO; (b) 
DLDD-16nclr; (c) LDLL-16dlnr; (d) DLLL-16qndr; (e) LLLL-16aaar; (f) Pep2-8; and (g) 
DMSO without PCSK9.  (h) Fluorescent intensity was quantified by ImageJ software.   
a
b
c
d
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Figure 4.7  Continued. 
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4.6 Syntheses of LDLL-16dlnr Mimic via Solution-phase Syntheses 
 
The results from binding and biological assays indicated the LDLL-16dlnr was a 
promising lead, so we decided to scale up the reaction via solution phase synthesis to 
prove accessibility.  LDLL-16dlnr can break down into 3 fragments, hydantoin, dipeptides 
and homoserine lactone.  The outline syntheses are shown in Scheme 4.4.  L-
homoserine lactone was prepared from L-methionine and bromoacetic acid according to 
the literature.179  This lactone was coupled with N-Fmoc-arginine, and subsequently 
nosyl-protected piperazine-asparagine using HBTU activator.  Deprotection conditions of 
nosyl group were screened with various reagents, and the best was the same used in 
solid-phase synthesis (mercaptoethanol/DBU).  Hydantoin ring was synthesized from 
Asp-Leu dipeptide.  After Fmoc deprotection, dipeptide was treated with p-nitrophenyl 
chloroformate in organic solvent, followed by addition of water to cyclization.  We 
observed the epimerization if organic base (e.g. Et3N) was used instead of water.  
Finally, benzyl was hydrogenolyzed, and the hydantoin was coupled with piperazine 
fragment to obtain protected form of LDLL-16dlnr.  Overall, we successfully prepared 16 
in gram scale via solution phase synthesis. 
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a 
 
b 
 
 
 
Scheme 4.4  Syntheses of LDLL-16dlnr in solution phase.  
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Scheme 4.4  Continued. 
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Scheme 4.4  Continued. 
 
4.7 Conclusion 
 
Compounds 12 implicated by EKO approach had weak binding affinity to be detectable 
in the TR-FRET experiment, as described in Chapter III.  To overcome this issue, the 
structural modifications with docking programs are desired.  We chose Glide in this work 
because (i) it allowed users to build their own libraries; (ii) docking parameters were 
adjustable to imitate ligand poses from EKO; and (iii) docking accuracy was reliable 
comparing with other similar docking programs.176  By using eight compounds 12 as 
parental templates, we substituted amino-acid lactones at the C-termini to conceive 
fifteen second-generation hydantoin-piperazine mimics 16.  Experiments from both 
binding and cellular assays revealed seven out of fifteen mimics 16 showed significant, 
measureable activities against PCSK9•LDLR interaction.  Further evaluation of those 
seven compounds indicated that LDLL-16dlnr was the lead among the second-
generation mimics with Kd = 24.8 ± 9.1 μM on PCSK9 based on SPR experiment, and 
approximately 50% increase of LDL uptake at 50 µM.  These results were in agreement 
with the photoaffinity data wherein the modified structure, LDLL-18dlnr, bound on the 
PCSK9 protein, and the ability of LDLL-16dlnr to restore LDLR display on HepG2 cells 
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observed by fluorescent imaging.  We also synthesized LDLL-16dlnr in solution phase to 
prove the syntheses of this analogue can be scaled up if desired.  Apart from this lead, 
DLDD-16nclk, LDLL-16dl(CN)r and LLLD-16qndr were also effective to disrupt 
PCSK9•LDLR interaction. 
 
There are opportunities for structural modifications to further improve binding affinities 
and increase LDL uptake characteristics.  Homoserine lactone is an appendix from 
cyanogen bromide cleavage, in which this lactone was not in our original strategy to 
improve binding affinities of mimics 12.  Indirect evidence from LDLL-18dlnr implied that 
this lactone might not significantly contribute the binding energy to PCSK9.  Moreover, it 
is reasonable to synthesize molecules bearing R1-R3 side-chains same as LDLR side-
chain sequences to mimic natural interaction between PCSK9•LDLR, thus those 
molecules are likely to dock on PCSK9 selectively.  However, there is a possibility to 
gain superior binding interactions with different side-chains apart from natural 
interaction, i.e. those mimics may fit well in the pockets of PCSK9 protein.  In this regard, 
we can explore the side-chain combinations that provide better docking score via 
CombiGlide.  Ultimately, the results from this project are a stepping stone to make better 
potent small molecules to disrupt PCSK9•LDLR interaction. 
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CHAPTER V 
EVALUATION OF SECONDARY STRUCTURE MIMICRY TO 
DISRUPT PROTEIN-PROTEIN INTERFACES  
 
5.1 Introduction 
 
Minimalist mimics are compounds that do not have peptidic backbones, but nevertheless 
preferentially project amino acid side-chains in orientations that resemble secondary 
structures.  Decades of research in this area has been driven by the assumption that if a 
secondary structure is found at a protein-protein interface then a corresponding 
minimalist mimic is a candidate to displace the protein it mimics from the interface,10,11,26 
and there are several instances in which minimalist mimics have been proven to disrupt 
PPIs (examples41-46 and reviews40,47-51).  However, the existence of a relationship 
between secondary structure- and interface-mimicry is an untested hypothesis; it cannot 
be confirmed on the basis of the experimental data available since there are not enough 
data points.  Consequently, even though secondary structure mimicry is widely seen as 
a fast-track to molecules that disrupt specific PPIs, the value of secondary structure 
mimicry is assumed rather than proven.  We saw an opportunity to test the hypothesis 
that secondary structure mimicry is important using a combination of four computational 
approaches: EKOS, EKO, DSSP, and STRIDE.  
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Figure 5.1  (a) The secondary structure mimic hypothesis involves (top row): (left) 
identification of a PPI with an interfacial secondary structure motif; (center) identification 
of a mimic of this secondary structure; and, (right) displacement of the protein having the 
secondary structure from the PPI.  (b) Work flow in this study: comparing preferred 
conformations with protein-protein interfaces (EKO), with ideal secondary structures 
(EKOS), then the matches in both to detect secondary structures at interfaces (DSSP 
and STRIDE).   
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As this research evolved, the validity of matching protein interface residues to secondary 
structures emerged as an important issue.  EKO is used to determine PPI interface 
segments where preferred conformations of the featured chemotypes overlay based on 
all three Ca - Cb vectors.  An open-source computational program called the Dictionary 
of Secondary Structures of Proteins (DSSP) was then used to evaluate the presence of 
secondary structures at protein-protein interfaces.  DSSP identifies secondary structure 
motifs based on hydrogen-bonding patterns.180,181  Throughout this work, DSSP was set 
so that all three Ca - Cb vectors must match on a particular secondary structure 
otherwise the overlay is called “segment”.  To verify DSSP data, another program, called 
“STRIDE”, was also used for the same purpose.  Like DSSP, STRIDE evaluates protein 
residues in terms H-bonding patterns, but it also uses dihedral-angle parameters.182,183  
Both programs report secondary structure motifs using same one-letter codes (H = a-
helix; G = 310-helix; I = p-helix; E = sheet; B = strand; T = turn; S = bend; _ = 
uncategorized segment).  STRIDE does not differentiate between turn and bend motifs 
like DSSP, so we combined those two results as turns/bends category.  We also 
combined sheet and strand motifs into the same group since both programs did not 
classify the type of sheet motifs (b-strand, parallel- or antiparallel-b sheet).  
 
Figure 5.2 illustrates some typical data.  All the data in Figure 5.2 relates to helices, 
though just for illustration; similar considerations apply to other secondary structures.  In 
Figure 5.2a a mimic overlays on a near-ideal a-helical fragment in a protein (at an 
interface); both DSSP and STRIDE call the region where the conformer overlaid as 
helical (H).  However, in Figure 5.2b a conformer is overlaid on an extended region 
between two helical segments; in fact DSSP calls the residues overlaid as turn, turn, and 
helical (TTH) while STRIDE concludes this is helical (HHH).  In this work, the DSSP 
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result is classified as “segment” (not overlaid on and particular secondary structure), 
while STRIDE “bins” this region as helical.  In our view, it is debatable if that extended 
region should be denoted as helical.  Similarly in Figure 5.2c, it is unclear that that 
extended, twisted region is helical: DSSP would bin that as a segment, while STRIDE 
calls it as a helix.  In Figure 5.2d, the mimic has overlaid on an extremely distorted 
region between two helical fragments; both DSSP and STRIDE bin this overlay as a 
segment.  Due to the distortion illustrated in these examples, we decided to set that all 
three Ca - Cb vectors must match on a particular secondary structure otherwise they 
were called “segment”.  
 
 
Figure 5.2  Illustrative examples of DSSP and STRIDE secondary structure assignment 
at protein interfaces where mimics overlay. 
 
a 
DSSP: HHH 
STRIDE: HHH 
near ideal 
a-helix 
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Figure 5.2  Continued. 
b 
DSSP: TTH 
STRIDE: HHH 
extended 
distortion 
c 
DSSP: HTH 
STRIDE: HHH 
extended 
twisted 
distortion 
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Figure 5.2  Continued. 
 
Only four illustrative examples are given in Figure 5.2, and these do not cover every 
case wherein distortions may present at PPI interfaces.  However, comparison of DSSP 
and STRIDE data reveals that STRIDE tends to allow more deviation from ideal than 
DSSP.  However, the difference in DSSP and STRIDE outputs is not significant enough 
to affect the overall conclusions.  
 
In this work we designed chemotypes that may present side-chains in orientations that 
resemble peptides and proteins without intending to target any particular secondary 
structure, then asked if their preferred conformers mimic secondary structures and 
interface regions.  Thus the research described here features eight minimalist mimics 
that have not been prepared or reported previously, and Arora’s oxopiperazine 
d 
heavily 
distorted 
region 
in helix 
DSSP: HHE 
STRIDE: HH_ 
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chemotype A38,184 was also included as a reference.  Our aims were to: (i) determine 
how these minimalist mimics compare with huge numbers of interfaces in approximately 
240,000 crystallographically characterized PPIs; (ii) compare this data with the bias of 
the same mimics to adopt conformations that mimic secondary structures; and, (iii) 
evaluate the presence of secondary structures at the interfaces where the mimics do 
overlay well (using EKO, EKOS, and DSSP/STRIDE, respectively; Figure 5.1).  If 
secondary structure mimicry is important in the design of interface mimics then 
chemotypes that overlay well on ideal secondary structures should match frequently at 
PPI interfaces.  A number of conformers and clusters of each chemotype used in these 
studies are summarized in Table E.1. 
 
 
Figure 5.3  Structures of chemotypes A, 1, 2, 24-29 
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Figure 5.3  Continued. 
 
5.2 Analyses of Peptidomimetics A, 1, 2, 24-29 
 
5.2.1. Arora’s Oxopiperazine A: A Benchmark 
 
EKOS simulations indicate the trimethyl-substituted chemotype LLL-Aaaa tends to 
overlay select common secondary structures with RMSDs smaller than the best-known 
minimalist mimics as of 2014.54  Consequently, chemotype A is a useful benchmark for 
good interface mimic design.  Figure 5.4a shows how each of the eight possible 
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stereoisomers (grouped on the x-axis) overlay on the ideal secondary structures, and 
Figure 5.4b arranges the best matching conformers in descending RMSD of the overlays 
irrespective of stereochemistry.  The best overlay identified was for LDD-A on a parallel 
b-sheet (RMSD 0.21 Å).  The second-best overlay had a significantly different RMSD 
(0.28 Å) indicating the optimal one was somewhat unique.  Overall, some conformers of 
A tends to overlay better on extended structures than the helical ones.  For any helical 
structure, the best overlay was for LLL-A on the i, i + 1, i + 3 side-chains of a p-helix 
(0.36 Å RMSD).  
 
 
 
Figure 5.4  RMSD (Å) of the overlays of mimics A on each of the ideal secondary 
structures, organized by stereochemistry (a) or by decreasing RMSD (b).  Statistical 
distribution of secondary structures at PPI interfaces derived by DSSP and STRIDE 
calculations; (c) the best 312 overlays of LLL-A (all RMSDs < 0.25 Å); and, (d) 320 
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overlays of LDD-A (RMSD < 0.25 Å). Note that calculations do not differentiate strand-
turn-strand, parallel- and antiparallel-sheets. 
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Figure 5.4  Continued. 
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Figure 5.4  Continued. 
 
LLL- and LDD-A were selected for a study featuring mining of most of the PPI interfaces 
in the PDB via EKO.  Taking a threshold of 0.25 Å gave 312 and 320 PPI interfaces, 
respectively.  Each match was then analyzed using DSSP and STRIDE.  Both 
calculations were set so that all three Ca - Cb vectors must match on a particular 
secondary structure otherwise the overlay is called “segment”.  Using these criteria, few 
of the matches observed corresponded to the mimic overlaid on an ideal secondary 
structure (Figure 5.4c and d).  EKOS analyses on ideal secondary structures predicted 
the isomer that best matches the secondary structures overall was LDD-A, and this 
favors sheets and turns over helices at interfaces, but most (>73 %) of the matches were 
on segments (Figure 5.4d).  Consistent with this, the EKO analysis on PPI interfaces 
gave optimal matches for sheet regions.  However, some stereoisomers like LLL-A also 
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showed biases towards helical conformation (based on EKOS; Figure 5.4a,c), though 
turns and bends were slightly dominant.   
 
5.2.2. Hydantoin-oxazoline Chemotype 1: A Universal Peptidomimetic 
 
Interface mimic 1 has the same “chain periodicity” as three continuous amino acids (i, 
i+1, i+2): each side-chain is separated by two atoms in the main-chain (Figure 5.5).  In 
its most stable conformation detected by quenched molecular dynamics (QMD; in a 
continuous dielectric of 80),56,57 the sequential Ca - Ca distances were ~3.7 Å, whereas 
for a peptide in most ideal secondary structures are only slightly longer ~3.8 Å.  This 
mimic has three chiral centers and no planar heterocyclic rings, so it is expected to 
extend chains in three dimensions that will vary amongst the eight (23) possible 
stereoisomers. 
 
Using EKOS, preferred conformers of mimic 1 were systematically overlaid on common 
secondary structures.  These ideal secondary structures are composed of L-amino 
acids, so it is tempting to assume that mimic LLL-1 that has the same chain periodicity 
would tend to overlay better than the other stereoisomers, but this is not so (Figure 
5.5a).  The LLL-isomer is a better a- and 310-helical mimic than any other in the series, 
but select other stereoisomers overlay more closely on the other secondary structures.  
In fact, this is a trend observed throughout for all the chemotypes featured in this study. 
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Figure 5.5  (a) RMSDs for overlay of the best matching accessible conformer of mimics 
1 on each of the ideal secondary structures; (b) data in a replotted in descending RMSD 
(left to right) irrespective of stereochemistry.  Statistical distribution of secondary 
structures at PPI interfaces derived by DSSP and STRIDE calculations; (c) the best 268 
overlays of LLL-1 (all RMSDs < 0.15 Å); and, (d) 1008 overlays of LDL-1 (< 0.10 Å 
RMSD). 
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Figure 5.5  Continued. 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
D
D
L 
LD
L 
D
LL
 
D
D
D
 
D
LD
 
LL
L 
LD
D
 
LL
L 
D
LD
 
D
D
D
 
LD
L 
LD
D
 
D
D
D
 
D
LL
 
D
D
D
 
LL
D
 
LD
L 
LL
D
 
D
LL
 
LL
L 
LL
L 
LD
D
 
LD
D
 
LD
L 
D
D
L 
LL
D
 
D
D
L 
D
D
D
 
LL
L 
D
D
D
 
LL
D
 
D
D
D
 
D
LL
 
D
D
D
 
LD
L 
 
LL
D
  
LL
L 
D
D
L 
LL
L 
LL
D
 
D
LD
 
D
D
L 
LL
L 
D
LL
 
D
LD
 
D
D
D
  
D
LL
 
D
LL
 
D
LL
 
LL
L 
 
LD
D
  
D
LL
  
LL
D
 
D
D
L 
D
LD
 
LL
D
 
D
D
L 
LD
D
 
LL
D
 
LD
D
 
D
D
L 
D
LD
  
D
LD
 
LD
D
 
D
D
L 
LD
D
 
D
LD
 
LD
L 
D
LD
 
LD
L 
LD
L 
LD
L 
R
M
SD
 (Å
) 
1
b
O
NN
H
N
R3
R2O
O
R1
1.5 0.0
4.1
0.4
9.7
84.3
4.5
0.0 0.0 0.7
19.0
75.7
0
10
20
30
40
50
60
70
80
90
100
α-helix 3-10 helix π-helix strands/sheets turns/bends segments
pe
rc
en
ta
ge
 (%
)
LLL-1
DSSP
STRIDE
  
 
99 
d
 
Figure 5.5  Continued. 
 
Figure 5.5b replots the data in Figure 5.5a, but from highest to lowest RMSD, 
irrespective of secondary structure. This presentation reveals that compared with A, 1 is 
a superior mimic, especially for the extended conformations (0.13 - 0.18 Å RMSD): 
strand-turn-strand (light blue), b-strand (navy blue), parallel and antiparallel b-sheets 
(light and dark violet), cf blue and violet bars.  Overlays of preferred conformers of 1 on 
more twisted helical structures (red, orange, yellow bars) occur at higher RMSDs.  
However, stereoisomers of chemotype 1 can be found to overlay on any of the ideal 
secondary structures with RMSD < 0.35 Å whereas, for comparison, chemotype A 
(Figure 5.4b; note the expansion of the y-axis showing RMSD, is different) only overlays 
well on antiparallel-, parallel b-sheets, and strand-turn-strand secondary structures with 
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RMSD < 0.35 Å.  Relatively, chemotype 1 is therefore an outstanding universal mimic53 
of ideal secondary structures.  
 
EKO mining of preferred conformers of LLL- and LDL-1 on most of the PPI interfaces in 
the PDB showed that over 75 and 56 %, respectively, of the matches were not on ideal 
secondary structures at the interface (Figure 5.5c-d).  The LDL-1 stereoisomer is 
interesting insofar as it does match on sheet-type structures with a 38 % frequency; 
several DSSP and STRIDE analyses were performed for this study, but the data in 
Figure 5.5d is notable because it shows the highest bias among all nine chemotypes 
towards any secondary structure relative to “segments”.  Chemotype 1 was synthesized 
to validate its accessibility as described in Chapter II.   
 
5.2.3. Triazole-oxazole Chemotype 2: No Difference Between Two Stereoisomers 
 
Chemotype 2 did not give preferred conformers that overlaid well with ideal secondary 
structures (< 0.35 Å).  However, it is informative to consider the reasons why it is not 
such a good secondary structure mimic.  Like the chemotypes 1, the oxazole-triazole 
interface mimics 2 resemble continuous sets of three amino acids, ie tripeptide 
fragments.  However, survey of favored conformers of 2 revealed their Ca - Ca 
distances tend to be around ~3.6 Å; this is shorter than for chemotype 1 and for 
tripeptides (~3.7 and 3.8 Å, respectively).  Another significant difference between 1 and 
2 is that the triazole-containing mimics 2 only have one chiral center.  Flipping the 
stereochemistry of this sole chiral center does not afford the same degree of three-
dimensional diversity as variation of three centers in chemotypes 1.  Consequently, it is 
unsurprising that none of the preferred conformers of 2 matched any of the ideal 
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secondary structures with RMSD < 0.35 Å (Figure 5.6b).  Both stereoisomers of 
chemotype 2 were subjected to combine EKO and DSSP/STRIDE analyses.  Both the L- 
and D-interface mimics of 2 showed a bias towards loosely wound helices (ie a- and p-) 
and towards turns, but not as dominant as uncategorized structure (Figure 5.6c-d).  
Compounds 2 were synthesized to explore how easily they could be made, as described 
in Chapter II.  One compound in this series, L-2fff, crystallized and structure of this was 
evaluated via EKOX as shown in Figure 1.6 of Chapter I.  
 
 
Figure 5.6  (a) RMSDs for overlay of the best matching accessible conformer of mimics 
2 on each of the ideal secondary structures; (b) Replotted data in descending RMSD.  
Statistical distribution of secondary structures at PPI interfaces derived by DSSP and 
STRIDE calculations; (c) the best 106 overlays of L-2 (all RMSDs <0.35 Å); and, (d) 98 
overlays of D-2 (<0.35 Å RMSD). 
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Figure 5.6  Continued. 
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Figure 5.6  Continued. 
 
5.2.4. Bistriazole Oxazoline Chemotype 24: A Surprisingly Helical Mimic 
 
Simulations in EKOS indicate mimic 24 can adopt a highly-populated conformation that 
overlays side-chains on the i, i + 4, i + 5 residues of a 310-helix and the i, i + 5, i + 6 
residues of an ideal a-helix.  This observation is unlike those in analyses of A, 1 and 2 
and, as it transpires, of 25 - 29; none of those chemotypes gave any helical low energy 
conformers that overlaid with RMSDs < 0.30 Å (see Figure 5.5a for the second best 
helical mimic LLL-1, on a 310-helix, 0.32 Å).  Collectively, these data indicate 24 is the 
best helical mimic in the series.  Further consideration indicates helical conformations 
are favored by mimics 24 with an L-configuration at the second position; the only 
exception is for DDD-24 which the simulations indicate also adopts helical conformations.  
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Conversely, mimics 24 with a D-configuration at the second position tend to adopt 
extended conformations (again, except for DDD-24).  Overall, by a small margin, the best 
overlays observed for 24 in EKOS analyses were for anti- and parallel-b-sheet motifs (ca 
0.20 and 0.21 Å, respectively; Figure 5.7b).  The fact that none of the preferred 
conformers of 24 overlaid on g-turns and b-strands is logical; the mimic is too long to fit 
g-turns and too kinked to overlay well on the linear b-strands motif.  
 
 
Figure 5.7  (a) RMSDs for overlay of the best matching accessible conformer of mimics 
24 on each of the ideal secondary structures; (b) Replotted data in descending RMSD.  
Statistical distribution of secondary structures at PPI interfaces derived by DSSP and 
STRIDE calculations; (c) the best 308 overlays of LLL-24 (RMSDs < 0.30 Å); and, (d) 
369 overlays of LDL-24 (RMSDs < 0.25 Å). 
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Figure 5.7  Continued. 
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Figure 5.7  Continued. 
 
In EKO analyses featuring PPI interfaces, LLL-24 overlaid most of the time on 
“segments” but showed a small bias towards a-helices out of all secondary structures. 
By contrast, after segments, LDL-24 shows a bias towards sheets at PPI interfaces 
(Figure 5.7c-d). These two observations are consistent with the conclusions from the 
EKOS analyses. 
 
5.2.5. Dihydantoin Chemotype 25: Short Side-chain Separation 
 
It now appears that chemotypes 25 are good-to-poor interface mimics, based on several 
observations.  First, the R1 and R2 on hydantoin motif are quite close together relative to 
dipeptides, so preferred conformers of this chemotype did not overlay on any ideal 
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secondary structure with RMSD <0.35 Å in EKOS analyses.  Above that threshold, loose 
overlays were observed for strand-turn-strand and a-helices (i, i+1, i+9 side-chains).  
When matched with PPI interfaces (EKO), the second frequent overlays apart from 
segments were on a turns/bends region classified by DSSP/STRIDE.  
 
 
Figure 5.8  (a) RMSDs for overlay of the best matching accessible conformer of mimics 
25 on each of the ideal secondary structures; (b) Replotted data in descending RMSD.  
(c) Statistical distribution of secondary structures at PPI interfaces derived by DSSP and 
STRIDE calculations of the best 120 overlays of LL-25 (<0.35 Å RMSD) on PPI 
interfaces 
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Figure 5.8  Continued. 
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5.2.6. Hydantoin Oxadiazole Oxazoline Chemotype 26: A Good Extended-sheet Mimic 
 
Generally, mimic 26 gives an excellent match on sheets, some good matches on turns, 
and barely hits for helices (Figure 5.9).  The “periodicity” of the hydantoin fragment that 
projects the R1 and R2 substituents of this mimic is identical to consecutive residues in 
peptides, ie both contain NCHR1CONCHR2CO motifs, (cf mimic 1).  In fact, the Ca - Ca 
seperation in the hydantoin fragment (3.8 Å) almost perfectly matches of that in an 
extended peptide conformation.  The R3 side-chain is further away (~6.8 Å), so to 
overlay with secondary structures this substituent must align with a distal residue.  If this 
occurs, it seems reasonable that chemotype 26 would be a good mimic of sheets.  
 
 
 
Figure 5.9  (a) RMSDs for overlay of the best matching accessible conformer of mimics 
26 on each of the ideal secondary structures; (b) Replotted data in descending RMSD.  
Statistical distribution of secondary structures at PPI interfaces derived by DSSP and 
STRIDE calculations; (c) the best 287 overlays of LDD-26 (all RMSDs <0.18 Å); and, (d) 
115 overlays of DDD-26 (<0.20 Å RMSD).   
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Figure 5.9  Continued. 
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Figure 5.9  Continued. 
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The Ca - Ca seperation for i and i + 1 residues in ideal antiparallel β-sheets is 3.9 Å, ie 
slightly longer than in parallel sheets (~3.8 Å), while the separation of i and i + 2 residues 
is slightly less at 6.6 Å (as opposed to 6.8 Å).  As a result, matching of mimic 26 on an 
ideal antiparallel sheet is not as good as on parallel sheets, but still acceptable.  Mimic 
26 also overlays on the i, i + 1, and i + 5 residues of an ideal p-helix, but with RMSD 
values > 0.35 Å.  The reason why this chemotype does not overlay very well is that the i 
+ 1 to i + 5 distance in an ideal p-helix is only 6.3 Å, but mimic 26 projects the third side-
chain at more distal positions (around 6.8 Å).  Similarly, that long R2 to R3 separation 
makes it impossible for 26 to overlay on turns. 
 
Mimic 26 was compared with a huge number of PPI interfaces using the EKO routine.  
Approximately 300 best-fitting conformers (all RMSD < 0.18 Å) were selected for the 
stereoisomer that best fit secondary structures in general, ie the LDD-form.  Most of the 
selected conformers matched on “segments” in the DSSP/STRIDE analysis, but 
approximately 15 % matched on sheets.  To test the relevance of matching on 
secondary structures, we also consider the DDD-isomer because it gave the worst 
matches in the stereoisomeric series.  In the EKO analysis of PPI interfaces, it was 
necessary to raise the RMSD threshold slightly, to 0.20 Å, to obtain 116 matches; > 95 
% of those matched on “segments” (Figure 5.9c-d).  These observations are consistent 
with the data from the EKOS analyses; the LDD-isomer tends to match on sheets more 
than other secondary structures, while the DDD-isomer has no obvious preference for 
any secondary structures. 
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5.2.7. Imidazolidinone Bisoxazoline Chemotype 27: Another Sheet Mimic 
 
Chemotypes 26 and 27 are similar insofar as they have two rigid fragments linked by two 
rotatable bonds.  In fact, both cores consist of three, 5-membered heterocyclic rings, 
wherein the ones that support the R1 and R2 side-chains are seperated by two rotatable 
bonds.  Consequently it is unsurprising that, like 26, mimic 27 shows a bias towards 
sheet-like conformations.  However, the fit is not quite as good: the Ca - Ca separations 
(R1 to R2, 3.7 Å; R2 to R3, 7.2 Å) are a little too long. 
 
 
Figure 5.10  (a) RMSDs for overlay of the best matching accessible conformer of mimics 
27 on each of the ideal secondary structures; (b) Replotted data in descending RMSD.  
(c) Statistical distribution of secondary structures at PPI interfaces derived by DSSP and 
STRIDE calculations of the best 288 overlays of LDL-27 (all RMSDs <0.20 Å) 
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5.2.8. Bistriazole Chemotype 28:  Long Side-chain Separation 
 
Triazole motifs in mimic 28 rigidly hold the Ca – Ca atoms 4.9 Å apart, and this is longer 
than the corresponding separation in a typical peptide (~3.8 Å).  This single observation 
accounts for the fact that chemotypes 28 did not overlay on any ideal secondary 
structures with RMSDs of <0.35 Å.  Within that group of poor matches, this structure 
overlays best on sheets, then 310-helices, but not at all well on strands and p-helices 
(Figure 5.11b).   
 
 
Figure 5.11  (a) RMSDs for overlay of the best matching accessible conformer of mimics 
28 on each of the ideal secondary structures; (b) Replotted data in descending RMSD.  
(c) Statistical distribution of secondary structures at PPI interfaces derived by DSSP and 
STRIDE calculations of the best 181 overlays of LLL-28 (<0.50 Å RMSD) on PPI 
interfaces. 
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Figure 5.11  Continued. 
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5.2.9. Compact Bistriazole Chemotype 29:  Poor Secondary Structure Mimicry 
 
Preferred conformations of chemotype 29 gave even worse overlays on ideal secondary 
structures than 28.  This mimic has more appropriate Ca – Ca separations for peptide 
mimicry, but the orientations of the Ca – Cb vectors are locked into the same plane as 
the triazole rings.  Interestingly, there are significant different results between DSSP and 
STRIDE on the turns/bends motif (Figure 5.12c).  This is likely due to the flexible criteria 
of STRIDE that allow more deviation than DSSP.   
 
 
Figure 5.12  (a) RMSDs for overlay of the best matching accessible conformer of mimics 
29 on each of the ideal secondary structures; (b) Replotted data in descending RMSD.  
(c) Statistical distribution of secondary structures at PPI interfaces derived by DSSP and 
STRIDE calculations of the best 654 overlays of L-29 (<0.50 Å RMSD) on PPI interfaces. 
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Figure 5.12  Continued. 
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5.3 Conclusion 
 
Aims of this work were to: (i) determine how these minimalist mimics compare with huge 
numbers of interfaces in crystallographically characterized PPIs; (ii) compare this data 
with the bias of the same mimics to adopt conformations that mimic secondary 
structures; and, (iii) evaluate the presence of secondary structures at the interfaces 
where the mimics do overlay well.  To summarize our findings towards the first aim, 
Figure 5.13a plots the number of EKO hits for each chemotype (all stereoisomers 
combined) with RMSDs <0.35 Å.  Chemotype 1 had 1,491,780 overlays, whereas the 
second-best interface mimic (26) had only 94,972.  Mimics 1, 26, 27, and 24 gave more 
matches than our “control” A, whereas 2, 25, 29, and 28 matched less frequently.  Thus, 
26, 27, 24 and A are fine interface mimics, and chemotype 1 seems to be a truly 
privileged structure.  One reason for this is that 1 incorporates one of the best dipeptide 
fragments analyzed in this work (see explanation in Appendix E). 
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a 
 
b 
 
Figure 5.13  Number of EKO hits with RMSD < 0.35 Å: (a) totals for each chemotype 
irrespective of stereochemistry for each chemotype; and, (b) per stereoisomer for 1, 26, 
27, 24 and A. 
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Our second aim was to compare this data with the bias of the same mimics to adopt 
conformations that mimic secondary structures.  Consideration of the EKOS data in each 
chemotype reveals that the potential of chemotypes 1, 26, 27, 24 and A for secondary 
structure mimicry ranks in exactly that order and this corresponds to the relative number 
of EKO hits (1 >> 26 > 27 > 24 > A) from Figure 5.13.  Chemotypes 24, 26, 27 and A are 
superior minimalist mimics of secondary structures, and 1 is truly exceptional.  
Chemotype 1 is also remarkable because minimalist mimics that display three side-
chains in orientations that align with three consecutive peptidic side-chains are rare; in 
fact, there may be only one well-known example, the Smith-Hirschmann b-strand 
mimics.40,185 
 
The third aim of this study was to evaluate the presence of secondary structures at the 
interfaces where the mimics do overlay well.  If all three side-chains matched in the 
DSSP or STRIDE analyses overlaid on an interface secondary structure then that 
overlay was “binned” accordingly, but if one of them did not then the overlay was 
recorded as being on a “segment”.  Segment overlays predominated for every 
stereoisomer on each of the chemotypes examined, without exception, and there were 
only a few instances for which a bias towards any secondary structure represents over 
30 % of the top hits.  Chemotype LDL-1 was exceptional because it matched sheets 38 
% of the time, and LDL-24 matched the same secondary structures in 31 % of the cases.  
Mimic L-29 matched turns/bends more than 30 % only in the STRIDE analysis, which 
was arguable about the bias towards these structures.  By comparison, mimic LDD-A 
had the next highest frequency, matching sheets with a 15 % hit-rate.  The overall, 
conclusion from analysis of >240,000 interfaces is clear: the particular preferred 
conformers of the minimalist mimics that overlaid well on PPI interfaces did not tend to 
do so on secondary structure interface motifs; they overlaid far more often on interface 
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regions that only partially overlap with a secondary structure motif, or do not overlap with 
one at all. 
 
To summarize, the overwhelming trend in the data collected indicates 1, 26, 27, 24 and 
A overlaid well on secondary structures and on many PPI interfaces.  However, in cases 
where they did overlay on protein-protein interfaces, it was most often not on secondary 
structure motifs.  Thus, this study comes to a pivotal conclusion: secondary structure 
mimicry is only an indirect indicator of interface mimicry.  
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CHAPTER VI 
PROTEIN-PROTEIN INTERFACE MIMICRY BY AN OXAZOLINE 
PIPERIDINE-2,4-DIONE*  
 
6.1 Introduction 
 
Early minimalist mimics of secondary structures inspired by Hamilton’s terphenyls27-
29,41,186,187 featured planar aromatic units that display side-chains in appropriate 
orientations.  More recently this field has turned toward chiral and heterocyclic designs 
that exist in coiled conformations, and/or tend to have superior water solubilities.188  It is 
convenient if mimics of this kind can be produced from amino acid starting materials, 
otherwise it is difficult to incorporate all the different side-chains.  The recently reported 
oligooxopiperazines, for example, are derived from amino acids.38 
 
Even though effective minimalist mimics are more rigid than peptides,52 most populate 
multiple solution conformers that display side-chains in different orientations.53  We 
developed two strategies, EKO58 and EKOS,54 to ascertain how conformations of 
minimalist mimics resemble protein-protein interface regions and ideal secondary 
structures, respectively.  Application of EKO exposes the enormous diversity of PPI 
interfaces: even a small fraction of these could not be accurately represented by all the 
secondary structure mimics reported in the literature to date.  Consequently, there is a 
need to develop and understand new chemotypes for the key issue of interface mimicry.  
                                               
* Reprinted with permission from “Protein-Protein Interface Mimicry by an Oxazoline Piperidine-
2,4-dione”, Li, X.; Taechalertpaisarn, J.; Xin, D.; Burgess, K. Org. Lett., 2015, 17(3), 632-635.  
Copyright 2017 American Chemical Society. 
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This research introduces chiral, nonaromatic, interface mimics 30 composed of 
piperidine-2,4-dione and oxazoline fragments linked by −NHCHR− units (Figure 6.1). 
The objectives of this study were to develop a synthesis of molecules 30 that could 
incorporate many genetically encoded amino acid side chains, to elucidate the bias of 
this scaffold toward all the common ideal secondary structures and to show illustrative 
cases where EKO predicts an excellent match of accessible conformers of 30 on PPI 
interface regions.  
 
 
Figure 6.1  Scaffold 30 is a minimalist mimic of secondary structures with favorable 
predicted properties for cell and oral bioavailability. 
 
6.2 Synthesis of Oxazoline Piperidine-2,4-dione 
 
Scheme 6.1 shows how the oxazoline fragments were prepared from Fmoc-protected or 
Cbz-protected amino acids and amino alcohols.  After a routine coupling to obtain 
molecules 31, the primary alcohol was mesylated and then treated with base to initiate 
oxazoline formation.  Some Fmoc-protected compounds related to 32 have been 
reported prior to this work,110,189 but most of the systems with the side chains indicated in 
Scheme 6.1 have not been prepared before.  The cyclization conditions in Scheme 6.1 
were arrived at after some optimization; they are a modification of those used in 
Sigman’s aminooxazoline syntheses.110  Many other conditions that did not use DMAP or 
relied upon activation via PPh3/CCl4 gave poor product yields.  Removal of the Fmoc 
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protecting group from the protected amines 32 gave the aminooxazolines 33.  A similar 
procedure was used, but with N-Cbz protected Phe, to access the ff chiron.  
 
 
 
 
Scheme 6.1  A Fmoc approach was used to obtain most chirons 33, but Cbz was used 
to access the ff chiron. 
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Having obtained a set of aminooxazolines, we developed two methods (A and B190 in 
Scheme 6.2) to add these to the piperidine-2,4-dione derivatives 34;55,191,192 product was 
obtained using either approach, but the yields differed on a case-by-case basis.  Overall, 
the synthetic route is divergent−convergent because any ketone 34 can be condensed 
with any amine 33.  
 
 
Scheme 6.2  Syntheses of the target compounds 30. 
 
6.3 Evaluation of Simulated Conformers By EKOS 
 
EKOS was used to relate the ensemble of simulated accessible conformers of 30aaa to 
ideal secondary structures.  This process was carried out for all stereoisomers of 30aaa, 
full data are shown in the Appendix F, and two select examples are given here.  Data 
here were calibrated relative to the average RMSDs for all the best fitting conformers for 
a given stereomer.  Thus, for LLL-30aaa, 0.41 Å was the average for the seven best 
fitting conformers on the seven secondary structures indicated.  Conformers LLL-30aaa 
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6.2a).  In our experience, it is much harder to design good helical mimics than ones that 
overlay other motifs.  Our application of EKOS on oligooxopiperazines A38 (all 
stereoisomers, Chapter V) indicate they have accessible conformations that overlay well 
on an ideal a-helix with a RMSD of 0.46 Å (DLL-A, based on the 6 Ca and Cb 
coordinates), and that is better than nearly all of the other mimics of ideal a-helical 
conformations in the literature.54  However, LLL-30aaa appears to be a superior a-helical 
mimic since it can adopt a conformation that matches an ideal a-helix with a RMSD of 
only 0.26 Å.54 
 
Achiral minimalist mimics like terphenyls have only one isomer to compare with ideal 
secondary structures.  Conformations of chiral minimalist mimics, however, are 
stereochemically dependent, and we offer two observations related to this.  First, 
stereochemical changes can significantly alter the conformational bias of many 
minimalist mimics such that one isomer can match extended conformations whereas 
another is more closely overlaid on helical motifs; comparison of LLL-30aaa with LDL-
30aaa illustrates this.  Thus, even though the LLL-isomer is disposed to a-helical 
conformations (blue bar) and can match sheet-turn-sheet motifs almost as well (red bar 
in Figure 6.2a), the LDL-form is bias toward extended motifs and not helical ones (Figure 
6.2b).  The second observation is that correlations of mimic stereochemistries and 
conformational biases are beyond what the human mind can perceive; systematic data 
mining (the EKOS strategy) is essential for this. 
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Figure 6.2  RMSD (Å) for the simulated conformers in the ensemble that best overlay 
the indicated ideal secondary structures, relative to the average values for the best 
conformers overlaid on each of the seven motifs are shown. 
 
Most of the compounds 30 prepared here were not solids, though in one case LLL-30fii 
we were able to collect crystals and obtain an X-ray structure.  That molecule 
crystallized in two similar conformations (differing by RMSD 0.28 Å, based on the 6 Ca 
and Cb coordinates, see Appendix F); but which nevertheless project the side-chains in 
slightly different orientations.  We recently outlined another technique based on 
exploring key orientations that can be used to relate X-ray structures to simulated 
solution conformations: EKOX (see Chapter I).55  Application of EKOX to LLL-30fii in the 
sheet-turn-sheet
better than average worse than average
RMSD Å
anti-parallel β-sheet
parallel β-sheet
β-strand
π-helix
α-helix
310-helix
RMSDavg
0.41 Å
a LLL-30aaa
b LDL-30aaa
sheet-turn-sheet
better than average worse than average
RMSD Å
anti-parallel β-sheet
parallel β-sheet
β-strand
π-helix
α-helix
310-helix
RMSDavg
0.42 Å
  
 
129 
crystal reveals that one conformer fits well on a one strand of a sheet-turn-sheet motif 
(Figure 6.3a), consistent with the predictions in Figure 6.2a (red bars, respectively); this 
is interesting because minimalist strand mimics are rare.  However, neither of the 
conformers in the crystal structure overlaid particularly well on an a-helix; the best one is 
shown in Figure 6.3b. 
 
 
Figure 6.3  One conformer in the crystal structure of LLL-30fii optimally overlays with a 
sheet-turn-sheet motif (a) while neither overlays particularly well on an ideal a-helix (b 
shows the best match). 
 
6.4 Evaluation of Simulated Conformers By EKO and DSSP 
 
When accessible conformers of LLL-30aaa were simulated and data mined on over 
125,000 PPIs in the PDB, 257 “hits” were found.  The applied definition of a hit was that 
i
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the three methyl side-chain coordinates of the mimic overlaid with three interface side-
chains with an RMSD of 0.30 Å or better.  The best overlay occurred on an interface 
sheet-turn-sheet motif as shown in Figure 6.4 (RMSD 0.12 Å).   
 
 
Figure 6.4  An accessible simulated conformer of LLL-30aaa overlays with excellent 
correspondence on the interface region of inosine 5’-monophosphate dehydrogenase 
(pdbid = 4ff0, RMSD = 0.12 Å). 
 
Despite Figure 6.2a, it would be incorrect to assume that simulated accessible 
conformers of LLL-30aaa overlay well on only sheet-turn-sheet and helical motifs at 
interfaces.  The statistical distribution of overlays in each of the featured ideal secondary 
structures is depicted in Figure 6.5.  Consistent with the findings from EKOS based on 
ideal secondary structures (Figure 6.2a), a-helical and sheet-turn-sheet motifs are the 
most common matches for LLL-30aaa at interfaces.  However, similar to the results 
observed in Chapter V, Figure 6.5 shows over 50 % of the overlays occur on nearly 
consecutive amino acids (“single segments” in Figure 6.5) that are not part of any ideal 
secondary structure.  Moreover, the next most common type of overlay was on amino 
acid sequences from different parts of the chain, and which also do not resemble any 
R259
L255
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ideal secondary structure (ie “multiple segments”).  Those two accounted for 87% of the 
“segments”; the same category we used in Chapter V.  Consequently, most of the 
potential for LLL-30aaa in interface mimicry appears not to be correlated with any 
particular secondary structure. 
 
 
Figure 6.5  Statistical distribution of the best 257 overlays of preferred conformers of 
LLL-30aaa (generated using EKO; all RMSD <0.31 Å). 
 
6.5 Conclusion 
 
In this work, we introduced a novel chemotype that has the potential to be a good 
secondary structure mimic.  By incorporating oxopiperazine moiety into the framework, 
this molecule showed a good helical mimic especially LLL-isomer.  This molecule can be 
synthesized by condensing two fragments, oxazoline and oxopiperazine.  Thus, the 
synthetic route is divergent−convergent, in which any pairs of oxazoline and 
oxopiperazine can be condensed to provide a variety of mimic 30.  Some parameters of 
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scaffolds 30 relevant to their use as cellular probes were also considered.  Molecule 
30aaa has a low molecular mass and no amide bonds; these characteristics are 
favorable for cellular- and oral-permeability.  QikProp193,194 was used to predict some 
other key parameters of 30aaa, (Figure 6.1).  Simulated permeability of 30aaa through 
Caco cells is excellent (ie, > 500 nm/s), and the estimated log octanol/water partition 
coefficient, 1.54, is near the mid-point of the optimal range (-2.0 to 6.5).  Moreover, there 
are no rule of five195 violations for this structure.  Obviously, these properties will be 
modulated when side-chains other than methyl are involved, but the scaffold provides a 
good framework for probe development. 
 
Overall, we conclude that compounds based on LLL-30aaa can be excellent helical 
mimics, but they may adopt a range of conformations that overlay well on other 
secondary structures, notably sheet-turn-sheet motifs.  Like many other minimalist 
mimics, however, molecules 30 can overlay on diverse interface regions, most of which 
are not directly related to secondary structures. 
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CHAPTER VII 
CONCLUSION 
 
Previous projects led by a former graduate student in Dr. Burgess group, Dr. KO, were 
to develop the Exploring Key Orientations (EKO) to find best matches between three Ca-
Cb side-chain vectors of semi-rigid small molecules and the side-chain vectors at PPI 
interfaces.  This approach was validated experimentally by discovering novel small 
molecules disrupting HIV-1 dimerization, and later by small molecules perturbing 
antithrombin oligomerization conducted by Dr. Xin.  However, only these two examples 
are not adequate to claim EKO can be used in general.  Consequently, my projects were 
not only to synthesize novel small molecules to disrupt medicinally relevant PPIs, but 
also to help validate EKO as a tool to identify PPI inhibitors.   
 
My initial project was to synthesize hydantoin-oxazoline scaffold; this structure is 
fascinating insofar as its conformers overlay well on many types of ideal secondary 
structures, and on PPI interfaces that may have distorted structure motifs.  Specifically, 
we coined this kind of molecule as “universal peptidomimetics”.  Moreover, this 
chemotype has a contiguous side-chains characteristic and a few numbers of degrees of 
freedom, which are rarely found in other peptidomimetics disrupting PPIs.  Apart from 
hydantoin-oxazoline scaffold, other similar derivatives, triazole-oxazole and triazole-
oxazoline, were developed, and those three chemotypes were tested their inhibitions 
against Nef•MHC-I•AP1 and NEDD8•NAE interactions (Chapter II).  Although, the 
outcomes did not reach our expectations, we learned a couple criteria to help increase 
success rate of disrupting PPI interactions; (i) chemotypes should be easily accessible in 
order to accumulate enough compounds within a reasonable time for biological tests, (ii) 
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EKO does not determine binding energies or steric clashes between proteins and 
ligands, so other calculation methods are necessary to enhance the quality of 
predictions, (iii) target selection is critical because large PPI interface areas and tight 
complexes are difficult to inhibit interactions.  
 
Based on experiences from Nef•MHC-I•AP1 and NEDD8•NAE projects, we moved to 
another target that was fit into our criteria as described above.  First, we chose a new 
PPI target, PCSK9•LDLR, which has relatively small PPI interface area and weak 
binding affinity.  Additionally, disrupting this complex has been validated as a target for 
medicinal chemistry by two FDA approved antibody drugs with no serious side effects.  
Thus, this is a suitable target for peptidomimetics disrupting PPI.  Meanwhile, we 
developed a new chemotype, hydantoin-piperazine, that can be prepared via solid-
phase synthesis, i.e. this chemotype is accessible by parallel syntheses to obtain a small 
library within short time.  A key feature within this chemotype is a new substructure “pip-
acids”, in which we introduced piperazine scaffolds onto amino acids.  The benefits 
behind these pip-acids are to increase rigidity of molecule relative to oligopeptides, and 
to add a piperazine motif found in many pharmaceutical drugs.  However, the first-
generation hydantoin-piperazine inhibitors, which compromised criteria (i) and (iii), did 
not show significant inhibitions in the first trial, so we used a docking program “Glide” to 
refine our structures (criteria ii).  By virtually adding amino acids at C-terminus, we 
obtained a second-generation hydantoin-piperazine library, in which showed 
improvements of docking scores comparing to the first generation.  Results from 
biological assays showed half of these second-generation inhibitors could disrupt 
PCSK9•LDLR interaction.  The lead compound, LDLL-16dlnr, significantly increased 
cLDL uptake in the hepatocytes, and had measurable binding affinity toward PCSK9.  
This is a proof of concept that we successfully improve inhibitory activities by combining 
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EKO and Glide routines, and this strategy had a hit rate (~50%) higher than conventional 
high-throughput screening. 
 
PCSK9•LDLR project is now starting the second phase to further improve efficiencies 
and bioavailability of lead compounds by a postdoctoral researcher in Dr. Burgess 
group.  Our plan is to utilize Glide and structure-activity relationship (SAR) to make 
compounds less peptidic while preserving key functional groups.  Consequently, I expect 
new scaffolds that can surpass LDLL-16dlnr in term of better cLDL uptake and ADME 
properties.  Besides, pip-acids are valuable as a novel building block for synthesizing 
other small molecules.  There are still opportunities to use them for many applications; 
this is a main project of another graduate student in Dr. Burgess group.   
 
At this stage, we intensively used EKOS to roughly determine how good chemotypes 
adopt their conformations to resemble ideal secondary structures, and EKO to search for 
the best overlays at PPI interfaces.  However, the relationship of results between EKOS 
and EKO has never been explored systematically.  Our study in Chapter V suggested 
that a good secondary structure mimicry tends to overlay more frequently on PPI 
interfaces within a given RMSD cutoff than a chemotype that does not match well on 
ideal secondary structure motifs.  Even though a good secondary structure mimicry had 
several hits on PPI interfaces, they mostly matched on non-ideal structures.  Thus, 
secondary structure mimicry is only an indirect indicator for interface mimicry.  Moreover, 
“chain periodicity” of chemotype is important for designing good secondary structure 
mimicry.  Excellent secondary structure matching usually comes from a chemotype with 
Ca-Ca distance close to the oligopeptide found in ideal secondary structures or at 
protein interfaces.  Other criteria such as rigid-core structure, minimum number of 
degrees of freedom, and bearing three side-chain residues are important to minimize 
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entropy loss and increase specificity when chemotypes dock on protein targets.  Again, 
the results from EKO should be further refined by docking programs, e.g. Glide. 
 
Another separate project in Chapter VI, I incorporated with Dr. Li, a visiting postdoctoral 
researcher in Dr. Burgess group, to prepare and analyze oxazoline-piperidine-2,4-dione 
minimalist mimics.  These compounds could be synthesized from two separate 
fragments, and then condensed them together; i.e. the synthetic route is divergent-
convergent.  Although this synthesis strategy may not be comparable with solid-phase 
syntheses in term of time expenditure, condensing two set of separate fragments yields 
a variety of different products.  Evaluation of preferred conformers showed this mimic, 
especially LLL-isomer, matched well on helical motif.  Unfortunately, this compound has 
not been tested with any protein targets.  I expect this new minimalist mimic can inhibit 
some interesting PPI targets.   
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APPENDIX A 
GENERAL EXPERIMENTAL PROCEDURES 
General Methods 
All reactions were carried out under an inert atmosphere (nitrogen, or argon where 
stated) with dry solvents under anhydrous conditions.  Glassware for anhydrous 
reactions was dried in an oven at 140 oC for minimum 6 h prior to use.  Dry solvents 
were obtained by passing the previously degassed solvents through activated alumina 
columns.  Reagents were purchased at a high commercial quality (typically 97 % or 
higher) and used without further purification, unless otherwise stated.  High field NMR 
spectra were recorded with Bruker Avance III at 400 MHz for 1H, and 100 MHz for 13C 
and were calibrated using residual non-deuterated solvent as an internal reference 
(CDCl3: 1H NMR = 7.27, 13C NMR = 77.0, MeOD: 1H NMR = 3.30, 13C NMR = 49.0, 
DMSO-d6: 1H NMR = 2.50, 13C NMR = 39.5).  Flash chromatography was performed 
using silica gel (230-600 mesh).  Analytical thin layer chromatography (TLC) was carried 
out on Merck silica gel plates with QF 254 indicator and visualized by UV, ceric 
ammonium molybdate, ninhydrin, para-methoxybenzaldehyde and/or potassium 
permanganate stains. The following abbreviations were used to explain the multiplicities: 
s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, dd = double doublet, dt = 
double triplet, dq = double quartet, m = multiplet, br = broad.  Electrospray ionization 
mass spectrometry (ESI-MS) data were collected on triple-stage quadrupole instrument 
in a positive mode.  LC-MS analyses were collected from Agilent 1260 Infinity 
Quaternary LC and Agilent 6120 Quadrupole LC/MS modules using Poroshell 120 EC-
C18 2.7 µM (4.6 x 50 mm) column in 5-95% MeCN/water gradient with 0.1% formic acid 
153 
over 10 minutes.  Microwave irradiation for solid-phase syntheses was done using CEM 
MARS 5® system.  All statistical analyses were carried out by Graphpad Prism version 
6.0 (Graphpad Software).  Student’s t-test was used to determine significant differences 
between compounds and negative control.  Results are represented as means ± SD.   
General Procedure For X-Ray Structure Determination 
A Leica MZ 75 microscope was used to identify a suitable colorless multi-faceted crystal 
with very well-defined faces with dimensions (max, intermediate, and min) 0.2 mm x 0.02 
mm x 0.02 mm from a representative sample of crystals of the same habit.  The crystal 
mounted on a nylon loop was then placed in a cold nitrogen stream maintained at 110 K.  
A BRUKER D8-GADDS X-ray (three-circle) diffractometer was employed for crystal 
screening, unit cell determination, and data collection. The goniometer was controlled 
using the FRAMBO software suite1.  The sample was optically centered with the aid of a 
video camera such that no translations were observed as the crystal was rotated through 
all positions.  The detector was set at 6.0 cm from the crystal sample (MWPC Hi-Star 
Detector, 512x512 pixel).  The X-ray radiation employed was generated from a Cu 
sealed X-ray tube (Ka = 1.54184 Å with a potential of 40 kV and a current of 40 mA) 
fitted with a graphite monochromator in the parallel mode (175 mm collimator with 0.5 
mm mono-capillary optics). 
The rotation exposure indicated acceptable crystal quality and the unit cell determination 
was undertaken.  2100 data frames were taken at widths of 0.5° with an exposure time 
of 10 seconds.  Over 6000 reflections were centered and their positions were 
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determined.  These reflections were used in the auto-indexing procedure to determine 
the unit cell.  A suitable cell was found and refined by nonlinear least squares and 
Bravais lattice procedures.  No super-cell or erroneous reflections were observed. 
After careful examination of the unit cell, a standard data collection procedure was 
initiated.  This procedure consists of collection of one hemisphere of data collected using 
omega scans, involving the collection 0.5° frames at fixed angles for f, 2q, and c (2q = -
28°, c = 54.73°, 2q = -90°, c = 54.73°), while varying omega.  Addition data frames were 
collected to complete the data set and for absolute structure determination.  Each frame 
was exposed for 5 sec.  The total data collection was performed for duration of 
approximately 24 hours at 110K.  No significant intensity fluctuations of equivalent 
reflections were observed. 
Data Reduction, Structure Solution, and Refinement 
Integrated intensity information for each reflection was obtained by reduction of the data 
frames with the program SAINT.2  The integration method employed a three dimensional 
profiling algorithm and all data were corrected for Lorentz and polarization factors, as 
well as for crystal decay effects.  Finally, the data was merged and scaled to produce a 
suitable data set.  The absorption correction program SADABS3 was employed to correct 
the data for absorption effects.  A solution was obtained readily using SHELXTL.4 All 
non-hydrogen atoms were refined with anisotropic thermal parameters.  The hydrogen 
atoms bound to carbon were placed in idealized positions [C–H = 0.96 Å, Uiso(H) = 1.2 x 
Uiso(C)].  The structure was refined (weighted least squares refinement on F2) to 
convergence.4  X-seed was employed for the final data presentation and structure plots.5 
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1 FRAMBO “Program for Data Collection on Area Detectors” BRUKER AXS Inc., 5465 East Cheryl Parkway, 
Madison, WI 53711-5373 USA 
2  SAINT, “Program for Data Reduction from Area Detectors” ” BRUKER AXS Inc., 5465 East Cheryl 
Parkway, Madison, WI 53711-5373 USA 
3 SADABS, Sheldrick, G.M. “Program for Absorption Correction of Area Detector Frames”, BRUKER AXS 
Inc., 5465 East Cheryl Parkway, Madison, WI 53711-5373 USA 
4 SHELXTL, Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122 
5 OLEX2,  Dolomanov, O.V., Bourhis, L.L., Gildea,  R.J., Howard, J.A.K. & Puschmann, H. (2009),  J. Appl. 
Cryst. 42, 339-341. 
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APPENDIX B 
EXPERIMENTAL PROCEDURES FOR CHAPTER II 
Table B.1  Matching results of compound 1 on Nef•MHC-I•AP1 complex. 
interface 
compound 
configuration 
sequence RMSD mimic on 
MHC-I•AP1 
LDL W408-P407-L406 0.08 AP1 
DLD L406-P407-W408 0.19 AP1 
LLD L406-P407-W408 0.23 AP1 
LDD V409-W408-P407 0.31 AP1 
LDD W408-P407-L406 0.33 AP1 
DDD W408-P407-L406 0.34 AP1 
LLL L406-P407-W408 0.35 AP1 
Nef•AP1 
LLD F68-P69-V70 0.22 Nef 
DLL E64-E65-V66 0.23 Nef 
DDL V66-E65-E64 0.26 Nef 
DDD P72-T71-V70 0.26 Nef 
LDL V70-P69-F68 0.29 Nef 
DLL V70-T71-P72 0.30 Nef 
DLL F301-K302-R303 0.31 AP1 
DDD K302-F301-Q300 0.31 AP1 
LDD V66-E65-E64 0.32 Nef 
DLD F301-K302-R303 0.32 AP1 
LLD E64-E65-V66 0.33 Nef 
DDL R303-K302-F301 0.34 AP1 
LDD V70-P69-F68 0.34 Nef 
LLL V70-T71-P72 0.35 Nef 
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Table B.1  Continued. 
MHC-I 
LLL D327-S328-A329 0.14 
DLL D327-S328-A329 0.20 
DDD A329-S328-D327 0.20 
LDD S321-Y320-S319 0.20 
LLD S321-Q322-A323 0.21 
DDL A329-S328-D327 0.21 
LDL S328-D327-S326 0.22 
LDD A323-Q322-S321 0.23 
LLD S319-Y320-S321 0.24 
DLD S326-D327-S328 0.26 
DLD D327-S328-A329 0.30 
DDD S328-D327-S326 0.33 
DLL Y320-S321-Q322 0.34 
LDL A329-S328-D327 0.34 
LLD D327-S328-A329 0.35 
DLD Q322-A323-A324 0.35 
Table B.2.  Matching results of compound 1 and 3 on C-terminal NEDD8
Compound 
compound 
configuration 
sequence RMSD 
1 
LDL L73-A72-L71 0.13 
LLD L71-A72-L73 0.22 
DLD L71-A72-L73 0.26 
3 DL L73-A72-L71 0.33 
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Conditions to Cyclize Oxazolines 
 
 
 
Figure B.1  a Successful oxazoline cyclization was performed using methanesulfonyl 
chloride in the 2-steps manner.  b Condition that involved PPh3 and CCl4 led to the side-
chain dehydrogenation at hydantoin ring.  c Using methanesulfonyl chloride in the 1-step 
method led to the chlorination instead of cyclization.  
(i) MsCl, DMAP, Et3N
 CH2Cl2, 0 ºC, 1 h
(ii) iPr2NEt, DMAP, pyridine
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General Procedure for the Preparation of Dipeptide 7 
A representative synthesis of the LD-7la is described as follows:  Boc-L-leucine (2.47 g, 
9.9 mmol) and HOBt (1.47 g, 10.9 mmol) were dissolved in dichloromethane (100 mL) at 
0 ºC.  EDCI (2.09 g, 10.9 mmol) was added subsequently and the solution was stirred at 
0 ºC for 30 min.  N-methyl morpholine (3.27 mL, 29.7 mmol) and D-alanine benzyl ester 
(1.77 g, 9.9 mmol) were added.  The reaction was stirred at ambient temperature for 12 
h under Ar.  The resulting solution was washed with 10 % citric acid, saturated NaHCO3 
solution and brine.  The organic layer was dried over MgSO4 and filtered.  The solvent 
was removed under vacuum to obtain 3.80 g (98 %) of white solid, which was used in 
next step without further purification. 
CO2HBocHN
R1
CO2PgH2N
R2
EDCI, HOBt, NMM
CH2Cl2, 25 ºC, 12 h
BocHN N
H
O
CO2Pg
R1
R2
LL-7ff, 87%; DL-7la, 88%
LD-7la, 99%; LL-7la, 91%
LD-7vf, 90%
7
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tert-Butyl (tert-butoxycarbonyl)-L-phenylalanyl-L-phenylalaninate (LL-7ff) 
Data for LL-7ff. White solid, 87 % yield.  1H NMR (400 MHz, CDCl3) δ 7.31-7.05 (m, 
8H), 7.06 (m, 2H), 6.30 (br, 1H), 4.92 (br, 1H), 4.65 (q, J = 6.4 Hz, 1H), 4.33 (br, 1H), 
3.05 (m, 4H), 1.41 (s, 9H), 1.37 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 170.8, 170.2, 
136.8, 136.3, 129.7, 129.6, 128.9, 128.5, 127.2, 127.1, 82.5, 53.9, 38.4, 28.5, 28.1; MS 
(ESI) m/z calcd for C27H36N2O5Na+ 491.25; found 491.25 (M+Na)+. 
1H NMR spectrum: 
13C NMR spectrum: 
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Benzyl (tert-butoxycarbonyl)-D-leucyl-L-alaninate (DL-7la) 
 
Data for DL-7la.  White solid, 88 % yield.  1H NMR (400 MHz, CDCl3) δ 7.36 (m, 5H), 
6.67 (br, 1H), 5.18 (dd, J = 22.2, 12.3 Hz, 2H), 4.79 (br, 1H), 4.61 (quint, J = 7.1 Hz, 1H), 
4.13 (br, 1H), 1.70 (m, 2H), 1.45 (s, 9H), 1.44 (m, 1H), 1.42 (d, J = 7.1 Hz, 3H), 0.95 (d, J 
= 4.2 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 172.8, 172.3, 156.0, 135.6, 128.8, 128.6, 
128.3, 80.4, 67.3, 53.2, 48.3, 41.4, 28.5, 25.0, 23.2, 22.1, 18.4; MS (ESI) m/z calcd for 
C21H32N2O5Na+ 415.22; found 415.22 (M+Na)+.  
1H NMR spectrum:  
 
13C NMR spectrum: 
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Benzyl (tert-butoxycarbonyl)-L-leucyl-D-alaninate (LD-7la) 
Data for LD-7la. White solid, 99 % yield.  1H NMR (400 MHz, CDCl3) δ 7.38-7.35 (m, 
5H), 6.66 (br, 1H), 5.18 (dd, J = 22.2, 12.3 Hz, 2H), 4.78 (br, 1H), 4.61 (quint, J = 7.1 Hz, 
1H), 4.13 (br, 1H), 1.69 (m, 2H), 1.45 (s, 9H), 1.44 (m, 1H), 1.42 (d, J = 7.1 Hz, 3H), 0.95 
(d, J = 4.2 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 172.8, 172.3, 156.0, 135.6, 128.8, 
128.6, 128.3, 80.4, 67.3, 53.2, 48.3, 41.4, 28.5, 25.0, 23.2, 22.1, 18.5; MS (ESI) m/z 
calcd for C21H32N2O5Na+ 415.22; found 415.22 (M+Na)+. 
1H NMR spectrum: 
 
13C NMR spectrum: 
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Benzyl (tert-butoxycarbonyl)-L-leucyl-L-alaninate (LL-7la) 
 
Data for LL-7la. White solid, 91 % yield.  1H NMR (400 MHz, CDCl3) δ 7.38-7.35 (m, 
5H), 6.52 (br, 1H), 5.18 (dd, J = 22.2, 12.3 Hz, 2H), 4.84 (br, 1H), 4.63 (quint, J = 7.1 Hz, 
1H), 4.10 (br, 1H), 1.70-1.62 (m, 2H), 1.58 (s, 1H), 1.45 (s, 9H), 1.44 (m, 1H), 1.43 (d, J 
= 7.1 Hz, 3H), 0.94 (d, J = 4.2 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 172.7, 172.4, 
155.9, 135.6, 128.8, 128.6, 128.3, 80.2, 67.3, 53.2, 48.3, 41.6, 28.5, 24.9, 23.1, 22.1, 
18.4; MS (ESI) m/z calcd for C21H32N2O5Li+ 399.25; found 399.25 (M+Li)+ 
1H NMR spectrum: 
 
13C NMR spectrum: 
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tert-Butyl (tert-butoxycarbonyl)-L-valyl-D-phenylalaninate (LD-7vf) 
 
Data for LD-7vf. White solid, 90 % yield.  1H NMR (400 MHz, CDCl3) δ 7.29-7.16 (m, 
5H), 6.39 (br, 1H), 4.99 (br, 1H), 4.76 (dd, J = 13.9, 6.4 Hz, 1H), 3.97 (br 1H), 3.08 (d, J 
= 6.2 Hz, 2H), 2.1 (m, 1H), 1.44 (s, 9H), 1.40 (s, 9H), 0.90 (d, J = 6.7 Hz, 3H), 0.82 (d, J 
= 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.2, 170.6, 155.9, 136.3, 129.6, 128.6, 
127.2, 82.5, 80.0, 59.9, 53.7, 38.5, 31.0, 28.5, 28.1, 19.4, 17.4; MS (ESI) m/z calcd for 
C23H36N2O5Na+ 443.25; found 443.26 (M+Na)+. 
1H NMR spectrum: 
 
13C NMR spectrum: 
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General Procedure of Boc Deprotection 
 
Method A:  This method was used for LL-7ff and LD-7vf.  The solution of 4 M HCl in 
dioxane (10 mL) was cooled down to 0 ºC in ice bath under Ar.  Then, this solution was 
transferred to pre-cool flask containing Boc-dipeptide (0.50 mmol).  The solution was 
stirred at ambient temperature for additional 30 min until starting material was 
disappeared as monitored by TLC.  The solvent was removed under vacuum.  The crude 
oil was triturated with ether and filtered to obtain the product as a salt.     
 
Method B:  This method was used for DL-7la, LD-7la and LL-7la.  Boc-dipeptide (1 
mmol) was dissolved in 3 mL of dichloromethane, then TFA (1 mL) was added and the 
solution was stirred for 1 h.  The solution was completely evaporated by rotavap, 
redissolved in dichloromethane and evaporated for at least 3 times to remove excess 
TFA.  The crude oil was used in the next step without further purification.   
 
General Procedure for the Preparation of C-protected Hydantoin 8 
 
A representative synthesis of the LL-8ff is described as follows: Boc-deprotected LL-7ff 
(1.35 g, 3 mmol), NaHCO3 (1.26 g, 15 mmol) were dissolved in acetonitrile (48 mL). 
Then, p-nitrophenyl chloroformate (0.79 g, 3.9 mmol) was added.  The cloudy solution 
was stirred at room temperature for 3 h under Ar.  Et3N (0.54 mL) was added, and the 
BocHN N
H
O
CO2Pg
R1
R2
(i) deprotect
(ii) 4-NO2C6H4OCOCl 
NaHCO3
MeCN, 25 ºC, 3 h
(iii) Et3N, 25 ºC, 12 h
HN
N
O
O R2
CO2PgR
1
LL-8ff, 72%; DL-8la, 44%
LD-8la, 39%; LL-8la, 58%
LD-8vf, 57%
7 8
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yellow solution was stirred for additional 12 h.  After removal of acetonitrile under 
vacuum, the crude was dissolved in ethyl acetate, washed 5 times with 5% K2CO3, brine 
and dried over MgSO4.  The organic solution was removed to obtain the crude oil.  The 
residue was purified by column chromatography on silica gel with hexanes-ethyl acetate 
(3:1) to afford the product (0.85 g, 72%) as pale yellow solid.   
 
tert-Butyl (S)-2-((S)-4-benzyl-2,5-dioxoimidazolidin-1-yl)-3-phenylpropanoate (LL-
8ff) 
 
Data for LL-8ff. pale yellow solid, 72 % yield.  1H NMR (400 MHz, CDCl3) δ 7.33-7.11 
(m, 10H), 5.39 (br, 1H), 4.88 (dd, J = 10.1, 6.9 Hz, 1H), 4.04 (dd, J = 10.7, 3.3 Hz, 1H), 
3.46-3.43 (m, 2H), 3.12 (dd, J = 13.9, 3.5 Hz, 1H), 2.22 (dd, J = 13.8, 10.9 Hz, 1H), 1.49 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 172.6, 167.6, 156.2, 137.2, 136.1, 129.3, 129.2, 
129.1, 128.7, 127.5, 127.0, 82.9, 58.3, 54.1, 38.6, 34.4, 28.1; HRMS (ESI) m/z calcd for 
C23H36N2O4Na+ 417.1785; found 417.1807 (M+Na)+ 
1H NMR spectrum: 
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13C NMR spectrum: 
Benzyl (S)-2-((R)-4-isobutyl-2,5-dioxoimidazolidin-1-yl)propanoate (DL-8la) 
Data for DL-8la. White solid, 44 % yield.  1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 
5H), 5.38 (br 1H), 5.22-5.14 (m, 2H), 4.82 (q, J = 7.4, 1H), 4.05 (m, 1H), 1.80 (m, 2H), 
1.67 (d, J = 7.4, 3H), 1.50-1.46 (m, 1H), 0.95 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 
173.9, 169.5, 156.9, 135.5, 128.8, 128.6, 128.3, 67.7, 56.0, 48.3, 41.0, 25.2, 23.2, 21.8, 
14.8; HRMS (ESI) m/z calcd for C17H23N2O4+ 319.1652; found 319.1646 (M+H)+ 
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
Benzyl (R)-2-((S)-4-isobutyl-2,5-dioxoimidazolidin-1-yl)propanoate (LD-8la) 
 
Data for LD-8la. White solid, 39 % yield.  1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 
5H), 5.38 (br 1H), 5.22-5.14 (m, 2H), 4.82 (q, J = 7.4, 1H), 4.05 (m, 1H), 1.80 (m, 2H), 
1.67 (d, J = 7.4, 3H), 1.54-1.46 (m, 1H), 0.95 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 
173.7, 169.3, 156.7, 135.3, 128.5, 128.4, 128.1, 67.5, 55.8, 48.1, 40.8, 25.0, 23.0, 21.6, 
14.6; HRMS (ESI) m/z calcd for C17H22N2O4Na+ 341.1472; found 341.1491 (M+Na)+ 
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
[ppm] 8  6  4  2 
[r
el
]
 0
 
 5
 
 1
0 
 1
5 
 2
0 
 2
5 
7.
38
7.
32
5.
38
5.
18
4.
84
4.
83
4.
81
4.
79
4.
06
4.
05
4.
04
4.
03
1.
80
1.
73
1.
73
1.
68
1.
66
1.
54
1.
51
1.
48
1.
46
1.
43
1.
27
1.
12
0.
96
0.
94
5.
0
0.
9
2.
0
1.
0
1.
0
2.
0
3.
0
2.
1
1.
2
6.
1
JT2014_026  1  1  /opt/data/jtaechal
[ppm] 150  100  50 
[r
el
]
 0
 
 1
0 
 2
0 
 3
0 
 4
0 
17
3.
70
53
16
9.
29
66
15
6.
71
75
13
5.
27
07
12
8.
53
75
12
8.
35
46
12
8.
08
69
67
.5
21
3
55
.7
56
3
48
.0
58
3
40
.7
71
0
25
.0
18
2
22
.9
62
2
21
.5
97
8
14
.5
91
4
JT2014_026  2  1  /opt/data/jtaechal
170 
Benzyl (S)-2-((S)-4-isobutyl-2,5-dioxoimidazolidin-1-yl)propanoate (LL-8la) 
Data for LL-8la. White solid, 39 % yield.  1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 
5H), 5.85 (br, 1H), 5.17 (dd, J = 38.1, 12.3 Hz, 2H), 4.79 (q, J = 7.3 Hz, 1H), 4.06-4.01 
(m, 1H), 1.81-1.69 (m, 2H), 1.67 (d, J = 7.4 Hz, 3H), 1.50-1.36 (m, 1H), 0.95 (m, 6H); 13C 
NMR (100 MHz, CDCl3) δ 174.0, 169.5, 157.0, 135.5, 128.8, 128.6, 128.5, 67.8, 55.9, 
48.3, 41.1, 25.3, 23.3, 21.7, 14.9; HRMS (ESI) m/z calcd for C17H23N2O4+ 319.1652; 
found 319.1642 (M+H)+
1H NMR spectrum: 
13C NMR spectrum: 
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tert-Butyl (R)-2-((S)-4-isopropyl-2,5-dioxoimidazolidin-1-yl)-3-phenylpropanoate 
(LD-8vf) 
 
Data for LD-8vf.  solid, 57 % yield.  1H NMR (400 MHz, CDCl3) δ 7.29-7.16 (m, 5H), 5.96 
(br, 1H), 4.89 (dd, J = 11.3, 5.5 Hz, 1H), 3.72 (dd, J = 3.8, 1.3 Hz, 1H), 3.5-3.39 (m, 2H), 
2.16-2.02 (m, 1H), 1.47 (s, 9H), 0.95 (d, J = 7.0 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 172.6, 167.6, 157.1, 137.0, 128.9, 128.4, 126.7, 82.7, 62.0, 
53.8, 34.2, 30.0, 27.9, 18.7, 16.0; HRMS (ESI) m/z calcd for C19H26N2O4Na+ 369.1785; 
found 369.1814 (M+Na)+ 
1H NMR spectrum: 
 
13C NMR spectrum: 
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Procedure for the Preparation of Scaffold 9 
Method A: (tert-butyl ester protecting group): A representative synthesis of the LLL-9fff 
is described as follows: Compound LL-8ff (0.2 g, 0.51 mmol) was dissolved in 
dichloromethane (4 mL).  TFA (1.3 mL) was added and the solution was stirred at room 
temperature for 3 h.  The solvent was removed under vacuum, and then repeated 
dissolve/evaporate cycles with dichloromethane several times to remove excess TFA. 
The crude oil was used for the next step without further purification.  The C-deprotected 
hydantoin, HOBt (76 mg, 0.56 mmol) were dissolved in dichloromethane (5 mL) in an ice 
bath.  EDCI (108 mg, 0.56 mmol) was added and the solution was stirred for 30 min at 0 
ºC.  N-methyl morpholine (0.17 mL, 1.53 mmol) and L-phenylalaninol (77 mg, 0.51 
mmol) were added subsequently.  The solution was stirred at ambient temperature for 
12 h under Ar.  Organic layer was washed with 1 N HCl solution, saturated NaHCO3, 
brine and dried over MgSO4 successively.  The solution was removed under reduced 
pressure to obtain the product as white solid (199 mg, 83 %). 
Method B: (benzyl ester protecting group): A representative synthesis of the LLD-9lal is 
described as follows: Compound LL-8la (0.47 g, 1.49 mmol) and 10 % Pd/C (0.15 g, 
0.15 mmol) were dissolved in dried methanol (20 mL) under Ar.  Then, H2 was purged 
LLD-ffs', 68%;  LLL-fff, 83% 
DLD-lal, 88%;  LDL-lal, 63%
LLD-lal, 58%;  LDL-vfc', 85%
HN
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H2N OH
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NMM, CH2Cl2
25 ºC, 12 h
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into the flask for 5 min and the solution was stirred under H2 atmosphere for 12 h.  The 
solution was filtered through celite.  The clear solution was removed under vacuum to 
obtain the oil product (0.34 g, 100 %), which was used in the next step without further 
purification.  The C-deprotected hydantoin (0.34 g, 1.48 mmol), HOBt (0.26 g, 1.93 
mmol) were dissolved in dichloromethane (20 mL) in an ice bath.  EDCI (0.37 g, 1.93 
mmol) was added and the solution was stirred for 30 min at 0 ºC.  N-methyl morpholine 
(0.49 mL, 4.45 mmol) and D-leucinol (0.22 g, 1.93 mmol) were added subsequently. 
The solution was stirred at ambient temperature for 12 h under Ar.  Organic layer was 
washed with 1 N HCl solution, saturated NaHCO3, brine and dried over MgSO4 
successively.  The solution was removed under reduced pressure to obtain white solid 
(0.28 g, 58 %). 
174 
 (S)-2-((S)-4-Benzyl-2,5-dioxoimidazolidin-1-yl)-N-((S)-1-(benzyloxy)-3-
hydroxypropan-2-yl)-3-phenylpropanamide (LLD-9ffs’) 
Data for LLD-9ffs’.  Solid, 68 % yield.  1H NMR (400 MHz, CDCl3) δ 7.37-7.18 (m, 13 H), 
7.10-7.01 (m, 2H), 6.86 (d, J = 7.6 Hz, 1H), 5.11 (s, 1H), 4.97 (dd, J = 10.7, 6.5 Hz, 1H), 
4.51 (s, 2H), 4.18-4.07 (m, 2H), 4.03-3.93 (m, 1H), 3.85-3.69 (m, 2H), 3.69-3.58 (m, 2H), 
3.52-3.37 (m, 2H), 3.00 (dd, J = 13.8, 3.6 Hz, 1H), 1.99 (dd, J = 13.9, 10.8 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 173.1, 168.8, 156.6, 137.8, 136.7, 135.9, 129.4, 129.2, 129.2, 
128.9, 128.7, 128.1, 127.9, 127.6, 127.3, 73.6, 70.0, 63.2, 58.4, 55.9, 51.4, 38.2, 34.9; 
HRMS (ESI) m/z calcd for C29H30N3O5- 500.2191; found 500.2174 (M-H)- 
1H NMR spectrum: 
13C NMR spectrum: 
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(S)-2-((S)-4-Benzyl-2,5-dioxoimidazolidin-1-yl)-N-((S)-1-hydroxy-3-phenylpropan-2-
yl)-3-phenylpropanamide (LLL-9fff) 
Data for LLL-9fff.  Solid, 83 % yield.  1H NMR (400 MHz, CDCl3) δ 7.37-7.15 (m, 14H), 
7.08 (m, 2H), 6.79 (d, J = 7.2 Hz, 1H), 5.05 (s, 1H), 4.90 (dd, J = 10.5, 6.8 Hz, 1H), 4.22-
4.10 (m, 1H), 4.05-3.98 (m, 1H), 3.71 (dd, J = 11.3, 3.6 Hz, 1H), 3.61 (dd, J = 11.2, 5.2 
Hz, 1H), 3.35-3.23 (m, 2H), 2.99 (dd, J = 13.8, 3.6 Hz, 1H), 2.92-2.86 (m, 2H), 1.95 (dd, 
J = 13.8, 10.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 173.1, 169.0, 156.8, 137.9, 136.5, 
135.8, 129.5, 129.4, 129.2, 129.1, 128.9, 128.8, 127.6, 127.4, 126.8, 63.9, 58.4, 56.4, 
53.8, 38.1, 37.0, 34.9; HRMS (ESI) m/z calcd for C28H28N3O4- 470.2085; found 470.2062 
(M-H)-
1H NMR spectrum: 
13C NMR spectrum:
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176 
 (S)-N-((R)-1-Hydroxy-4-methylpentan-2-yl)-2-((R)-4-isobutyl-2,5-dioxoimidazolidin-
1-yl)propanamide (DLD-9lal) 
Data for DLD-9lal. White solid, 88 % yield.  1H NMR (400 MHz, CDCl3) δ 6.10 (br, 1H), 
5.72 (br, 1H), 4.72 (q, J = 7.3 Hz, 1H), 4.11-3.98 (m, 2H), 3.74 (dd, J = 11.2, 3.5 Hz, 1H), 
3.52 (dd, J = 11.3, 5.5 Hz, 1H), 1.88-1.73 (m, 2H), 1.70-1.49 (m, 6H), 1.49-1.30 (m, 2H), 
0.99 (t, J = 6.6 Hz, 6H), 0.94 (dd, J = 6.6, 2.9 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 
174.8, 169.7, 157.4, 65.2, 56.0, 50.6, 50.1, 41.1, 40.2, 25.2, 25.1, 23.3, 23.2, 22.4, 21.8, 
15.1; HRMS (ESI) m/z calcd for C16H30N3O4+ 328.2231; found 328.2253 (M+H)+ 
1H NMR spectrum: 
13C NMR spectrum: 
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R)-N-((S)-1-Hydroxy-4-methylpentan-2-yl)-2-((S)-4-isobutyl-2,5-dioxoimidazolidin-1-
yl)propanamide (LDL-9lal) 
 
Data for LDL-9lal. White solid, 63 % yield.  1H NMR (400 MHz, CDCl3) δ 6.10 (br, 1H), 
5.72 (br, 1H), 4.72 (q, J = 7.3 Hz, 1H), 4.11-3.98 (m, 2H), 3.74 (dd, J = 11.3, 3.3 Hz, 1H), 
3.52 (dd, J = 11.3, 5.5 Hz, 1H), 1.88-1.76 (m, 2H), 1.66-1.58 (m, 5H), 1.49-1.30 (m, 3H), 
0.99 (t, J = 6.6 Hz, 6H), 0.94 (dd, J = 6.6, 2.9 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 
175.0, 169.7, 157.6, 65.0, 55.9, 50.5, 50.0, 41.1, 40.2, 25.2, 25.1, 23.3, 23.2, 22.4, 21.8, 
15.0; HRMS (ESI) m/z calcd for C16H30N3O4+ 328.2231; found 328.2228 (M+H)+ 
 
1H NMR spectrum: 
 
13C NMR spectrum: 
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 (S)-N-((R)-1-Hydroxy-4-methylpentan-2-yl)-2-((S)-4-isobutyl-2,5-dioxoimidazolidin-
1-yl)propanamide (LLD-9lal) 
 
Data for LLD-9lal. White solid, 58 % yield.  1H NMR (400 MHz, CDCl3) δ 6.05 (br, 1H), 
5.71 (br, 1H), 4.73 (q, J = 7.3 Hz, 1H), 4.11 (m, 1H), 4.08-3.99 (m, 1H), 3.73 (dd, J = 
11.2, 3.5 Hz, 1H), 3.52 (dd, J = 11.3, 5.5 Hz, 1H), 1.86-1.76 (m, 2H), 1.65-1.53 (m, 5H), 
1.47-1.29 (m, 3H), 0.99 (t, J = 6.6 Hz, 6H), 0.94 (dd, J = 6.6, 3.4 Hz, 6H); 13C NMR (100 
MHz, CDCl3) δ 175.1, 169.7, 157.5, 65.1, 56.1, 50.5, 49.9, 41.0, 40.1, 25.1, 25.0, 23.2, 
23.1, 22.4, 21.8, 15.2; HRMS (ESI) m/z calcd for C16H30N3O4+ 328.2231; found 328.2276 
(M+H)+ 
 
1H NMR spectrum: 
 
13C NMR spectrum: 
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(R)-N-((R)-1-(Benzylthio)-3-hydroxypropan-2-yl)-2-((S)-4-isopropyl-2,5-
dioxoimidazolidin-1-yl)-3-phenylpropanamide (LDL-9vfc’) 
  
Data for LDL-9vfc’. White solid, 85 % yield.  1H NMR (400 MHz, CDCl3) δ 7.31-7.13 (m, 
10H), 6.70 (d, J = 7.9 Hz, 1H), 6.25 (s, 1H), 4.92 (dd, J = 10.5, 6.5 Hz, 1H), 4.05 (m, 1H), 
3.71-3.64 (m, 4H), 3.64-3.58 (m, 1H), 3.50-3.39 (m, 2H), 2.93 (br, 1H), 2.54 (d, J = 6.8 
Hz, 2H), 2.05-1.95 (m, 1H), 0.89 (d, J = 7.0 Hz, 3H), 0.68 (d, J = 6.8 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 173.2, 168.7, 157.5, 137.8, 136.4, 128.9, 128.9, 128.6, 127.2, 
127.0, 63.1, 62.1, 55.5, 50.6, 36.3, 34.4, 32.1, 30.1, 18.6, 16.0; HRMS (ESI) m/z calcd 
for C25H32N3O4S+ 470.2108; found 470.2146 (M+H)+ 
 
1H NMR spectrum: 
13C NMR spectrum: 
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General Procedure for the Preparation of Scaffold 1 
 
 
 
 
A representative synthesis of LLD-1ffs is described as follows:  Compound LLD-9ffs’ (86 
mg, 0.17 mmol) and DMAP (2 mg, 0.02 mmol) were dissolved in dichloromethane at 0 
ºC under Ar.  Then, Et3N (0.07 mL, 0.52 mmol) and methanesulfonyl chloride (0.02 mL, 
0.21 mmol) were added successively.  Solution was stirred for 1 h at 0 ºC until starting 
material was disappeared as monitored by TLC.  The organic layer was washed with 
water, brine and dried over MgSO4, then was completely removed by vacuum.  Crude oil 
was dissolved in 1,2-dichloroethane (2 mL), then DMAP (2 mg, 0.02 mmol), iPr2NEt 
(0.09 mL, 0.52 mmol) and pyridine (0.04 mL, 0.52 mmol) were added together.  Solution 
was stirred at room temperature for 12 h, and then was washed with 10 % citric acid, 
saturated NaHCO3 and brine.  Organic solution was dried over MgSO4 and removed 
under reduce pressure.  The final product was purified by silica gel column 
(i) MsCl, DMAP, Et3N
 CH2Cl2, 0 ºC, 1 h
(ii) iPr2NEt, DMAP, pyridine
C2H4Cl2, 25ºC, 12 h
(iii) BBr3, CH2Cl2 
-40 ºC, 5 min (for LLD-ffs')
LLD-ffs', 68%;  LLL-fff, 83% 
DLD-lal, 88%;  LDL-lal, 63%
LLD-lal, 58%;  LDL-vfc', 85%
HN
N
O
O R2
R1
N
H
O
OH
R3
9
HN
N
O
O R2
R1 N
O
R3
1
LLD-1ffs', 45%; LLL-1fff, 39%
DLD-1lal, 41%; LDL-1lal, 40%
LLD-1lal, 39%; LDL-1vfc', 49%
LLD-1ffs, 89%
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chromatography using hexanes:ethyl acetate (1.5:1) to afford 37 mg (45 %) of LLD-1ffs’ 
as a white solid.  Compound LLD-1ffs’ (4.7 mg, 0.01 mmol) was dissolved in 
dichloromethane (1.3 mL) under Ar atmosphere.  The solution was cooled down to -40 
ºC, then the solution of BBr3 (0.03 mL, 0.03 mmol) was added dropwise within 5 min and 
the reaction was stirred for 5 min.  The reaction was quenched with saturated NaHCO3.  
The organic phase was separated, and extracted with saturated NaHCO3 and saturated 
NH4Cl.  The organic layer was collected, dried over MgSO4 and removed under reduce 
pressure.  Crude oil was purified by column chromatography using 5 % MeOH/CH2Cl2 to 
obtain product LLD-1ffs (3.4 mg, 89 %) as a solid. 
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 (S)-5-Benzyl-3-((S)-1-((R)-4-((benzyloxy)methyl)-4,5-dihydrooxazol-2-yl)-2-
phenylethyl)imidazolidine-2,4-dione (LLD-1ffs’) 
 
Data for LLD-1ffs’. White solid, 45 % yield.  1H NMR (400 MHz, CDCl3) δ 7.41-7.15 (m, 
13H), 7.10 (m, 2H), 5.24 (br, 1H), 5.07 (dd, J = 11.6, 4.6 Hz, 1H), 4.58 (s, 2H), 4.46-4.37 
(m, 1H), 4.34 (m, 1H), 4.24 (m, 1H), 4.02 (dd, J = 10.5, 3.0 Hz, 1H), 3.70 (dd, J = 9.5, 
4.1 Hz, 1H), 3.61-3.43 (m, 3H), 3.03 (dd, J = 13.9, 3.5 Hz, 1H), 2.14 (dd, J = 13.8, 10.6 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 172.5, 165.2, 155.8, 138.3, 136.9, 136.0, 129.4, 
129.2, 128.7, 128.6, 127.9, 127.9, 127.6, 127.1, 73.7, 72.0, 71.5, 66.5, 58.2, 49.2, 38.4, 
34.9; HRMS (ESI) m/z calcd for C29H30N3O4+ 484.2231; found 484.2246 (M+H)+ 
 
1H NMR spectrum: 
 
13C NMR spectrum: 
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(S)-5-Benzyl-3-((S)-1-((S)-4-benzyl-4,5-dihydrooxazol-2-yl)-2-
phenylethyl)imidazolidine-2,4-dione (LLL-1fff) 
Data for LLL-1fff.  Solid, 39 % yield.  1H NMR (400 MHz, CDCl3) δ 7.35-7.20 (m, 13H), 
7.11 (m, 2H), 5.07 (m, 1H), 5.03 (br, 1H), 4.48 (m, 1H), 4.28 (t, J = 8.9 Hz, 1H), 4.1-4.01 
(m, 2H), 3.62 (dd, J = 14.1, 11.8 Hz, 1H), 3.47 (dd, J = 14.2, 5.2 Hz, 1H), 3.17 (dd, J = 
13.8, 5.3 Hz, 1H), 3.06 (dd, J = 13.8, 3.6 Hz, 1H), 2.71 (dd, J = 13.8, 8.6 Hz, 1H), 2.13 
(dd, J = 13.9, 10.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 172.6, 164.1, 155.9, 138.1, 
136.9, 136.0, 129.5, 129.4, 129.2, 128.8, 127.6, 127.2, 126.7, 72.8, 67.9, 58.2, 49.4, 
41.8, 38.4, 34.9; HRMS (ESI) m/z calcd for C28H28N3O3+ 454.2125; found 454.2153 
(M+H)+
1H NMR spectrum: 
13C NMR spectrum: 
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(R)-5-Isobutyl-3-((S)-1-((R)-4-isobutyl-4,5-dihydrooxazol-2-yl)ethyl)imidazolidine-
2,4-dione (DLD-1lal) 
  
Data for DLD-1lal.  Oil, 41 % yield.  1H NMR (400 MHz, CDCl3) δ 6.36 (br, 1H), 4.82 (m, 
1H), 4.31 (m, 1H), 4.18 (m, 1H), 4.04 (m, 1H), 3.87 (t, J = 7.6 Hz, 1H), 1.87-1.67 (m, 3H), 
1.64 (d, J = 7.2 Hz, 3H), 1.62-1.50 (m, 2H), 1.28 (m, 1H), 0.97 (m, 6H), 0.92 (m, 6H); 13C 
NMR (100 MHz, CDCl3) δ 173.9, 164.1, 157.0, 73.9, 65.2, 55.8, 45.4, 44.2, 41.0, 25.6, 
25.3, 23.3, 23.2, 22.7, 21.8, 15.5; HRMS (ESI) m/z calcd for C16H28N3O3+ 310.2125; 
found 310.2142 (M+H)+ 
1H NMR spectrum: 
 
13C NMR spectrum: 
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(S)-5-Isobutyl-3-((R)-1-((S)-4-isobutyl-4,5-dihydrooxazol-2-yl)ethyl)imidazolidine-
2,4-dione (LDL-1lal) 
Data for LDL-1lal.  Oil, 40 % yield.  1H NMR (400 MHz, CDCl3) δ 5.77 (s, 1H), 4.85 (q, J 
= 7.1 Hz, 1H) 4.33 (m, 1H), 4.25-4.09 (m, 1H), 4.05 (m, 1H), 3.89 (t, J = 7.6 Hz, 1H), 
1.85-1.75 (m, 2H), 1.66 (d, J = 7.2 Hz, 3H), 1.62-1.53 (m, 2H), 1.35-1.24 (m, 2H), 0.98 (t, 
J = 6.8 Hz, 6H), 0.93 (t, J = 6.4 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 173.8, 164.1, 
156.8, 74.0, 65.2, 55.8, 45.5, 44.3, 41.1, 29.9, 25.6, 25.4, 23.3, 22.7, 21.9, 15.6; HRMS 
(ESI) m/z calcd for C16H28N3O3+ 310.2125; found 310.2140 (M+H)+
1H NMR spectrum: 
13C NMR spectrum: 
HN
N
O
O
N
O
[ppm] 8  6  4  2 
[r
el
]
 0
 
 5
 
 1
0 
 1
5 
 2
0 
5.
77
4.
86
4.
84
4.
35
4.
33
4.
31
4.
23
4.
21
4.
19
4.
17
4.
15
4.
14
4.
12
4.
06
4.
04
3.
91
3.
89
3.
87
1.
81
1.
80
1.
72
1.
71
1.
69
1.
67
1.
65
1.
62
1.
60
1.
58
1.
56
1.
54
1.
32
1.
30
1.
28
1.
26
1.
00
0.
98
0.
96
0.
94
0.
93
0.
91
0.
88
1.
00
0.
99
1.
12
1.
08
0.
83
3.
54
3.
56
2.
45
2.
13
6.
54
6.
27
1H_JT2014_031_LDL_hydantoin_LAL_oxazoline_7_9
1Hhw CDCl3 /opt/data/jtaechal jtaechal 8
JT2014_031  2  1  /data/jtaechal
[ppm] 150  100  50 
[r
el
]
 0
 
 5
 
 1
0 
 1
5 
 2
0 
17
3.
82
16
4.
08
15
6.
78
73
.9
6
65
.2
2
55
.7
7
45
.4
7
44
.2
7
41
.0
5
29
.9
0
25
.6
0
25
.3
7
25
.3
3
23
.2
8
23
.2
5
23
.1
8
22
.7
3
21
.8
9
21
.8
7
15
.5
6
13C_JT2014_031_LDL_hydantoin_LAL_oxazoline
13Chw CDCl3 /opt/data/jtaechal jtaechal 8
JT2014_031  4  1  /data/jtaechal
186 
(S)-5-Isobutyl-3-((S)-1-((R)-4-isobutyl-4,5-dihydrooxazol-2-yl)ethyl)imidazolidine-
2,4-dione (LLD-1lal) 
Data for LLD-1lal.  Oil, 39 % yield.  1H NMR (400 MHz, CDCl3) δ 5.71 (br, 1H), 4.84 (m, 
1H), 4.38-4.30 (m, 1H), 4.24-4.15 (m, 1H), 4.05 (m, 1H), 3.88 (m, 1H), 1.86-1.76 (m, 
2H), 1.67 (d, J = 7.2 Hz, 3H), 1.61-1.52 (m, 2H), 1.36-1.22 (m, 2H), 0.98 (m, 6H), 0.93 
(m, 6H); 13C NMR (100 MHz, CDCl3) δ 173.9, 164.1, 156.8, 74.0, 65.2, 55.8, 45.5, 44.3, 
41.1, 25.6, 25.3, 23.3, 23.1, 22.8, 21.8, 15.6; HRMS (ESI) m/z calcd for C16H28N3O3+ 
310.2125; found 310.2120 (M+H)+ 
1H NMR spectrum: 
13C NMR spectrum: 
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(S)-3-((R)-1-((R)-4-((Benzylthio)methyl)-4,5-dihydrooxazol-2-yl)-2-phenylethyl)-5-
isopropylimidazolidine-2,4-dione (LDL-1vfc’) 
Data for LDL-1vfc’.  Yellow solid, 49 % yield.  1H NMR (400 MHz, CDCl3) δ 7.33-7.13 
(m, 10H), 5.97 (br, 1H), 5.09 (m, 1H), 4.39-4.26 (m, 2H), 4.16-4.08 (m, 1H), 3.77 (s, 2H), 
3.71 (m, 1H), 3.60 (dd, J = 14.5, 11.7 Hz, 1H), 3.49 (dd, J = 14.5, 5.1 Hz, 1H), 2.79 (dd, 
J = 13.4, 4.4 Hz, 1H), 2.48 (dd, J = 13.4, 7.9 Hz, 1H), 2.10-2.00 (m, 1H), 0.91 (d, J = 7.0 
Hz, 3H), 0.69 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.8, 165.0, 157.3, 
138.5, 136.8, 129.1, 129.0, 128.8, 128.7, 127.3, 127.0, 66.6, 62.1, 53.6, 49.2, 36.9, 36.2, 
34.7, 30.3, 18.9, 16.1; HRMS (ESI) m/z calcd for C25H30N3O3S+ 452.2002; found 
452.2041 (M+H)+ 
1H NMR spectrum: 
13C NMR spectrum 
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(S)-5-Benzyl-3-((S)-1-((R)-4-(hydroxymethyl)-4,5-dihydrooxazol-2-yl)-2-
phenylethyl)imidazolidine-2,4-dione (LLD-1ffs) 
Data for LLD-1ffs.  Solid, 89 % yield.  1H NMR (400 MHz, CDCl3) δ  7.36-7.22 (m, 8H), 
7.09 (m, 2H), 5.36 (s, 1H), 5.16 (m, 1H), 4.44 (m, 1H), 4.40 (m, 1H), 4.27-4.20 (m, 1H), 
4.05 (m, 1H), 3.82 (m, 1H), 3.55-3.41 (m, 3H), 3.00 (dd, J = 13.8, 3.7 Hz, 1H), 2.54 (m, 
1H), 2.01 (dd, J = 13.8, 10.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 172.5, 165.4, 156.1, 
136.7, 136.0, 129.5, 129.2, 129.1, 128.8, 127.6, 127.3, 70.7, 67.6, 64.1, 58.4, 49.3, 38.4, 
35.1; HRMS (ESI) m/z calcd for C22H24N3O4+ 394.1716; found 394.1787 (M+H)+ 
1H NMR spectrum: 
13C NMR spectrum 
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General Preparation of Ethyl-N-Boc-Dipeptide Thioester 4 
A representative synthesis of compound LL-4e’v is described as follows: Boc-valine 
(1.52 g, 7 mmol) was dissolved in dichloromethane (40 mL) at 0 ºC under Ar.  Et3N (6.83 
mL, 49 mmol) was added in one portion followed by ethyl chloroformate (2.40 mL, 25 
mmol) over 15 min.  DMAP (0.09 g, 0.7 mmol) and EtSH (2.59 mL, 35 mmol) were 
added subsequently and the reaction was stirred for additional 2 h at 0 ºC.  The reaction 
was quenched using 2.0 mL of glacial acetic acid.  The mixture was then evaporated 
under reduced pressure and redissolved in dichloromethane.  Solution was washed 3 
times with 10 % citric acid, 3 times with saturated NaHCO3, brine and dried over MgSO4. 
Solvent was removed to obtain crystalline solid, which was used for the next step without 
further purification.  Boc deprotection of the Boc-valine-SEt (1.02 g, 3.89 mmol) was 
performed according to the Method B of the General Procedure of Boc Deprotection as 
described above.   
Solution of Boc-L-glutamic acid g-benzyl ester (1.31 g, 3.89 mmol) and HOBt (0.58 g, 
4.28 mmol) were dissolved in dichloromethane (50 mL) at 0 ºC.  EDCI (0.82 g, 4.28 
mmol) was added and the solution was stirred for 30 min.  N-methyl morpholine (1.28 
BocHN CO2H
R3
(i) EtOCOCl, NEt3
CH2Cl2,  0 ºC, 3 h
(ii) EtSH, DMAP, 25 ºC, 12 h
BocHN
R3
SEt
O
4
BocHN N
H
O R3
R2
SEt
O
LL-4if, 87%; LL-4e'v, 93%
DL-4e'e', 47% (3 steps)
(i) TFA, CH2Cl2, 25 ºC, 2 h
CO2HBocHN
R2
(ii) EDCI, HOBt, NMM 
CH2Cl2, 25 ºC, 12 h
190 
mL, 11.7 mmol) and the NH2-valine-SEt from the previous step dissolved in 
dichloromethane (20 mL) were added, and the reaction was stirred at ambient 
temperature for 12 h under Ar.  Solution was washed with 10 % citric acid, saturated 
NaHCO3, brine and dried over MgSO4, then was removed under reduced pressure to 
obtain compound 4 (1.74 g, 93 %) as solid. 
General Preparation of N-Boc Oxazole 6 
A representative synthesis of L-6e’v is described as follows: Dipeptide 4 (1.16 g, 2.41 
mmol) was added with 10 % Pd/C (0.12 g, 0.02 mmol) and small amount of MgSO4 in 
round-bottom flask and flushed with Ar.  Acetone (5 mL) was added into, then Et3SiH 
(1.15 mL, 7.23 mmol) was added dropwise over 10 min.  The solution was stirred for 30 
min, and monitored the reaction by TLC until starting material disappeared.  Once the 
reaction completed, the solution was filtered through celite and evaporated under 
reduced pressure to obtain crude aldehyde 5 as oil.  In the round-bottom flask, 
hexachloroethane (1.71 g, 7.23 mmol) and PPh3 (1.90 g, 7.23 mmol) were dissolved in 
acetonitrile (19 mL) in an ice bath.  Aldehyde 5 in 7 mL acetonitrile was added dropwise 
and the solution was stirred for 10 min at 0 ºC.  Et3N (2.02 mL, 14.5 mmol) was added to 
the solution, and the reaction was stirred at ambient temperature for 12 h.  Solution was 
removed under reduced pressure, and then redissolved in ethyl acetate.  Organic 
solution was washed with water 3 times, brine and dried over MgSO4, and then dried 
4
BocHN N
H
O R3
R2
SEt
O
C2Cl6, PPh3
Et3N, CH2Cl2
N
O
BocHN
R2
R3
L-65ff, 40%; L-6if, 37%
L-6e'v, 57%; D-6e'e', 39%
6
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completely. Crude was purified by silica gel column chromatography using hexanes:ethyl 
acetate to obtain oxazole 6 (0.49 g, 57 %) as solid. 
tert-Butyl (S)-(1-(4-benzyloxazol-2-yl)-2-phenylethyl)carbamate (L-6ff) 
 
Data for L-6ff.  Solid, 40 % yield.  1H NMR (400 MHz, CDCl3) δ 7.32-7.17 (m, 10H), 7.01 
(m, 2H), 5.14 (br, 1H), 3.82 (s, 2H), 3.25-3.11 (m, 2H), 1.40 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 163.6, 155.1, 140.5, 138.5, 136.3, 135.1, 129.6, 128.9, 128.7, 128.6, 127.0, 
126.7, 80.1, 50.4, 40.5, 32.9, 28.5; HRMS (ESI) m/z calcd for C23H27N2O3+ 379.2016; 
found 379.1984 (M+H)+ 
1H NMR spectrum: 
 
13C NMR spectrum: 
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tert-Butyl ((1S,2S)-1-(4-benzyloxazol-2-yl)-2-methylbutyl)carbamate (L-6if) 
 
Data for L-6if.  Solid, 37 % yield.  1H NMR (400 MHz, CDCl3) δ 7.33-7.21 (m, 5H), 7.17 
(s, 1H), 5.22 (m, 1H), 4.80 (m, 1H), 3.87 (s, 2H), 1.90 (m, 1H), 1.52-1.38 (m, 1H), 1.44 
(s, 9H), 1.18 (m, 1H), 0.92 (t, J = 7.4 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 164.0, 155.5, 140.5, 138.4, 134.9, 128.9, 128.6, 126.6, 79.9, 56.6, 39.7, 
33.0, 28.5, 25.3, 15.3, 11.6; MS (ESI) m/z calcd for C20H29N2O3+ 345.22; found 345.20 
(M+H)+ 
1H NMR spectrum: 
 
13C NMR spectrum 
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Benzyl (S)-4-((tert-butoxycarbonyl)amino)-4-(4-isopropyloxazol-2-yl)butanoate (L-
6e’v) 
Data for L-6e’v  Oil, 57 % yield.  1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 5H), 7.25 
(d, J = 1.2 Hz, 1H), 5.23 (br, 1H), 5.12 (s, 2H), 4.91 (br, 1H), 2.80 (m, 1H), 2.54-2.37 (m, 
2H), 2.35-2.22 (m 1H), 2.20-2.07 (m, 1H), 1.45 (s, 9H), 1.22 (d, J = 6.9 Hz, 6H); 13C 
NMR (100 MHz, CDCl3) δ 172.7, 163.0, 155.3, 147.5, 136.0, 132.8, 128.7, 128.4, 80.1, 
66.6, 48.7, 30.4, 29.6, 28.5, 26.5, 21.6, 21.5; HRMS (ESI) m/z calcd for C22H31N2O5+ 
403.2227; found 403.2164 (M+H)+ 
1H NMR spectrum: 
13C NMR spectrum: 
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Benzyl (R)-4-(4-(3-(benzyloxy)-3-oxopropyl)oxazol-2-yl)-4-((tert-
butoxycarbonyl)amino)butanoate (D-6e’e’) 
Data for D-6e’e’  Oil, 39 % yield.  1H NMR (400 MHz, CDCl3) δ 7.39-7.28 (m, 11H), 5.20 
(br, 1H), 5.12 (m, 4H), 4.91 (br, 1H), 2.84 (m, 2H), 2.70 (m, 2H), 2.51-2.37 (m, 2H), 2.32-
2.22 (m, 1H), 2.17-2.05 (m, 1H), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 172.5, 
172.4, 163.2, 155.2, 139.2, 135.9, 135.8, 134.6, 128.6, 128.3, 128.2, 128.2, 80.2, 66.5, 
66.4, 48.5, 32.9, 30.2, 29.7, 29.4, 28.3, 21.6; MS (ESI) m/z calcd for C29H35N2O7+ 
523.24; found 523.26 (M+H)+ 
1H NMR spectrum: 
13C NMR spectrum: 
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General Procedure for the Preparation of Scaffold 2 
A representative synthesis of L-2ee’v is described as follows: Boc-deprotection of L-6e’v 
(218 mg, 0.54 mmol) was performed same as Method B of the General Procedure of 
Boc Deprotection as described above.  Crude oxazole was dissolved in methanol (3.5 
mL), then CuSO4.5H2O (1.25 mg, 0.005 mmol) and K2CO3 (112 mg, 0.81 mmol) 
dissolved in water (1.75 mL) was added into the reaction.  Then, fresh TfN3 (3 mmol) in 
dichloromethane was added directly to the reaction.  Solution was stirred for 12 h at 
room temperature.  Organic solvent was removed under vacuum at room temperature. 
The remaining liquid was diluted with water and pH was adjusted to 2 with concentrated 
HCl.  The aqueous layer was extracted 4 times with ethyl acetate, then combined 
organic layer was washed with brine and dried over MgSO4.  The solvent was removed 
under reduced pressure to afford azido-oxazole, which was used in the next step without 
further purification.  Azido-oxazole and 4-pentynoic acid (55.9 mg, 0.57 mmol) were 
dissolved in THF (1.7 mL) and water (0.3 mL).  Subsequently, copper powder (34 mg, 
0.54 mmol) and 1 M solution of CuSO4 (0.05 mL, 0.05 mmol) were added.  The solution 
N
O
BocHN
R2
R3
L-65ff, 40%; L-6if, 37%
L-6e'v, 57%; D-6e'e', 39%
6
TfN3, CuSO4.5H2O, K2CO3
H2O, MeOH, 25 ºC, 12 h
N
O
N3
R2
R3
R1
(i) Cu, CuSO4,
THF, H2O, 25 ºC, 12 h
(ii) TFA, CH2Cl2, 25 ºC, 3 h
(L-2ee'v and D-2ve'e')
N
O
N
R2
R3
NN
R1
L-2fff, 40%; L-2fif, 37%
L-2ee'v, 64%; D-2ve'e', 61%
(3 steps)
L-2eev, 100%; D-2vee, 100%
2
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was stirred for 12 h.  After the reaction was complete, pH was adjusted to 2 using 
concentrated HCl, then aqueous layer was extracted 4 times with ethyl acetate.  Organic 
layer was combined, dried over MgSO4 and removed under reduced pressure.  Crude 
product was purified by silica gel column chromatography using hexanes : ethyl acetate 
(1:2) to obtain product L-2ee’v (148 mg, 64%) as solid.  The hydrogenolysis of L-2ee’v 
and D-2ve’e’ was performed as same as Method B in the General Procedure for the 
Preparation of scaffold 9 to obtain L-2eev and D-2vee as oil. 
 
(S)-4-Benzyl-2-(1-(4-benzyl-1H-1,2,3-triazol-1-yl)-2-phenylethyl)oxazole (L-2fff) 
 
Data for L-2fff.  Solid, 40 % yield.  1H NMR (400 MHz, CDCl3) δ 7.33-7.15 (m, 15H), 
6.99 (m, 2H), 5.96 (t, J = 7.8 Hz, 1H), 4.04 (s, 2H), 3.85 (s, 2H), 3.62 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 159.6, 147.7, 141.3, 139.1, 138.1, 136.2, 135.2, 129.2, 128.9, 
128.8, 128.8, 128.8, 128.7, 127.5, 126.8, 126.6, 121.2, 59.8, 40.3, 32.9, 32.4; HRMS 
(ESI) m/z calcd for C27H25N4O+ 421.2023; found 421.1885 (M+H)+ 
 
1H NMR spectrum: 
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13C NMR spectrum: 
4-Benzyl-2-((1S,2S)-1-(4-benzyl-1H-1,2,3-triazol-1-yl)-2-methylbutyl)oxazole (L-2fif) 
Data for L-2fif.  Solid, 37 % yield.  1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 7.35-7.22 
(m, 11H), 5.62 (d, J = 10.2 Hz, 1H), 4.11 (s, 2H), 3.88 (s, 2H), 2.53-2.41 (m, 1H), 1.26-
1.14 (m, 1H), 1.12-0.97 (m, 1H), 0.92 (d, J = 6.7 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 160.1, 147.9, 141.3, 139.1, 138.0, 135.8, 128.9, 128.8, 128.7, 
126.8, 126.6, 120.8, 63.2, 39.6, 32.9, 32.4, 25.3, 15.6, 10.5; HRMS (ESI) m/z calcd for 
C24H27N4O+ 387.2179; found 387.2030 (M+H)+ 
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
(S)-3-(1-(4-(Benzyloxy)-1-(4-isopropyloxazol-2-yl)-4-oxobutyl)-1H-1,2,3-triazol-4-
yl)propanoic acid (L-2ee’v) 
 
Data for L-2ee’v  White solid, 64 % yield.  1H NMR (400 MHz, CDCl3) δ 7.55 (s, 1H), 
7.39-7.29 (m, 6H), 5.967 (t, J = 7.8 Hz, 1H), 5.11 (s, 2H), 3.04 (t, J = 7.2 Hz, 2H), 2.87-
2.66 (m, 5H), 2.37 (m, 2H), 1.22 (d, J = 6.8 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 176.6, 
171.9, 159.2, 148.2, 146.9, 135.8, 134.1, 128.8, 128.6, 128.5, 121.0, 66.9, 57.4, 33.5, 
30.2, 29.0, 26.5, 21.5, 21.5, 21.0; HRMS (ESI) m/z calcd for C22H26N4O5Na+ 449.1795; 
found 449.1795 (M+Na)+ 
1H NMR spectrum: 
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13C NMR spectrum 
Benzyl (R)-4-(4-(3-(benzyloxy)-3-oxopropyl)oxazol-2-yl)-4-(4-isopropyl-1H-1,2,3-
triazol-1-yl)butanoate (D-2ve’e’) 
Data for D-2ve’e’  White solid, 61 % yield.  1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 
12H), 5.91 (dd, J = 8.8, 6.8 Hz, 1H), 5.13 (s, 2H), 5.12 (s, 2H), 3.07 (m, 1H), 2.88 (t, J = 
7.3 Hz, 2H), 2.71 (t, J = 7.6 Hz, 2H), 2.68-2.58 (m, 2H), 2.40-2.33 (m, 2H), 1.31 (d, J = 
2.9 Hz, 3H), 1.29 (d, J = 2.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.5, 171.9, 159.6, 
155.3, 140.1, 136.1, 135.8, 135.7, 128.8, 128.8, 128.6, 128.5, 128.4, 118.4, 66.9, 66.6, 
57.2, 33.0, 30.2, 29.1, 26.1, 22.6, 22.6, 21.8; HRMS (ESI) m/z calcd for C29H33N4O5+ 
517.2445; found 517.2419 (M+H)+ 
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1H NMR spectrum: 
 
13C NMR spectrum 
 
 
(S)-4-(4-(2-Carboxyethyl)-1H-1,2,3-triazol-1-yl)-4-(4-isopropyloxazol-2-yl)butanoic 
acid (L-2eev) 
 
Data for L-2eev  Colorless oil, 100 % yield.  1H NMR (400 MHz, MeOD) δ 7.86 (s, 1H), 
7.58 (s, 1H), 6.00 (dd, J = 8.9, 6.7 Hz, 1H), 2.98 (t, J = 7.4 Hz, 2H), 2.81 (m, 1H), 2.73-
2.56 (m, 4H), 2.26 (m, 2H), 1.22 (d, J = 6.92 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 
176.2, 175.6, 161.0, 149.1, 148.4, 135.8, 122.8, 58.7, 34.3, 30.6, 29.5, 27.5, 21.9, 21.8, 
21.7; HRMS (ESI) m/z calcd for C15H20N4O5Na+ 359.1326; found 359.1319 (M+Na)+ 
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1H NMR spectrum: 
 
13C NMR spectrum 
 
 
(R)-4-(4-(2-Carboxyethyl)oxazol-2-yl)-4-(4-isopropyl-1H-1,2,3-triazol-1-yl)butanoic 
acid (D-2vee) 
 
Data for D-2vee  Colorless oil, 100 % yield.  1H NMR (400 MHz, MeOD) δ 7.84 (s, 1H), 
7.65 (s, 1H), 6.01 (dd, J = 9.0, 6.6 Hz, 1H), 3.04 (m, 1H), 2.81 (t, J = 7.4 Hz, 2H), 2.75-
2.65 (m, 2H), 2.65-2.59 (m, 3H), 2.32-2.22 (m, 3H), 1.29 (m, 3H), 1.28 (m, 3H); 13C NMR 
(100 MHz, MeOD) δ 176.3, 175.6, 161.2, 156.0, 141.6, 137.4, 121.0, 58.6, 33.6, 30.7, 
29.5, 27.0, 22.8, 22.7, 22.5; HRMS (ESI) m/z calcd for C15H21N4O5+ 337.1506; found 
337.1532 (M+H)+ 
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
Preparation of compound DL-10al 
 
 
Alanine (0.45 g, 5.0 mmol) was dissolved in 30 mL MeOH, then the solution of CuSO4 
and K2CO3 in 15 mL water was added.  Fresh solution of TfN3 was added, and the 
reaction was stirred at room temperature for 12 h.  Organic solvent was removed by 
rotavap, and then the aqueous phase was acidified with concentrated HCl until pH ~2.  
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Solution was extracted 4 times with EtOAc, dried with MgSO4, and evaporated to get the 
azido-Ala, which was used in the next step without further purification.  To the solution of 
azido-Ala (5.0 mmol), HOBt (0.74 g, 5.5 mmol) and EDCI (1.05 g, 5.5 mmol) in 
dichloromethane (50 mL) was added with N-methyl morpholine (1.65 mL, 15 mmoL) and 
leucinol (0.59 g, 5.0 mmol) at 0 ºC.  Reaction was stirred under Ar atmosphere for 12 h 
while allowing temperature to rise to room temperature.  Organic layer was washed with 
1N HCl (x3), Sat. NaHCO3 (x3), and brine.  Solvent was dried over MgSO4, and removed 
under reduce pressure to obtain DL-10al as solid (0.42 g, 39%), which was reasonable 
pure enough without further purification.   
(R)-2-Azido-N-((S)-1-hydroxy-4-methylpentan-2-yl)propanamide (DL-10al) 
Data for DL-10al  39 % yield.  1H NMR (400 MHz, CDCl3) δ 6.38 (br, 1H), 4.10 (q, J = 
7.0 Hz, 1H), 4.03 (m, 1H), 3.69 (dd, J = 11.0, 3.6 Hz, 1H), 3.57 (dd, J = 11.0, 5.7 Hz, 
1H), 1.64 (m, 2H), 1.57 (d, J = 7.0 Hz, 3H), 1.42 (m, 2H), 0.96 (d, J = 6.7 Hz, 3H), 0.94 
(d, J = 6.6 Hz, 3H) 
N3 N
H
O
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1H NMR spectrum: 
 
IR 
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Preparation of Compound DL-11lal 
 
 
Compound DL-10al (200 mg, 0.94 mmol) and 4-methylpentyne (0.12 mL, 0.98 mmol) 
were dissolved in 0.5 mL of water and 3 mL of THF.  After that, the solution of 1M 
CuSO4 (0.09 mL, 0.09 mmol) and Cu powder (60 mg, 0.94 mmol) was added, and the 
reaction was stirred for 12 h.  Solvent was then completely removed by rotavap, and the 
crude was dissolved in EtOAc.  Organic solvent was washed with 50 % NH4OH (20 mL) 
and brine.  Solution was dried over MgSO4, evaporated, and the crude material was 
purified by flash column chromatography with EtOAc:hexanes (1.5:1 to 2.5:1 ratio) to 
obtain product as solid (173 mg, 62 %).   
 
(R)-N-((S)-1-Hydroxy-4-methylpentan-2-yl)-2-(4-isobutyl-1H-1,2,3-triazol-1-
yl)propanamide (DL-11lal) 
 
Data for DL-11lal  solid, 62 % yield.  1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 6.42 (br, 
1H), 5.34 (q, J = 7.2 Hz, 1H), 4.01 (m, 1H), 3.63 (m, 1H), 3.49 (m, 1H), 2.91 (br, 1H), 
2.60 (d, J = 7.0 Hz, 2H), 1.97 (septet, J = 6.7 Hz, 1H), 1.83 (d, J = 7.2 Hz, 3H), 1.52 (m, 
1H), 1.36 (m, 2H), 0.94 (d, J = 6.6 Hz, 6H), 0.90 (d, J = 6.6 Hz, 6H); 13C NMR (100 MHz, 
N3 N
H
O
OH
Cu, CuSO4
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CDCl3) δ 169.3, 147.8, 121.0, 65.3, 60.0, 50.6, 40.1, 34.9, 28.8, 25.1, 23.1, 22.5, 22.5, 
22.4, 18.9; HRMS (ESI) m/z calcd for C15H29N4O2+ 297.2285; found 297.2276 (M+H)+ 
 
1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
Preparation of Compound DL-3lal 
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Compound DL-11lal (85 mg, 0.29 mmol) was dissolved in MeCN (3 mL), then PPh3 (226 
mg, 0.87 mmoL), Et3N (0.16 mL, 1.15 mmol), and CCl4 (0.15 mL, 1.58 mmol) were 
added subsequently.  The reaction was stirred at room temperature for 12 h.  Reaction 
was diluted with CH2Cl2, and then extracted with water twice and brine.  Crude product 
was purified by flash column chromatography using EtOAc:hexanes (1:2) to obtain 
product as a solid (54 mg, 67%). 
 
(S)-4-Isobutyl-2-((R)-1-(4-isobutyl-1H-1,2,3-triazol-1-yl)ethyl)-4,5-dihydrooxazole 
(DL-3lal) 
 
Data for DL-3lal  solid, 62 % yield.  1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 5.50 (q, J 
= 7.1 Hz, 1H), 4.37 (m, 1H), 4.18 (m, 1H), 3.87 (t, J = 8.1 Hz, 1H), 2.60 (d, J = 7.0 Hz, 
2H), 1.98 (septet, J = 6.7 Hz, 1H), 1.82 (d, J = 7.2 Hz, 3H), 1.73 (m, 1H), 1.59 (m, 1H), 
1.30 (m, 1H), 0.94 (m, 12H); 13C NMR (100 MHz, CDCl3) δ 164.1, 147.5, 120.2, 74.1, 
65.2, 54.1, 45.4, 35.1, 28.8, 25.6, 23.0, 22.8, 22.5, 19.2; HRMS (ESI) m/z calcd for 
C15H27N4O+ 279.2179; found 279.2198 (M+H)+ 
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1H NMR spectrum: 
 
13C NMR spectrum: 
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APPENDIX C 
EXPERIMENTAL PROCEDURES FOR CHAPTER III 
Synthesis of Trisubstituted-nosyl Diethanolamine 13 
Diethanolamine (5.6 g, 53 mmol) and Et3N (27 mL, 192 mmol) were dissolved in 80 mL 
THF at 0 ºC under Ar atmosphere.  The solution of p-nitrophenyl sulfonyl chloride (39.6 
g, 179 mmol) in 45 mL THF was added dropwise over 30 minutes.  Reaction was 
maintained at 0 ºC for 1 h, then allowed to stir at 25 ºC for 48 h.  Solvent was completely 
removed by vacuo, and CH2Cl2 was added to dissolve the crude material.  The mixture 
was kept in fridge to initiate precipitation, and the solid was collected by filtration. 
Remaining mother liquor was evaporated and reprecipitate again until no further solid 
forms.  All crops were combined and recrystallized in hot THF/MeOH solution to obtain 
the final product as white solid (19.3 g, 55%).  NMR spectra of this compound are 
identical to the reference.168   
N
H
OHHO N
Ns
ONsNsONsCl, Et3N
THF, 25 ºC, 24 h
87%
13
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General Procedure of Carboxylic-protected Piperazine-amino Acids 14 Syntheses 
 
 
Trisubstituted-nosyl diethanolamine (1 eq) and amino-acid ester (1.2 eq) were dissolved 
in MeCN at 0.1 M concentration.  Reaction was initiated by adding iPr2NEt (3 eq) and 
stirred at 70 ºC for 24 h under Ar atmosphere.  After reaction completed, solvent was 
evaporated, and then redissolved in CH2Cl2.  Mixture was extracted 3 times with 10% 
citric acid, 3 times with Sat. NaHCO3 solution and brine.  The organic layer was 
collected, dried with MgSO4 and evaporated.  Product was purified by flash column 
chromatography to obtain product as solid.   
 
General Procedure of Ester Deprotection 15 
 
 
CO2PgH2N
R3
CO2PgN
R3 
iPr2NEt, MeCN, 70 ºC
12 h
D-Asn-OMe, 26%; L-Asn-OtBu, 56%
L-Asn(Trt)-OMe, 93%; D-Asp(tBu)-OMe, 90%
L-Asp(tBu)-OMe, 65%; L-His(Trt)-OMe, 32% 
L-Ile-OBn, 100%; L-Leu-OtBu, 48%
 D-Lys(Boc)-OMe, 70%; L-Lys(Boc)-OMe, 81%
L-Phe-OtBu, 90%; D-Trp-OMe, 97%
L-Trp(Boc)-OMe, 66%; L-Val-OtBu, 46%
N
Ns
ONsNsO
14
NsN
CO2PgN
R3
14
CO2HN
R3
NsN
Method A
for -OtBu
L-Asn, 99%; L-Asn(Trt), 97%
 D-Asp(tBu), 95% ;L-Asp(tBu), 86% 
L-His(Trt), 93%; L-Ile, 90%
D-Leu, 93%; L-Leu, 93%
D-Lys(Boc), 100% ; L-Lys(Boc), 100%
L-Phe, 89%; D-Trp, 88%
Method B
for -OMe
Method C
for -OBn
15
NsN
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Method A (tert-butyl ester deprotection):  Compounds 14 were stirred in 75% of 
TFA/CH2Cl2 for 3 h.  After reaction completed, solvent was evaporated and repeated 
dissolvation/evaporation cycle with CH2Cl2 for 3 times.  Dried crude was stirred in 1M 
HCl in MeOH for 15 min, then completely evaporated solvent to obtain products as HCl 
salts.  
 
Method B (methyl ester deprotection):  Compounds 14 (1 eq) and LiOH (3 eq) were 
dissolved in THF/H2O mixture.  MeOH was added dropwise until the solution became 
homogeneous.  Mixture was stirred for 3 h until the reaction completed monitored by 
TLC.  Organic solvent was removed by rotavap, and the aqueous layer was acidified 
with citric acid until pH = 2.  The aqueous layer was extracted 4 times with ethyl acetate.  
Combined organic phase was extracted with brine, dried with MgSO4 and evaporated to 
obtain product as solids. 
 
Method C (benzyl ester deprotection):  Compound L-14i (1 eq) was dissolved in CH2Cl2 
in the ice-propanol bath (-10 ºC) under Ar.  Boron tribromide solution (3 eq) was added 
dropwise over 10 minutes, then the mixture was allowed to stir at 25 ºC for 4 h.  The 
solution was then evaporated to dryness, redissolved crude material in 5 % Na2CO3 and 
extracted 3 times with diethyl ether.  The aqueous layer was acidified with concentrated 
HCl to pH = 2, then extracted 3 times with ethyl acetate.  Organic phase was washed 
with brine and dried with MgSO4.  Solvent was completely removed to obtain L-15i as 
solid.   
 
 
 
 
  
 
212 
tert-Butyl (S)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-3-phenylpropanoate (L-
14f) 
 
Data for L-14f.  Yield 90%.  1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 8.8 Hz, 2H), 7.94 
(d, J = 8.8 Hz, 2H), 7.26-7.09 (m, 5H), 3.33 (dd, J = 9.3, 6.0 Hz, 1H), 3.15-3.02 (m, 4H), 
3.03-2.95 (m, 1H), 2.88-2.82 (m, 2H), 2.82-2.76 (m, 1H), 2.76-2.69 (m, 2H), 1.34 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 170.0, 150.2, 142.1, 137.6, 129.1, 128.9, 128.3, 126.5, 
124.3, 81.6, 69.5, 48.8, 46.5, 35.7, 28.1; HRMS (ESI) m/z calcd for C23H30N3O6S+ 
476.1850; found 476.1843 (M+H)+ 
1H NMR spectrum: 
 
13C NMR spectrum: 
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HRMS 
 
 
(S)-2-(4-((4-Nitrophenyl)sulfonyl)piperazin-1-yl)-3-phenylpropanoic acid (L-15f) 
 
Data for L-15f.  Yield 100%.  1H NMR (400 MHz, MeOD-d4) δ 8.48 (d, J = 8.9 Hz, 2H), 
8.09 (d, J = 8.9 Hz, 2H), 7.35-7.24 (m, 5H), 4.27 (dd, J = 9.7, 5.1 Hz, 1H), 3.67-3.57 (m, 
2H), 3.56-3.39 (m, 7H), 3.16 (dd, J = 13.6, 9.7 Hz, 1H); 13C NMR (100 MHz, MeOD-d4) δ 
169.7, 152.2, 142.5, 135.5, 130.4, 130.2, 129.9, 128.7, 125.9, 69.9, 51.3, 44.5, 34.6; 
HRMS (ESI) m/z calcd for C19H22N3O6S+ 420.1224; found 420.1219 (M+H)+ 
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
HRMS 
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215 
tert-Butyl (S)-4-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)pentanoate (L-
14l) 
 
Data for L-14l.  Yield 48%.  1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 7.9 Hz, 2H), 7.95 
(d, J = 7.9 Hz, 2H), 3.14-2.98 (m, 5H), 2.79 (m, 2H), 2.68 (m, 2H), 1.57-1.49 (m, 2H), 
1.46 (s, 9H), 1.43-1.35 (m, 1H), 0.86 (dd, J = 16.4, 5.8 Hz, 6H); 13C NMR (100 MHz, 
CDCl3) δ 171.1, 150.2, 142.0, 128.9, 124.3, 81.4, 65.9, 48.4, 46.6, 38.1, 28.3, 24.8, 22.6, 
22.4; HRMS (ESI) m/z calcd for C20H32N3O6S+ 442.2006; found 442.2004 (M+H)+ 
1H NMR spectrum: 
 
13C NMR spectrum: 
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216 
HRMS 
 
(S)-4-Methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)pentanoic acid (L-15l) 
 
Data for L-15l.  Yield 93%.  1H NMR (400 MHz, MeOD-d4) δ 8.48 (d, J = 8.9 Hz, 2H), 
8.09 (d, J = 8.9 Hz, 2H), 3.97 (m, 1H), 3.57 (m, 2H), 3.44 (m, 6H), 1.88-1.66 (m, 3H), 
0.99 (m, 6H); 13C NMR (100 MHz, MeOD-d4) δ 170.6, 152.2, 142.5, 130.5, 125.8, 67.5, 
50.8, 44.7, 37.3, 26.6, 23.6, 21.5; HRMS (ESI) m/z calcd for C16H24N3O6S+ 386.1380; 
found 386.1376 (M+H)+ 
1H NMR spectrum:
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217 
13C NMR spectrum:
 
HRMS 
 
 
 
(R)-4-Methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)pentanoic acid (D-15l) 
 
Data for D-15l.  Yield 93%.  1H NMR (400 MHz, MeOD-d4) δ  8.46 (d, J = 8.0 Hz, 2H), 
8.05 (d, J = 8.1 Hz, 2H), 3.56 (m, 1H), 3.23 (m, 4H), 3.08 (m, 4H), 1.72-1.56 (m, 3H), 
0.92 (m, 6H); 13C NMR (100 MHz, MeOD-d4) δ 173.1, 152.3, 142.9, 130.4, 125.6, 67.1, 
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50.2, 46.4, 38.2, 26.3, 23.1, 22.3 HRMS (ESI) m/z calcd for C16H24N3O6S+ 385.1380; 
found 386.1375 (M+H)+ 
1H NMR spectrum:
 
13C NMR spectrum:
 
HRMS 
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Benzyl (2S,3S)-3-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)pentanoate (L-
14i) 
 
Data for L-14i.  Yield 89%.  1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 8.9 Hz, 2H), 7.93 
(d, J = 8.9 Hz, 2H), 7.36 (m, 5H), 5.14 (s, 2H), 3,13-2.97 (m, 4H), 2.90 (d, J = 10.6 Hz, 
1H), 2.70 (m, 2H), 2.60 (m, 2H), 1.86 (m, 1H), 1.54 (m, 1H), 1.02 (m, 1H), 0.79 (m, 6H); 
13C NMR (100 MHz, CDCl3) δ 170.7, 150.2, 142.1, 135.6, 128.8, 128.6, 128.4, 128.3, 
124.3, 72.2, 66.0, 48.6, 46.5, 32.3, 24.7, 15.6, 10.1; HRMS (ESI) m/z calcd for 
C23H30N3O6S+ 476.1850; found 476.1846 (M+H)+ 
1H NMR spectrum:
 
13C NMR spectrum:
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HRMS 
 
 
(2S,3S)-3-Methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)pentanoic acid (L-1i5) 
 
Data for L-15i.  Yield 90%. 1H NMR (400 MHz, MeOD-d4) δ 8.44 (d, J = 8.6 Hz, 2H), 
8.01 (d, J = 8.6 Hz, 2H), 3.10 (m, 4H), 2.90 (d, J = 9.6 Hz, 1H), 2.76 (m, 2H), 2.67 (m, 
2H), 1.81 (m, 1H), 1.57 (m, 1H), 1.09 (m, 1H), 0.83 (m, 6H); 13C NMR (100 MHz, MeOD-
d4) δ 173.5, 151.9, 143.1, 130.3, 125.5, 73.7, 50.1, 47.4, 33.4, 26.2, 15.8, 10.7; HRMS 
(ESI) m/z calcd for C16H23N3O6S 386.1380; found 386.1376 (M+H)+ 
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
HRMS 
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222 
tert-Butyl (S)-3-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)butanoate (L-
14v) 
 
Data for L-14v.  Yield 46%.  1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 8.9 Hz, 2H), 7.95 
(d, J = 8.9 Hz, 2H), 3.14-2.97 (m, 4H), 2.73 (m, 2H), 2.61 (m, 2H), 2.57 (d, J = 10.7 Hz, 
1H), 1.94 (m, 1H), 1.46 (s, 9H), 0.84 (dd, J = 8.4, 6.6 Hz, 6H); 13C NMR (100 MHz, 
CDCl3) δ 170.3, 150.2, 142.2, 128.9, 124.3, 81.3, 77.3, 77.0, 76.7, 74.9, 48.5, 46.6, 28.4, 
26.6, 19.5, 19.2; HRMS (ESI) m/z calcd for C19H30N3O6S+ 428.1850; found 428.1843 
(M+H)+ 
1H NMR spectrum:
 
13C NMR spectrum:
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223 
HRMS 
 
 
tert-Butyl (S)-3-(3-methoxy-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-3-
oxopropyl)-1H-indole-1-carboxylate (L-14w’) 
 
Data for L-14w’.  Yield 66%.  1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 8.8 Hz, 2H), 8.06 
(d, J = 7.9 Hz, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.45 (d, J = 7.7 Hz, 1H), 7.45 (s, 1H), 7.30 
(m, 1H), 7.20 (m, 1H), 3.65 (s, 3H), 3.58 (dd, J = 8.4, 6.5 Hz, 1H), 3.20-3.03 (m, 5H), 
2.96-2.83 (m, 3H), 2.78-2.69 (m, 2H), 1.63 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 171.2, 
150.3, 149.6, 142.0, 135.2, 130.3, 128.9, 124.4, 124.3, 123.6, 122.4, 118.5, 116.2, 
115.3, 83.6, 67.0, 51.4, 48.7, 46.4, 28.2, 24.7; HRMS (ESI) m/z calcd for C27H33N4O8S+ 
573.2014; found 573.2011 (M+H)+ 
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1H NMR spectrum:
 
13C NMR spectrum
 
HRMS 
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Methyl (R)-3-(1H-indol-3-yl)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)propanoate 
(D-14w) 
 
Data for D-14w.  Yield 97%.  1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 8.8 Hz, 2H), 7.98 
(br, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.18 
(t, J = 7.5 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 6.97 (s, 1H), 3.60 (s, 3H), 3.57 (d, J = 5.7 Hz, 
1H), 3.24 (dd, J = 14.4, 9.3 Hz, 1H), 3.17-3.05 (m, 4H), 3.01 (dd, J = 14.4, 5.6 Hz, 1H), 
2.87 (m, 2H), 2.75 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 171.6, 150.3, 142.0, 136.1, 
128.9, 127.3, 124.3, 122.4, 122.1, 119.5, 118.4, 111.5, 111.2, 67.9, 51.3, 48.8, 46.5, 
25.1; HRMS (ESI) m/z calcd for C22H25N4O6S+ 473.1489; found 473.1486 (M+H)+ 
1H NMR spectrum:
 
13C NMR spectrum:
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226 
HRMS 
 
 
(R)-3-(1H-Indol-3-yl)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)propanoic acid (D-
15w) 
 
Data for D-15w.  Yield 88%.  1H NMR (400 MHz, MeOD-d4) δ 8.45 (d, J = 8.6 Hz, 2H), 
8.05 (d, J = 8.6 Hz, 2H), 7.57 (d, J = 7.8 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.17 (s, 1H), 
7.10 (t, J = 7.5 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 4.21 (m, 1H), 3.55-3.40 (m, 6H), 3.40-
3.33 (m, 4H); 13C NMR (100 MHz, MeOD-d4) δ 171.0, 152.2, 142.6, 138.1, 130.4, 128.2, 
125.8, 125.1, 122.9, 120.3, 119.0, 112.6, 108.2, 69.2, 51.2, 44.9, 25.1; HRMS (ESI) m/z 
calcd for C21H23N4O6S+ 459.1333; found 459.1329 (M+H)+ 
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1H NMR spectrum:
 
13C NMR spectrum:
 
HRMS 
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228 
Methyl (S)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-4-oxo-4-
(tritylamino)butanoate (L-14n’) 
 
Data for L-14n’.  Yield 93%. 1H NMR (400 MHz, CDCl3) δ 8.40 (d, J = 7.8 Hz, 2H), 7.93 
(d, J = 7.8 Hz, 2H), 7.25-7.09 (m, 15H), 3.77 (t, J = 7.1 Hz, 1H), 3.71 (s, 4H), 3.04 (m, 
4H), 2.87 (m, 2H), 2.70-2.61 (m, 3H), 2.57 (dd, J = 15.5, 8.4 Hz, 1H); 13C NMR (100 
MHz, CDCl3 ) δ 170.7, 169.2, 168.4, 150.3, 144.7, 144.4, 142.1, 128.8, 128.7, 128.5, 
127.8, 127.0, 126.9, 124.4, 70.4, 63.5, 51.8, 48.7, 46.2, 36.3; HRMS (ESI) m/z calcd for 
C34H35N4O7S+ 643.2221; found 643.2219 (M+H)+ 
1H NMR spectrum: 
 
13C NMR spectrum: 
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229 
HRMS 
 
 
(S)-2-(4-((4-Nitrophenyl)sulfonyl)piperazin-1-yl)-4-oxo-4-(tritylamino)butanoic acid 
(L-15n’) 
 
Data for L-15n’.  Yield 97%.  1H NMR (400 MHz, MeOD-d4) δ 8.39 (d, J = 8.0 Hz, 2H), 
7.99 (d, J = 8.1 Hz, 2H), 7.12 (m, 15H), 3.73 (dd, J = 10.0, 4.5 Hz, 1H), 3.06 (m, 4H), 
3.00 (m, 2H), 2.78 (dd, J = 15.3, 10.4 Hz, 1H), 2.71 (m, 2H), 2.53 (dd, J = 15.4, 4.1 Hz, 
2H); 13C NMR (100 MHz, MeOD-d4) δ 171.8, 170.7, 150.4, 144.4, 141.2, 129.0, 128.6, 
127.2, 126.4, 124.3, 70.2, 63.6, 48.3, 46.2, 35.5; HRMS (ESI) m/z calcd for 
C33H33N4O7S+ 629.2064; found 629.2056 (M+H)+ 
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230 
1H NMR spectrum:
 
13C NMR spectrum
 
HRMS 
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231 
tert-Butyl (S)-4-amino-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-4-oxobutanoate 
(L-14n) 
 
Data for L-14n.  Yield 56%.  1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 8.7 Hz, 2H), 794 
(d, J = 8.7 Hz, 2H), 6.04 (br, 1H), 5.45 (br, 1H), 3.62 (t, J = 7.2 Hz, 1H), 3.09 (m, 4H), 
2.88 (m, 2H), 2.69 (m, 2H), 2.62 (dd, J = 15.6, 7.0 Hz, 1H), 2.43 (dd, J = 15.6, 7.3 Hz, 
1H), 1.47 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 172.4, 169.5, 150.6, 142.3, 129.1, 
124.6, 82.8, 64.4, 49.0, 46.6, 35.4, 28.4; HRMS (ESI) m/z calcd for C18H27N4O7S+ 
443.1595; found 443.1591 (M+H)+ 
1H NMR spectrum:
 
13C NMR spectrum: 
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232 
HRMS 
 
 
(S)-4-Amino-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-4-oxobutanoic acid (L-
15n) 
 
Data for L-15n.  Yield 99%. 1H NMR (400 MHz, MeOD-d4) δ 8.48 (d, J = 8.9 Hz, 2H), 
8.08 (d, J = 8.9 Hz, 2H), 4.35 (t, J = 5.7 Hz, 1H), 3.73 (t, J = 6.6 Hz, 1H), 3.59 (t, J = 6.6 
Hz, 1H), 3.51-3.36 (m, 8H), 3.00 (d, J = 5.6 Hz, 2H) MeOD-d4; 13C NMR (100 MHz, 
MeOD-d4) δ 173.1, 169.5, 152.2, 142.5, 130.5, 125.8, 64.9, 51.4, 44.7, 32.9; HRMS 
(ESI) m/z calcd for C14H19N4O7S+ 387.0969; found 387.0966 (M+H)+ 
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233 
1H NMR spectrum
 
13C NMR spectrum 
 
HRMS 
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234 
Methyl (R)-4-amino-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-4-oxobutanoate (D-
14n) 
 
Data for D-14n.  Yield 26%.  1H NMR (400 MHz, MeOD-d4) δ 8.43 (d, J = 8.9 Hz, 2H), 
8.00 (d, J = 8.8 Hz, 2H), 3.73 (t, J = 7.6 Hz, 1H), 3.68 (s, 3H), 3.05 (m, 4H), 2.81 (m, 
2H), 2.61 (m, 3H), 2.49 (dd, J = 15.2, 7.8 Hz, 1H); 13C NMR (100 MHz, MeOD-d4) δ 
173.6, 170.5, 149.9, 141.1, 128.3, 123.5, 62.7, 49.9, 47.9, 45.8, 33.8; HRMS (ESI) m/z 
calcd for C15H21N4O7S+ 401.1125; found 401.1123 (M+H)+ 
1H NMR spectrum
 
13C NMR spectrum
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235 
HRMS 
 
 
4-(tert-Butyl) 1-methyl (S)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)succinate (L-
14d’) 
 
Data for L-14d’.  Yield 65%.  1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 8.8 Hz, 2H), 7.93 
(d, J = 8.8 Hz, 2H), 3.71 (s, 3H), 3.67 (m, 1H), 3.04 (m, 4H), 2.80 (m, 2H), 2.69 (dd, J = 
15.7, 8.2 Hz, 1H), 2.62 (m, 2H), 2.43 (dd, J = 15.7, 7.0 Hz, 1H), 1.35 (s, 9H); 13C NMR 
(100 MHz, CDCl3) δ 170.6, 169.9, 150.2, 141.9, 128.9, 124.3, 81.0, 63.4, 51.6, 48.7, 
46.4, 35.5, 27.9; HRMS (ESI) m/z calcd for C19H28N3O8S+ 458.1592; found 458.1587 
(M+H)+ 
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1H NMR spectrum
 
13C NMR spectrum
 
HRMS 
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237 
(S)-4-(tert-Butoxy)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-4-oxobutanoic acid 
(L-15d’) 
 
Data for L-15d’.  Yield 81%. 1H NMR (400 MHz, MeOD-d4) δ 8.44 (d, J = 8.8 Hz, 2H), 
8.01 (d, J = 8.9 Hz, 2H), 3.63 (t, J = 7.7 Hz, 1H), 3.05 (m, 4H), 2.84 (m, 2H), 2.64 (m, 
3H), 2.45 (dd, J = 15.5, 7.5 Hz, 1H), 1.34 (s, 9H); 13C NMR (100 MHz, MeOD-d4) δ 
173.1, 172.0, 151.9, 142.9, 130.4, 125.5, 82.0, 64.9, 49.9, 47.7, 36.3, 28.2; HRMS (ESI) 
m/z calcd for C18H25N3O8S 444.1435; found 444.1430 (M+H)+ 
1H NMR spectrum:
 
13C NMR spectrum
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238 
HRMS 
 
 
4-(tert-Butyl) 1-methyl (R)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)succinate (D-
14d’) 
 
Data for D-14d’.  Yield 42%.  1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 8.0 Hz, 2H), 7.93 
(d, J = 8.0 Hz, 2H), 3.71 (s, 3H), 3.68 (t, J = 7.7 Hz, 1H), 3.05 (m, 4H), 2.81 (m, 2H), 
2.70 (dd, J = 15.7, 8.1 Hz, 1H), 2.61 (m, 2H), 2.44 (dd, J = 15.7, 6.9 Hz, 1H), 1.36 (s, 
9H); 13C NMR (100 MHz, CDCl3) δ 170.6, 169.9, 150.2, 141.9, 128.9, 124.3, 81.0, 63.4, 
51.6, 48.7, 46.4, 35.5, 27.9; HRMS (ESI) m/z calcd for C19H28N3O8S+ 458.1592; found 
458.1593 (M+H)+ 
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239 
1H NMR spectrum:
 
13C NMR spectrum: 
 
HRMS 
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(R)-4-(tert-Butoxy)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-4-oxobutanoic acid 
(D-15d’) 
 
Data for D-15d’.  Yield 66%.  1H NMR (400 MHz, MeOD-d4) δ 8.47 (d, J = 8.5 Hz, 2H), 
8.04 (d, J = 8.5 Hz, 2H), 3.68 (t, J = 7.6 Hz, 1H), 3.08 (m, 4H), 2.88 (m, 2H), 2.68 (m, 
3H), 2.49 (dd, J = 15.6, 7.4 Hz, 1H), 1.37 (s, 9H); 13C NMR (100 MHz, MeOD-d4) δ 
173.1, 172.0, 151.9, 142.9, 130.4, 125.5, 82.0, 64.9, 49.9, 47.7, 36.3, 28.2; HRMS (ESI) 
m/z calcd for C18H26N3O8S+ 444.1435; found 444.1434 (M+H)+ 
1H NMR spectrum:
 
13C NMR spectrum: 
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HRMS  
 
 
Methyl (S)-6-((tert-butoxycarbonyl)amino)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-
yl)hexanoate (L-14k’) 
 
Data for L-14k’.  Yield 58%.  1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 8.6 Hz, 2H), 7.91 
(d, J = 8.6 Hz, 2H), 4.54 (br, 1H), 3.64 (s, 3H), 3.11 (t, J = 7.3 Hz, 1H), 3.01 (m, 6H), 
2.71 (m, 2H), 2.60 (m, 2H), 1.63 (m, 1H), 1.55 (m, 1H), 1.43-1.31 (m, 11H), 1.31-1.11(m, 
2H); 13C NMR (100 MHz, CDCl3) δ 171.9, 155.8, 150.1, 141.8, 128.8, 124.6, 79.0, 66.7, 
51.2, 48.3, 46.3, 40.1, 29.7, 28.4, 28.2, 23.1 HRMS (ESI) m/z calcd for C22H35N4O8S+ 
515.2170; found 515.2172 (M+H)+ 
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1H NMR spectrum
 
13C NMR spectrum
 
HRMS 
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(S)-6-((tert-Butoxycarbonyl)amino)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-
yl)hexanoic acid (L-15k’) 
 
Data for L-15k’.  Yield 100%.  1H NMR (400 MHz, MeOD-d4) δ 8.45 (d, J = 8.0 Hz, 2H), 
8.02 (d, J = 8.0 Hz, 2H), 3.21 (t, J = 6.9 Hz, 1H), 3.15 (m, 4H), 2.98 (t, J = 6.7 Hz, 2H), 
2.87 (m, 2H), 2.81 (m, 2H), 1.68 (m, 2H), 1.44 (m, 2H), 1.39 (s, 9H), 1.31 (m, 2H); 13C 
NMR (100 MHz, MeOD-d4) δ 174.4, 158.5, 151.9, 143.1, 130.4, 125.6, 79.8, 68.7, 49.9, 
47.1, 41.0, 30.7, 29.4, 28.8, 24.2; HRMS (ESI) m/z calcd for C21H33N4O8S+ 501.2014; 
found 501.2012 (M+H)+ 
1H NMR spectrum
 
13C NMR spectrum
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HRMS 
 
 
Methyl (R)-6-((tert-butoxycarbonyl)amino)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-
1-yl)hexanoate (D-14k’) 
 
Data for D-14k’.  Yield 60%.  1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 8.3 Hz, 2H), 7.94 
(d, J = 8.3 Hz, 2H), 4.48 (br, 1H), 3.69 (s, 3H), 3.14 (t, J = 7.4 Hz, 1H), 3.07 (m, 6H), 
2.74 (m, 2H), 2.64 (m, 2H), 1.68 (m, 2H), 1.59 (m, 1H), 1.42 (m, 10 H), 1.28 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 172.0, 155.9, 150.3, 141.9, 128.9, 124.3, 79.2, 66.9, 51.3, 
48.5, 46.4, 40.2, 29.8, 28.6, 28.4, 23.2; HRMS (ESI) m/z calcd for C22H35N4O8S+ 
515.2170; found 515.2168 (M+H)+ 
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1H NMR spectrum:
 
13C NMR spectrum:
 
HRMS 
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(R)-6-((tert-Butoxycarbonyl)amino)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-
yl)hexanoic acid (D-15k’) 
 
Data for D-15k’.  Yield 70%.  1H NMR (400 MHz, MeOD-d4) δ 8.45 (d, J = 7.9 Hz, 2H), 
8.03 (d, J = 7.9 Hz, 2H), 3.25 (t, J = 6.8 Hz, 1H), 3.15 (m, 4H), 2.98 (t, J = 6.7 Hz, 2H), 
2.91 (m, 2H), 2.84 (m, 2H), 1,69 (m, 2H), 1.49-1.41 (m, 3H), 1.39 (s, 9H), 1.31 (m, 2H); 
13C NMR (100 MHz, MeOD-d4) δ 174.2, 158.8, 151.9, 143.0, 130.4, 125.6, 79.8, 68.7, 
50.0, 47.0, 41.0, 30.6, 29.3, 28.8, 24.2; HRMS (ESI) m/z calcd for C21H33N4O8S+ 
501.2014; found 501.2014 (M+H)+ 
1H NMR spectrum
 
13C NMR spectrum
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HRMS 
 
 
Methyl (S)-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-3-(1-trityl-1H-imidazol-4-
yl)propanoate (L-14h’) 
 
Data for L-14h’.  Yield 39%.  1H NMR (400 MHz, CDCl3) δ 8.37 (d, J = 8.7 Hz, 2H), 7.93 
(d, J = 8.7 Hz, 2H), 7.35-7.24 (m, 10H), 7.08 (m, 6H), 6.51 (s, 1H), 3.63 (dd, J = 8.6, 6.5 
Hz, 1H), 3.58 (s, 3H), 3.04 (m, 4H), 2.97 (dd, J = 14.3, 8.9 Hz, 1H), 2.84-2.72 (m, 3H), 
2.68 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 171.7, 150.4, 142.6, 142.5, 138.6, 137.4, 
129.9, 129.1, 128.2, 124.5, 119.4, 75.4, 67.3, 53.6, 51.5, 48.9, 46.7, 28.5; HRMS (ESI) 
m/z calcd for C36H36N5O6S+ 666.2381; found 666.2373 (M+H)+ 
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1H NMR spectrum
 
13C NMR spectrum 
 
HRMS 
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(S)-2-(4-((4-Nitrophenyl)sulfonyl)piperazin-1-yl)-3-(1-trityl-1H-imidazol-4-
yl)propanoic acid (L-15h’) 
 
Data for L-15h’.  Yield 100%. 1H NMR (400 MHz, MeOD-d4) δ 8.41 (d, J = 8.8 Hz, 2H), 
7.99 (d, J = 8.8 Hz, 2H), 7.43-7.17 (m, 11H), 7.06 (m, 5H), 6.89 (m, 1H), 3.53 (t, J = 7.7 
Hz, 1H), 3.08 (m, 1H), 2.96 (m, 5H), 2.87 (m, 2H), 2.63 (m, 2H); 13C NMR (100 MHz, 
MeOD-d4) δ 151.9, 148.9, 145.5, 143.3, 142.5, 137.8, 130.7, 130.3, 129.5, 129.3, 125.6, 
122.2, 78.4, 67.4, 47.8, 26.9; HRMS (ESI) m/z calcd for C35H34N5O6S+ 652.2224; found 
652.2224 (M+H)+ 
1H NMR spectrum
 
13C NMR spectrum
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HRMS 
 
 
 
Solid-phase Syntheses and Characterizations of Compounds 12 
 
Loading pip-acids on resin:  2-Cl-Trt resin (200 mg, 1.2 mequiv/g) in fritted syringe was 
swollen in CH2Cl2 for 1 h.  Pip-acid (1.2 eq) and iPr2NEt (3 eq) in 3 mL of CH2Cl2/DMF 
(1:1) were added into the syringe, and beads were subjected to the microwave 
irradiation (100 W, 50 ºC, 30 min).  Loading process was repeated with a fresh solution.  
Beads were washed thrice with CH2Cl2 (4 mL x 3), then the remaining active beads were 
blocked with CH2Cl2 / MeOH / iPr2NEt (17:2:1) cocktail for 1 h.  Beads were washed 
thoroughly with CH2Cl2 (4 mL x 5 mL), MeOH (4 mL x 3), CH2Cl2 (4 mL x 3) and DMF (4 
mL x 3).    
 
Nosyl deprotection:  Beads containing nosyl-protected pip-acids were treated with the 
solution of mercaptoethanol (5 eq) and DBU (5 eq) in DMF for 15 minutes at 25 ºC.  The 
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orange solution was drained, and the fresh deprotection cocktail was added to the 
beads.  After the second treatment, beads were washed thoroughly with DMF (4 mL x 
5).  The completeness of reaction was monitored by chloranil test.   
 
Amide coupling:  Resin containing free-amine functional group was added with the 
solution of Fmoc-protected amino acids (4 eq), iPr2NEt (8 eq) and 0.25 M HATU/HOAt 
solution in DMF.  Beads were subjected to microwave irradiation (100 W, 50 ºC, 15 min).  
Then, beads were washed with 4 mL x 5 of DMF.  The completeness of amide coupling 
can be monitored by Kaiser test (for a primary amine) or chloranil test (for a secondary 
amine). 
 
Fmoc deprotection:  Beads were shaken in 2 mL of 20% piperidine/DMF for 1 minute at 
25 ºC.  Then, the solution was drained and the fresh deprotection solution was added.  
Beads were heated under microwave irradiation (160 W, 75 ºC, 3 min) to deprotect 
Fmoc group.  Solution was drained, and washed thoroughly with DMF (4 mL x 5), 
CH2Cl2 (4 mL x 3), MeOH (2 mL x 3) and DMF (4 mL x 3).  Positive blue color of Kaiser 
test was monitored for completeness of reaction.  
 
Hydantoin cyclization:  After Fmoc deprotection at the R1 position, beads were treated 
with the solution of p-nitrophenyl chloroformate (2 eq) and iPr2NEt (4 eq) in CH2Cl2 
(~0.05 M), and were shaken for 30 minutes at 25 ºC.  The solution was drained, and 
beads were treated again with a fresh coupling reagent.  After that, beads were washed 
with CH2Cl2 (4 mL x 5) and NMP (4mL x 3).  Solution of 5% iPr2NEt in NMP was added , 
and the beads were shaken for 1 h.  The yellow solution was discarded, and the process 
was repeated with 5% iPr2NEt/NMP for 4 more times.  At the end of removing 
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byproducts, beads were washed with NMP (4 mL x 5), CH2Cl2 (4 mL x 5), MeOH (4 mL x 
5) and dried in vacuum.  
 
Cleavage from solid support:  Products were cleaved from the beads with 20% 
HFIP/CH2Cl2 solution for 24 h.  Crude material was dried under N2 stream, and purified 
by preparative reverse-phase HPLC (50-95% MeCN/water containing 0.05% TFA).  The 
purified products were lyophilized to obtain protected-form of compounds 12 as white 
powders.   
 
Side-chain deprotection:  Purified lyophilized compounds were stirred in TFA/Et3SiH/H2O 
(95: 2.5: 2.5 v/v) cocktail for 4 h at room temperature to remove acid-labile protecting 
group.  Crude materials were dried under vacuum, and then precipitated with cold tert-
butyl methyl ether.  Solid compounds were collected, washed several times with ether 
and the final products were lyophilized to obtain products as white powders.    
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(S)-2-(4-((R)-2-((R)-4-(2-Amino-2-oxoethyl)-2,5-dioxoimidazolidin-1-yl)-3-
mercaptopropanoyl)piperazin-1-yl)-4-methylpentanoic acid (DLL-12ncl) 
 
Data for DLL-12ncl.  1H NMR (400 MHz, MeOD-d4) δ 4.91 (m, 1H), 4.34 (m, 1H), 3.85-
3.50 (m, 4H), 3.50-3.36 (m, 1H), 3.13 (d, J = 7.5 Hz, 2H), 3.02-2.85 (m, 4H), 2.80 (dd, J 
= 16.1, 4.2 Hz, 1H), 2.68 (dd, J = 16.1, 6.5 Hz, 1H), 1.81-1.49 (m, 3H), 0.96 (m, 6H);  
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254 
 
13C NMR (100 MHz, MeOD-d4) δ 175.4, 173.4, 167.6, 167.4, 158.2, 73.5, 55.0, 54.7, 
50.9, 45.7, 42.7, 38.5, 37.3, 27.2, 26.4, 24.0, 23.2, 22.4 
 
 
 
HRMS (ESI) m/z calcd for C18H30N5O6S+ 444.1911; found 444.1910 (M+H)+
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06052017_DLL-Ancl+nacl #6-133 RT: 0.06-1.27 AV: 128 NL: 3.66E7
T: FTMS + p ESI Full ms [100.0000-1000.0000]
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(R)-2-(4-((S)-2-((R)-4-Isopropyl-2,5-dioxoimidazolidin-1-yl)-3-
mercaptopropanoyl)piperazin-1-yl)-4-methylpentanoic acid (DDD-12vcl) 
 
Data for DDD-12vcl. 1H NMR (400 MHz, MeOD-d4) δ 4.95 (m, 1H), 4.05 (m, 1H), 4.00 
(m, 1H), 3.96-3.64 (m, 3H), 3.62-3.43 (m, 3H), 3.43-3.32 (m, 2H), 3.28-3.20 (m, 1H), 
3.20-3.09 (m, 1H), 2.18 (m, 1H), 1.95-1.70 (m, 3H), 1.10-0.98 (m, 9H), 0.94 (d, J = 6.9 
Hz, 3H) 
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256 
 
13C NMR (100 MHz, MeOD-d4) δ 175.5, 170.3, 168.2, 158.5, 67.7, 63.4, 54.9, 51.1, 43.5, 
40.6, 37.1, 31.6, 26.7, 23.8, 23.7, 21.4, 19.1, 16.8  
 
 
HRMS (ESI) m/z calcd for C19H33N4O5S+ 429.2166; found 429.2165 (M+H)+
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06052017_DDD-Acnd+nacl #99-205 RT: 0.95-1.96 AV: 107 NL: 1.02E8
T: FTMS + p ESI Full ms [100.0000-1000.0000]
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(S)-4-Amino-2-(4-((S)-3-carboxy-2-((S)-4-isobutyl-2,5-dioxoimidazolidin-1-
yl)propanoyl)piperazin-1-yl)-4-oxobutanoic acid (LLL-12ldn) 
 
Data for LLL-12ldn. 1H NMR (400 MHz, MeOD-d4) δ 5.46 (s, 1H), 5.20 (t, J = 7.2 Hz, 
1H), 4.07 (m, 1H), 3.75 (t, J = 6.9 Hz, 1H), 3.62-3.37 (m, 4H), 3.13 (dd, J = 16.4, 7.8 Hz, 
1H), 2.91-2.75 (m, 3H), 2.74-2.50 (m, 4H), 1.81 (m, 1H), 1.64 (m, 1H), 1.52 (m, 1H), 0.95 
(m, 6H) 
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13C NMR (100 MHz, MeOD-d4) δ 176.0, 175.9, 174.1, 173.5, 168.0, 157.8, 65.5, 56.7, 
51.2, 50.0, 49.7, 46.7, 43.9, 42.2, 35.6, 34.5, 25.9, 23.6, 21.9  
 
 
HRMS (ESI) m/z calcd for C19H30N5O8+ 456.2089; found 456.2073 (M+H)+
 
[ppm] 150  100  50 
[re
l]
 0
.0
 
 0
.1
 
 0
.2
 
 0
.3
 
 0
.4
 
 0
.5
 
JT2015_049  5  1  /Users/jaru/NMR_all/jtaechal
CO2HN
N
O
N
HN O
O
HO2C
CONH2
1 
1 
1 
1 2 
2 
3 
3 
4 
4 
5 
5 
6 
6 
6 
7 
7 
8 
8 
8 
9 
9 
10 
10 
11 
11 
12 
12 
13 
13 
14 
14 
15 
15 
16 
16 
06232017_ldl-LDN #83-174 RT: 0.79-1.67 AV: 92 NL: 3.04E7
T: FTMS + p ESI Full ms [100.0000-1000.0000]
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(S)-4-Amino-2-(4-((R)-2-((S)-4-(carboxymethyl)-2,5-dioxoimidazolidin-1-yl)-4-
methylpentanoyl)piperazin-1-yl)-4-oxobutanoic acid (LDL-12dln) 
 
Data for LDL-12dln. 1H NMR (400 MHz, MeOD-d4) δ 4.87 (m, 1H), 4.30 (m, 1H), 3.78 
(m, 1H), 3.72-3.37 (m, 4H), 2.95-2.76 (m, 3H), 2.77-2.54 (m, 5H), 2.20 (m, 1H), 1.63 (m, 
2H), 0.92 (m, 6H) 
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13C NMR (100 MHz, MeOD-d4) δ 175.8, 175.3, 173.3, 172.9, 169.4, 158.7, 65.5, 54.8, 
51.3, 50.7, 46.6, 43.6, 38.2, 36.4, 35.3, 25.9, 23.4, 21.9  
 
 
HRMS (ESI) m/z calcd for C19H30N5O8+ 456.2089; found 456.2089 (M+H)+
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06052017_LDL-Acnd+nacl-good #1-28 RT: 0.01-0.27 AV: 28 NL: 6.46E7
T: FTMS + p ESI Full ms [100.0000-1000.0000]
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(R)-2-(4-((S)-4-Amino-2-((S)-4-(mercaptomethyl)-2,5-dioxoimidazolidin-1-yl)-4-
oxobutanoyl)piperazin-1-yl)succinic acid (DLD-12cnd) 
 
Data for DLD-12cnd. 1H NMR (400 MHz, MeOD-d4) δ 5.32 (m, 1H), 4.31 (m, 1H), 3.86 
(t, J = 7.0 Hz, 1H), 3.75-3.52 (m, 4H), 3.14 (m, 1H), 2.97-2.87 (m, 4H), 2.87-2.79 (m, 
2H), 2.79-2.65 (m, 3H) 
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262 
13C NMR (100 MHz, MeOD-d4) δ 174.6, 174.3, 174.0, 172.6, 168.0, 158.1, 65.1, 59.4, 
50.8, 49.1, 46.4, 43.6, 35.4, 34.4, 26.1  
 
HRMS (ESI) m/z calcd for C16H23N5O8SNa+ 468.1160; found 468.1160 (M+Na)+
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06052017_DLD-Acnd+nacl #1-54 RT: 0.01-0.52 AV: 54 NL: 1.42E7
T: FTMS + p ESI Full ms [100.0000-1000.0000]
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(S)-2-(4-((S)-4-Amino-2-((S)-4-(mercaptomethyl)-2,5-dioxoimidazolidin-1-yl)-4-
oxobutanoyl)piperazin-1-yl)succinic acid (DLL-12cnd) 
 
Data for DLL-12cnd. 1H NMR (400 MHz, MeOD-d4) δ 5.31 (m, 1H), 4.31 (m, 1H), 3.76 
(t, J = 7.3 Hz, 1H), 3.69-3.45 (m, 4H), 3.11 (dd, J = 15.5, 7.9 Hz, 1H), 2.90 (m, 2H), 2.87-
2.73 (m, 4H), 2.72-2.56 (m, 3H) 
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13C NMR (100 MHz, MeOD-d4) δ 174.6, 174.0, 168.0, 158.1, 65.1, 59.4, 50.6, 48.9, 46.8, 
44.0, 35.4, 34.7, 26.1  
 
HRMS (ESI) m/z calcd for C16H23N5O8SNa+ 468.1160; found 468.1162 (M+Na)+  
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06052017_DLL-Acnd+nacl_20170605043521 #125-200 RT: 1.39-2.11 AV: 76 NL: 3.39E7
T: FTMS + p ESI Full ms [100.0000-1000.0000]
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(R)-2-(4-((S)-4-Amino-2-((R)-4-(mercaptomethyl)-2,5-dioxoimidazolidin-1-yl)-4-
oxobutanoyl)piperazin-1-yl)succinic acid (LLD-12cnd) 
 
Data for LLD-12cnd.  1H NMR (400 MHz, MeOD-d4) δ 5.31 (m, 1H), 4.33 (m, 1H), 3.88 
(t, J = 6.9 Hz, 1H), 3.82-3.53 (m, 4H), 3.15 (m, 1H), 3.00-2.82 (m, 5H), 2.82-2.65 (m, 4H) 
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13C NMR (100 MHz, MeOD-d4) δ 174.8, 174.2, 173.9, 172.3, 168.0, 158.1, 66.9, 65.1, 
59.4, 50.8, 48.8, 46.1, 43.1, 35.3, 34.1, 26.2  
 
 
HRMS (ESI) m/z calcd for C16H23N5O8SNa+ 468.1160; found 468.1163 (M+Na)+ 
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06052017_LLD-Acnd+nacl #15-147 RT: 0.14-1.42 AV: 133 NL: 9.47E6
T: FTMS + p ESI Full ms [100.0000-1000.0000]
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(S)-2-(4-((S)-4-Amino-2-((R)-4-(mercaptomethyl)-2,5-dioxoimidazolidin-1-yl)-4-
oxobutanoyl)piperazin-1-yl)succinic acid (LLL-12cnd) 
 
Data for LLL-12cnd. 1H NMR (400 MHz, MeOD-d4) δ 5.31 (t, J = 7.1 Hz, 1H), 4.31 (m, 
1H), 3.80 (t, J = 7.0 Hz, 1H), 3.71-3.50 (m, 4H), 3.14 (m, 1H), 2.97-2.88 (m, 2H), 2.88-
2.75 (m, 4H), 2.75-2.58 (m, 3H) 
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13C NMR (100 MHz, MeOD-d4) δ 174.7, 174.5, 173.9, 172.9, 168.0, 158.1, 65.1, 59.4, 
50.6, 48.9, 46.6, 43.8, 35.4, 34.5, 27.2, 26.2 
 
 
 
HRMS (ESI) m/z calcd for C16H23N5O8SNa+ 468.1160; found 468.1160 (M+Na)+ 
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Determination of PCSK9•LDLR Inhibitory Efficiency by Time-Resolved Förster 
Resonance Enengy Transfer (TR-FRET) Assay 
 
Compounds 12 were screened for their inhibitory efficiencies using PCSK9•LDLR TR-
FRET assay kit (BPS Bioscience, CA) following manufacture’s protocol.  LDLR-Eu (125 
ng/mL), dye-labeled acceptor and assay buffer were added into 384-well microplate.  
Compounds 12, Pep2-8 and vehicle at various concentrations were added, and the 
reactions were initiated by adding biotinylated PCSK9 (2 µg/mL).  Plates were shaken at 
room temperature for 2 h.  TR-FRET fluorescent intensities were measured using plate 
reader with two excitation/emission wavelengths (320/620 and 320/665 nm) with 60 µs 
lag time and 500 µs integration time.  Results were analyzed by normalizing TR-FRET 
emission ratio (665/620 nm) of vehicle with biotinylated PCSK9 as 0% (negative; no 
inhibition) and vehicle without biotinylated PCSK9 as 100% (positive; no interaction).  
FRET intensities of each compound were scaled according to those controls. 
 
Table C.1  QikProp calculations of compounds 12   
 
Compounds QPlogPo/w PSA (Å3) 
QPPCaco 
(nm/s) 
Rule of 
Five 
Rule of 
Three 
DLL-12ncl -2.30 188 0.51 1 2 
DDD-12vcl -0.04 137 10.80 0 1 
LLL-12ldn -3.93 238 0.017 1 2 
LDL-12dln -3.63 241 0.01 1 2 
LLL-12cnd -3.92 235 0.037 1 2 
DLL-12cnd -3.92 235 0.037 1 2 
LLD-12cnd -3.92 235 0.037 1 2 
DLD-12cnd -3.92 235 0.037 1 2 
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QlogPo/w – predicted octanol/water partition coefficient; PSA – Van der Waals surface 
area of polar nitrogen and oxygen atoms; QPPCaco – predicted Caco-2 cell 
permeability; Rule of Five – number of violations of Lipinski’s rule of five; Rule of Three – 
number of violations of Jorgensen’s rule of three. 
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APPENDIX D 
EXPERIMENTAL PROCEDURES FOR CHAPTER IV 
 
Glide 
 
Molecular dockings of the virtual libraries were performed using Glide in the Schrödinger 
package (version 2015-4) 172-175 171-174.  Selected hits from EKO analyses (Table 3.1) 
were used as the templates for optimizations.  Side-chain substitutions and C-terminus 
modifications were enumerated using CombiGlide to obtain virtual combinatorial 
libraries, and those virtual structures were docked using Glide.  Specifically, PCSK9 
protein was obtained by deleting the LDLR protein from the same PDB file (3gcx).  
Alanine side-chain residues from EKO matching hits were substituted with side-chain 
residues corresponding to the side-chain residues from LDLR protein.  Docking of virtual 
compounds was performed using OPLS 2005 force field within 20 Å of the grid box, and 
the conformations of virtual molecules were restricted within 5 Å from the parental 
conformers.  Structures from these results represented compounds 12 docked on 
PCSK9 protein, and docking scores here were set as baselines.  Next, another round of 
CombiGlide was done to substituted C-terminus with amino-acid lactones, in which R4 
residues were the library of D-, L- amino-acid side-chains.  Docking scores from this step 
(compounds 16) were compared with the previous step (compounds 12).  Top results 
were chosen, mostly positive functional groups, for further syntheses.  However, due to 
the synthetic difficulty and poor stability of the hydantoin when R1 was cysteine, this 
position was enumerated with other amino-acid side-chains to obtain other residues that 
had best docking scores, which were glutamine and glutamic derivatives.  
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DLLD-16nclr 
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DDDL-16vclr 
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DDDD-16vclr 
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LLLD-16ldnq 
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LDLL-16dl(CN)r 
 
 
CO2HN
N
O
N
HN O
O
iPr
HO2C
CONH2
LDL-12dln (gold), ΔG = -1.25 kcal/mol
O
N
H
O
N
N
O
N
HN O
O
H
N
O
O
NH
CN
iPr
HO2C
LDLL-16dl(CN)r (silver), ΔG = -2.67 kcal/mol
NH2HN
  
 
278 
LLLD-16qndw 
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LLLD-16qndr 
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DLLL-16qndr 
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LLDL-16qndr 
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LLDD-16qndr 
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DLDL-16endr 
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DLDD-16endh 
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LDL-uptake Assay 
 
HepG2 cells were seeded into 96-well plate at a density of 3 x 104 cells/well in DMEM + 
10% FBS medium (Sigma-Aldrich).  After 24 h, the medium was aspirated, and cells 
were washed two times with PBS.  Cells were treated with 10% lipoprotein-deficient 
serum (Gemini) in DMEM and incubated for another 24 h.  After washing cells with PBS 
twice, 100 µL of Pep2-8 (30 µM) or inhibitors at various concentrations (50, 5, 0.5 µM), 
which were preincubated with 15 µg/mL PCSK9 in 10% lipoprotein-deficient/DMEM 
containing 0.5% DMSO for 30 minutes before use, were added, and cells were 
incubated for 2 h.  BODIPY-LDL (10 µg/mL, Invitrogen) was added to each well, and 
microplate was incubated for another 3 h.  Cells were washed three times with PBS, and 
fluorescent intensities were measured on Synergy H4 plate reader (Biotek) with 
excitation and emission wavelength at 488 and 520 nm, respectively.  
 
In vitro PCSK9-LDLR Binding Assay   
 
Direct inhibitions of compounds 16 toward PCSK9•LDLR interaction were tested using 
the PCSK9•LDLR in vitro binding assay kit (MBL Int. Co., MA) according to the 
manufacture’s protocol.  Briefly, compounds (50 µM), Pep2-8 (50 µM) or vehicle (DMSO) 
were preincubated with 50 ng/mL of His-tagged PCSK9 in the reaction buffer (100 µL) 
30 minutes prior the experiments.  The premix mixtures were added microplate 
containing pre-coated EGF-AB domain of LDLR protein.  Microplate was incubated for 2 
h at room temperature while shaking at 300 rpm on an oribital microplate shaker.  Each 
well was washed 4 times with washing buffer (350 µL each), and the biotinylated anti-
His-tag mAb was added (100 µL).  Microplate was shaken at 300 rpm for 1 h at room 
temperature.  After washing 4 times with washing buffer, HRP-conjugated Streptavidin 
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(100 µL) was added into each well, incubated for 20 minutes at room temperature while 
shaking at 300 rpm.  Microplate was washed 4 times with washing buffer, then the 
substrate reagent (tetra-methylbenzidine, 100 µL) was added into each well, and the 
microplate was shaken for 20 minutes at room temperature.  Finally, the reaction was 
stopped with 1 N H2SO4 (100 µL), and the absorbance was measured on plate reader at 
dual wavelengths of 450/540 nm.   
 
MTT Assay 
 
HepG2 cells were seeded at 3000 cells/well in 96-well plate, and incubated in DMEM + 
10% FBS medium for 24 h.  Medium containing inhibitors was added to the final 
concentrations of 50 µM or 100 µM (100 µL) and cells were incubated for another 2 
days.  MTT substrate in HBSS buffer (5 mg/mL, 20 µL) was added, and cells were 
incubated for additional 3 h.  Medium was aspirated, then DMSO (100 µL) was added 
subsequently.  Microplate was shaken for 5 minutes, then the absorbance was 
measured with plate reader at 570 nm wavelength. 
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Figure D.1.  Seven featured compounds 16 and one partial negative control were tested 
for their cytotoxicity with HepG2 cells.  All compounds showed no cytotoxicity compared 
to the control (DMSO, black).    
 
Determination of Water Solubilities 
 
Compound solubilities in water were measured by UV absorbance following the 
literature.196  Briefly, compounds dissolved in MeOH were plated on 96-well plate, then 
solvent was evaporated at room temperature.  Water at various volumes were added to 
each well to reach at different concentrations, microplate was shaken for 5 h, and left 
overnight at room temperature to reach equilibrium.  Microplate was centrifuged for 20 
min to remove any particulates.  The clear solution was transfer to a 96-well UV-
transparent plate to measure the UV absorbance at 230 nm wavelength.  For this study, 
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UV absorbances are linear beyond 100 µM for every compound, thus the solubilities of 
compounds are at least 100 µM. 
 
 
Figure D.2.  Selected compounds 16 were tested for their solubility in water by UV 
absorbance method.  Compounds at seven concentrations up to 100 µM gave linear 
absorbance trend, which implied the solubility of compounds were at least > 100 µM 
concentration.    
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Photoaffinity Labeling  
 
Compounds 18 (100, 200 and 300 µM) were incubated with 0.25 µg/µL PCSK9 in 100 
mM HEPES buffer to a final volume of 20 µL at 4 ºC for 1.5 h.  Mixtures were transferred 
into 96-well plate, and then irradiated by a LED UV flashlight (365 nm) at 4 ºC for 30 
min.  Samples (19.5 µL) were transferred into Eppendorf tubes, mixed with 2.5 µL of 
10% SDS, and added 0.5 µL of 10 mM azide-fluor 488 (Sigma-Aldrich) to each tube.  
Huisgen cycloaddition was initiated by adding 2.5 µL of catalyst mixture, which was 
prepared immediately before use by mixing 3:1:1 v/v of 1.7 mM TBTA in 80 % tert-
butanol/20% DMSO, 50 mM CuSO4 and 50 mM TCEP.  Reaction was kept at room 
temperature for 4 h.  Finally, the reactions were quenched with 5 µL of 6x SDS buffer, 
and boiled at 95 ºC for 10 min to denature PCSK9 protein.  SDS-PAGE was performed 
by loading on 10% polyacrylamide gel.  The in-gel fluorescence was determined by 
Typhoon FLA 9500 imager at 488 nm wavelength, and all proteins were stained with 
Coomassie Brilliant Blue G250.  For the competitive experiment, 50-fold concentration of 
compounds 17 were incubated with PCSK9 at 4 ºC for 1 h before adding compounds 18.  
Also, the mixture of compound 18 and PCSK9 without irradiating UV flashlight (negative 
control) had been tested to gauge non-specific binding. 
 
Surface Plasmon Resonance (SPR)  
 
Direct binding of each compound to PCSK9 was measured by SPR using a Biacore 
T200 optical biosensor (GE Healthcare) at 25˚C. CM5 sensor chips (GE Healthcare) 
were used to create PCSK9 biosensors using standard amine coupling chemistry. 
Briefly, after mixing equal volume mixture of 0.1 M N-hydroxysuccinimide and 0.4 M 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide, the mixture was injected for 7 min at 10 
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µl/min to activate the flow cell surface. PCSK9 stock (about 1 mg/ml) was diluted to 10 
µg/ml in 50 mM sodium acetate (pH 5.5) and injected to the activated surface and 
immediately followed by a 5-min injection of 1 M ethanolamine (pH 9) to deactivate the 
surface. By varying the ligand contact times for 5, 7 or 10 minutes, different density of 
PCSK9 surfaces were generated: 2600, 4300 and 5400 RU respectively. Phosphate 
buffered saline (PBS: 8.06 mM Na2HPO4 and 1.94 mM KH2PO4, pH 7.4, 2.7 mM KCl, 
137 mM NaCl) was used as running buffer for immobilization. A reference flow cell was 
prepared with activation and deactivation steps but no protein coupled.  All binding 
experiments were performed in a running buffer of 50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, and 5% (v/v) DMSO (TBSD) using a flow rate of 50 µl/min.  
 
To evaluate compound binding, each compound was dissolved in 100% DMSO to 10 
mM and then diluted 20-fold in TBS to 500 µM final concentration as working stock for 
further dilution in TBSD. Samples were injected over the PCSK9 surface for 30 s 
followed by 60 s of dissociation and a subsequence wash step with 50% DMSO solution. 
In the screening experiment, the positive control Pep2-8 was injected three times 
(beginning, middle and end) during the run. The signal 10 s before injection stop of the 
sensorgram was treated as PCSK9-binding response. The SPR sensorgrams were 
solvent corrected, reference and buffer subtracted, and evaluated using the Biacore 
T200 Evaluation Software (version 3.1). 
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Table D.1.  Confirmation of compound binding and their dissociation constants for 
PCSK9 as determined by SPR. 
 
Compound 
ka  
(x 103 M-1s-1) 
kd 
(x 10-2 s-1) 
KDKin  
(µM) 
%Rmax 
KDSS 
(µM) 
DLLD-16nclk 2.99 (0.89) 10.2 (1.1) 41.2 (17.5) 30 (13) 303 (94) 
LDLL-16dlnr 4.04 (2.20) 8.74 (3.40) 24.8 (9.1) 70 (24) 55.4 (13.2) 
LDLL-16dl(CN)r 2.50 (1.44) 8.06 (3.07) 35.8 (11.4) 59 (12) 74.5 (15.6) 
Pep2-8 435 (202) 156 (78) 3.56 (0.16) 32 (11) 7.63 (1.42) 
 
Data are average of three independent experiments using different PCSK9 surface 
density (RPCSK9 = 2600 RU, 4300 RU, or 5400 RU) with standard deviations shown in 
parentheses. The theoretical maximal binding response of each surface was calculated 
using equation: Rmax = (MWcompound/MWPCSK9) x RPCSK9. The experimental maximal binding 
was obtained from the kinetic fitting and convert to %Rmax so that the compound MW and 
PCSK9 density for each experiment can be normalized and compared. 
 
Flow Cytometry 
 
HepG2 cells were seeded at a density of 1.0x105 cells/well in 24-well plate with DMEM + 
10% FBS medium for 18 h.  After aspiration, cells were washed two times with PBS and 
treated with DMEM supplemented with 10% lipoprotein-deficient serum for another 18 h.  
Inhibitors (50 µM) or pep2-8 (50 µM) at 0.5 % DMSO level and 3 µg/mL PCSK9 in 10% 
lipoprotein-deficient DMEM were pre-incubated for 30 minutes at room temperature 
before adding into each well.  Cells were incubated for 4 h at 37 ºC with 5% CO2.  After 
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treatment, cells were washed twice with PBS and detached with enzyme-free cell 
dissociation buffer (gibco) for 15 min at 37 ºC.  After centrifugation (500 rcf, 5 mins, 4 
ºC), cells were incubated with anti-LDLR antibody (100 µL of 10 µg/mL in 0.5% 
BSA/PBS, Invitrogen) on ice for 20 minutes.  Cells were washed twice with 0.5% 
BSA/PBS and incubated with goat anti-mouse IgG (H+L) Alexa Fluor 647 (100 µL of 10 
µg/mL in 0.5 % BSA/PBS, Invitrogen) on ice for 10 minutes.  After washing twice with 
0.5% BSA/PBS, cells were resuspended in 100 µL 0.5% BSA/PBS and analyzed by flow 
cytometer (BD Accuri™ C6 cytometer, BD Biosciences).  The fluorescence of 30,000 
events of each sample was acquired for data analysis.  Forward scatter versus side 
scatter gates were set to exclude dead cells and debris.  Mean values of the cells 
treated with PCSK9 were set as the minimum LDLR level (0%, negative), and without 
PCSK9 as the maximum LDLR level (100%, positive).  Data from inhibitors were scaled 
as 0-100% according to the negative and positive controls.  All experiments were 
repeated three times individually.   
 
Fluorescent Imaging 
 
HepG2 cells were seeded at the density of 1.0x104 cells/well in 24-well plate with DMEM 
+ 10% FBS medium overnight, and then incubated in 10% lipoprotein-deficient DMEM 
for another 24 h.  Inhibitors (50 µM) or Pep2-8 (50 µM) at 0.5 % DMSO level and 3 
µg/mL PCSK9 in 10% lipoprotein-deficient DMEM were pre-incubated for 30 minutes at 
room temperature before adding into each well.  Cells were incubated for 4 h at 37 ºC 
with 5% CO2.  After treatment, cells were washed twice with PBS and incubated with 300 
µL anti-LDLR antibody (5 µg/mL in delipidated DMEM, Invitrogen) at 37 ºC for 30 
minutes.  Cells were washed twice with PBS and incubated with 300 µL goat anti-mouse 
IgG (H+L) Alexa Fluor 647 (10 µg/mL in delipidated DMEM, Invitrogen) at 37 ºC for 30 
  
 
293 
minutes.  Cells were washed twice with PBS, and then treated with FluoroBrite™ DMEM 
(gibco), and then analyzed with fluorescent microscope (Evos FL Auto 2, Invitrogen).  
The average corrected total cell fluorescence (CTCF) was quantified by ImageJ 
software.  Cells treated with PCSK9 alone were calibrated as 0% (negative), untreated 
with PCSK9 as 100% (positive), and cells treated with compounds and PCSK9 were 
scaled according to the controls.   
 
Table D.2.  QikProp calculations of compounds 16   
Compounds QPlogPo/w PSA (Å3) 
QPPCaco 
(nm/s) 
Rule of 
Five 
Rule of 
Three 
DLLD-16nclk -2.01 278 0.031 3 2 
DLLD-16nclr -2.59 319 0.023 3 2 
DDDL-16vclr -0.38 257 0.62 3 2 
DDDD-16vclr -0.34 262 0.55 3 2 
LDLL-16dlnr -5.68 366 0.001 3 2 
LDLL-16dl(CN)r -4.37 338 0.006 3 2 
LLLL-16qndw -6.19 362 0.001 3 2 
LLLD-16qndr -8.54 421 0 3 2 
DLLL-16qndr -8.54 421 0 3 2 
LLDL-16qndr -8.54 421 0 3 2 
LLDD-16qndr -8.54 421 0 3 2 
DLDL-16endr -7.12 416 0 3 2 
DLDD-16endh -6.45 368 0 3 2 
LLLD-16ldnq -7.08 348 0.002 3 2 
LLLL-16aaar -2.38 270 0.27 3 2 
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QlogPo/w – predicted octanol/water partition coefficient; PSA – Van der Waals surface 
area of polar nitrogen and oxygen atoms; QPPCaco – predicted Caco-2 cell 
permeability; Rule of Five – number of violations of Lipinski’s rule of five; Rule of Three – 
number of violations of Jorgensen’s rule of three. 
 
Solid-phase Syntheses and Characterizations of Compounds 16 
 
Loading methionine linker on resin:  Tentagel-amine resin (600 mg, 0.26 mequiv/g) was 
swollen with CH2Cl2 (5 mL) in a fritted syringe for 15 min, and then in DMF for at least 1 
h.  After removing DMF, Fmoc-Met-OH (232 mg, 0.62 mmol), iPr2NEt (0.22 mL, 1.25 
mmol) dissolved 2.5 mL of 0.25 M HATU/HOAt in DMF solution were added into the 
fritted syringe.  The reaction was heated while stirring under microwave irradiation (100 
W, 75 ºC, 10 min).  Solution was drained, and washed with DMF (4 mL x 5).  The 
completeness of loading was determined by negative Kaiser test.   
 
Fmoc deprotection:  The Fmoc deprotection was performed by shaking beads in 2 mL of 
20% piperidine in DMF for 1 min, drained and the fresh 4 mL of 20% piperidine solution 
was added and heated under microwave irradiation (160 W, 75 ºC, 3 min).  Solution was 
drained, and beads were washed with DMF (4 mL x 5), CH2Cl2 (4 mL x 3), MeOH (4 mL 
x 3) and DMF (4 mL x 3).  
 
Amide coupling:  Fmoc-amino acids or nosyl-containing pip-acids (4 eq) and iPr2NEt (8 
eq) dissolved 2.5 mL of 0.25 M HATU/HOAt in DMF solution were added into the resin 
containing primary- or secondary-amine.  Beads were heated under microwave 
irradiation (100 W, 75 ºC, 10 min), then washed with 4 mL x 5 of DMF.   For arginine 
amino acid, beads were shaken in the coupling solution for 20 minutes at room 
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temperature, and then irradiated with microwave (100 W, 75 ºC, 10 min). The solution 
was changed with the fresh Fmoc-arginine coupling solution and irradiated again with 
the same condition.  For cysteine and histidine amino acids, the coupling reaction was 
performed under microwave at lower temperature to avoid epimerization (100 W, 50 ºC, 
15 min). 
 
Nosyl deprotection:  After coupling with nosyl-containing pip-acids, beads were shaken 
in the solution of mercaptoethanol (5 eq) and DBU (5 eq) in 3 mL of DMF for 15 min at 
room temperature.  The orange solution was drained, washed thrice with 3 mL DMF, and 
beads were shaken again with the fresh solution of mercaptoethanol/DBU for 15 min at 
room temperature.  Beads were washed 5 times with DMF, and a few beads were 
analyzed by chloranil test to confirm the presence of secondary amine.   
 
Hydantoin cyclization:  After the Fmoc deprotection at the R1 position, beads were 
treated twice with the solution of 2 equiv of p-nitrophenyl chloroformate and 4 equiv of 
iPr2NEt in MeCN at ~ 0.05 M concentration.  Beads were shaken at room temperature 
for 30 min each.  After coupling step, beads were washed with MeCN (4 mL x 3), CH2Cl2 
(4 mL x 3) and NMP (4 mL x 3).  Beads were shaken 5 times with 5 mL of 5 % iPr2NEt 
/NMP solution for 1 h each to remove any byproducts.  Beads were washed with NMP (4 
mL x 5), CH2Cl2 (4 mL x 5) and MeOH (4 mL x 5) and dried. 
 
Cleavage from the resin:  Compounds were cleaved off from the beads by treating with 
cyanogen bromide (30 mg/mL) in MeCN/acetic acid/H2O (5:4:1 v/v) solution.  Beads 
were shaken at room temperature for at least 24 h.  After filtration, the crude material 
was dried under nitrogen stream and purified by preparative reversed-phase HPLC (50% 
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- 95% MeCN/water containing 0.05% TFA).  Products were lyophilized to obtain white 
powders. 
 
Side-chain deprotection:  Purified compounds were stirred in TFA/Et3SiH/water 
(95:2.5:2.5 v/v) cocktail for 4 h at room temperature.  Crude materials were dried under 
vacuum, and then precipitated with cold tert-butyl methyl ether.  Solid compounds were 
collected, washed several times with tert-butyl methyl ether to remove any byproducts.  
Compounds were dissolved in water and lyophilized to obtain final products as white 
solids. 
 
(R)-6-Amino-2-((S)-2-(4-((R)-2-((R)-4-(2-amino-2-oxoethyl)-2,5-dioxoimidazolidin-1-yl)-3-
mercaptopropanoyl)piperazin-1-yl)-4-methylpentanamido)-N-((S)-2-oxotetrahydrofuran-
3-yl)hexanamide (DLLD-16nclk) 
 
Data for DLLD-16nclk.  1H NMR (400 MHz, DMSO-d6) δ 8.56 (br, 1H), 8.32 (m, 1H), 
7.79 (m, 4H), 7.48 (m, 1H), 6.99 (m, 1H), 4.72 (m, 1H), 4.50 (m, 1H), 4.37 (m, 1H), 4.33-
4.17 (m, 3H), 3.49-3.39 (m, 4H), 3.37 (m, 1H), 3.10 (m, 1H), 2.94 (m, 1H), 2.75 (m, 2H), 
2.64-2.54 (m, 5H), 2.49-2.36 (m, 2H), 2.16 (m, 1H), 1.69-1.22 (m, 9H), 0.88 (m, 6H);  
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13C NMR (100 MHz, DMSO-d6) δ 175.0, 173.7, 173.6, 171.5, 170.2, 165.0, 155.7, 65.4, 
57.1, 53.4, 53.1, 52.9, 51.9, 49.8, 49.1, 48.2, 44.5, 41.8, 38.6, 36.5, 36.3, 31.0, 28.0, 
26.4, 24.7, 23.0, 22.6, 22.0 
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HRMS (ESI) m/z calcd for C28H47N8O8S+ 655.3232; found 655.3222 (M+H)+  
 
LC 
 
 
06122017_dlld-NCLK #1-73 RT: 0.01-0.70 AV: 73 NL: 6.57E7
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(S)-2-(4-((R)-2-((R)-4-(2-Amino-2-oxoethyl)-2,5-dioxoimidazolidin-1-yl)-3-
mercaptopropanoyl)piperazin-1-yl)-N-((R)-5-guanidino-1-oxo-1-(((S)-2-
oxotetrahydrofuran-3-yl)amino)pentan-2-yl)-4-methylpentanamide (DLLD-16nclr) 
 
Data for DLLD-16nclr. 1H NMR (400 MHz, DMSO-d6) δ 8.57 (m, 1H), 8.32 (m, 1H), 7.58 
(br, 1H), 7.47 (m, 1H), 7.00 (br, 1H), 4.72 (m, 1H), 4.48 (m, 1H), 4.37 (m, 1H), 4.28 (m, 
2H), 4.21 (m, 1H), 3.62 (m, 1H), 3.40-3.23 (m, 4H), 3.10 (m, 3H), 2.94 (m, 1H), 2.63-2.55 
(m, 3H), 2.53-2.48 (m, 2H), 2.48-2.44 (m, 1H), 2.44-2.36 (m, 1H), 2.17 (m, 1H), 1.66 (m, 
1H), 1.61-1.32 (m, 6H), 0.88 (m, 6H);  
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13C NMR (100 MHz, DMSO-d6) δ 174.9, 173.7, 172.5, 171.4, 170.2, 165.0, 156.7, 156.0, 
65.4, 64.6, 57.0, 53.5, 52.9, 51.8, 49.0, 48.3, 44.8, 42.1, 40.4, 36.8, 36.4, 28.9, 28.0, 
24.9, 23.0, 22.5, 22.1 
 
 
HRMS (ESI) m/z calcd for C28H47N10O8S+ 683.3294; found 683.3284 (M+H)+ 
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LC 
 
 
2-((S)-1-((R)-1-(4-((S)-4-Amino-1-(((S)-5-guanidino-1-oxo-1-(((S)-2-oxotetrahydrofuran-
3-yl)amino)pentan-2-yl)amino)-1,4-dioxobutan-2-yl)piperazin-1-yl)-4-methyl-1-
oxopentan-2-yl)-2,5-dioxoimidazolidin-4-yl)acetic acid (LDLL-16dlnr) 
 
 
Data for LDLL-16dlnr. 1H NMR (400 MHz, DMSO-d6) δ 8.31-8.18 (m, 2H), 7.57-7.44 (m, 
1H), 6.92 (br, 1H), 4.70 (m, 1H), 4.20 (m, 1H), 4.13 (m, 1H), 3.91 (m, 1H), 3.86 (m, 1H), 
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3.76 (m, 1H), 3.51-3.25 (m, 4H), 3.10 (m, 2H), 2.68 (d, J = 4.9 Hz, 2H), 2.65-2.45 (m, 
6H), 2.08 (m, 2H), 1.94 (m, 1H), 1.69 (m, 2H), 1.53 (m, 6H), 0.84 (dd, J = 9.4, 6.2 Hz, 
6H) 
 
 
13C NMR (100 MHz, DMSO-d6) δ; 173.9, 172.3, 171.3, 170.1, 168.5, 168.3, 167.3, 
157.1, 157.0, 63.5, 61.5, 54.1, 53.2, 51.9, 49.8, 49.6, 45.1, 42.2, 40.9, 36.9, 35.4, 34.5, 
32.8, 30.7, 24.6, 24.4, 23.4, 21.6 
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HRMS (ESI) m/z calcd for C29H47N10O10+ 695.3471; found 695.3455 (M+H)+ 
 
 
LC 
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2-((S)-1-((R)-1-(4-((S)-3-Cyano-1-(((S)-5-guanidino-1-oxo-1-(((S)-2-oxotetrahydrofuran-
3-yl)amino)pentan-2-yl)amino)-1-oxopropan-2-yl)piperazin-1-yl)-4-methyl-1-oxopentan-2-
yl)-2,5-dioxoimidazolidin-4-yl)acetic acid (LDLL-16dl(CN)r) 
 
Data for LDLL-16dl(CN)r. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (br, 1H), 8.34-8.23 (br, 
2H), 8.06 (br, 1H), 7.45-6.97 (br, 3H), 4.68 (m, 1H), 4.59 (m, 1H), 4.38-4.26 (m, 2H), 
4.26-4.16 (m, 2H), 3.69 (m, 1H), 3.59-3.45 (m, 4H), 3.10 (m, 2H), 2.79 (m, 2H), 2.67-
2.54 (m, 4H), 2.46-2.29 (m, 3H), 2.19 (m, 1H), 2.01 (m, 1H), 1.72 (m, 1H), 1.67-1.41 (m, 
5H), 0.87 (d, J = 6.1 Hz, 3H), 0.85 (d, J = 6.4 Hz, 3H) 
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13C NMR (100 MHz, DMSO-d6) δ 175.0, 173.4, 171.3, 171.2, 168.0, 166.5, 156.8, 156.3, 
119.1, 65.3, 62.7, 53.1, 51.9, 49.2, 48.9, 48.4, 47.9, 45.1, 42.3, 40.2, 36.8, 36.0, 29.2, 
27.9, 24.7, 24.0, 23.0, 21.4, 15.3 
 
HRMS (ESI) m/z calcd for C29H45N10O9+ 677.3365; found 677.3361 (M+H)+
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LC 
 
 
 (S)-3-(4-((S)-4-Amino-2-((S)-4-(3-amino-3-oxopropyl)-2,5-dioxoimidazolidin-1-yl)-4-
oxobutanoyl)piperazin-1-yl)-4-(((R)-5-guanidino-1-oxo-1-(((S)-2-oxotetrahydrofuran-3-
yl)amino)pentan-2-yl)amino)-4-oxobutanoic acid (LLLD-16qndr) 
 
Data for LLLD-16qndr. 1H NMR (400 MHz, DMSO-d6) δ 8.57 (m, 1H), 8.33 (s, 1H), 8.25 
(d, J = 8.3 Hz, 1H), 7.60 (br, 1H), 7.41 (br, 2H), 7.30 (br, 2H), 6.81 (m, 3H), 5.09 (t, J = 
7.0 Hz, 1H), 4.50 (m, 1H), 4.36 (m, 1H), 4.30 (m, 1H), 4.21 (m, 1H), 4.09 (m, 1H), 3.67 
(m, 1H), 3.42-3.17 (m, 4H), 3.09 (m, 2H), 2.87 (dd, J = 15.5, 7.1 Hz, 1H), 2.65 (dd, J = 
15.3, 6.8 Hz, 1H), 2.56 (m, 1H), 2.42 (m, 6H), 2.16 (m, 3H), 1.89 (m, 1H), 1.75 (m, 1H), 
1.69 (m, 1H), 1.58 (m, 1H), 1.47 (m, 2H) 
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13C NMR (100 MHz, DMSO-d6) δ 175.0, 173.6, 173.3, 172.8, 171.4, 171.1, 169.9, 165.8, 
156.7, 155.7, 65.4, 63.4, 55.4, 51.7, 48.9, 48.3, 47.2, 45.0, 42.3, 40.4, 34.2, 30.9, 30.0, 
29.1, 28.0, 27.4, 24.7 
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HRMS (ESI) m/z calcd for C28H44N11O11+ 710.3216; found 710.3218 (M+H)+
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(S)-3-(4-((S)-4-Amino-2-((R)-4-(3-amino-3-oxopropyl)-2,5-dioxoimidazolidin-1-yl)-4-
oxobutanoyl)piperazin-1-yl)-4-(((S)-5-guanidino-1-oxo-1-(((S)-2-oxotetrahydrofuran-3-
yl)amino)pentan-2-yl)amino)-4-oxobutanoic acid (DLLL-16qndr) 
 
Data for DLLL-16qndr. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J = 7.7 Hz, 1H), 8.43-
8.34 (m, 3H), 8.23 (br, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.73 (br, 1H), 7.42 (m, 1H), 7.28 (m, 
2H), 6.81 (m, 2H), 5.08 (m, 1H), 4.53 (m, 1H), 4.39-4.26 (m, 2H), 4.21 (m, 1H), 4.07 (m, 
1H), 3.67 (m, 1H), 3.29 (m, 4H), 3.08 (m, 2H), 2.89 (m, 1H), 2.67-2.53 (m, 2H), 2.48-2.30 
(m, 6H), 2.26-1.99 (m, 3H), 1.90 (m, 1H), 1.73 (m, 2H), 1.64-1.40 (m, 2H), 1.34 (m, 1H) 
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13C NMR (100 MHz, DMSO-d6) δ 175.0, 173.5, 173.3, 171.3, 171.2, 169.8, 167.5, 165.7, 
156.7, 155.7, 65.3, 63.5, 55.4, 51.8, 49.0, 48.0, 47.2, 45.1, 42.2, 40.4, 34.1, 31.7, 30.0, 
29.2, 27.8, 27.5, 24.9 
 
 
 
HRMS (ESI) m/z calcd for C28H44N11O11+ 710.3216; found 710.3216 (M+H)+
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LC 
 
 
(R)-3-(4-((S)-4-Amino-2-((R)-4-(2-carboxyethyl)-2,5-dioxoimidazolidin-1-yl)-4-
oxobutanoyl)piperazin-1-yl)-4-(((S)-5-guanidino-1-oxo-1-(((S)-2-oxotetrahydrofuran-3-
yl)amino)pentan-2-yl)amino)-4-oxobutanoic acid (DLDL-16endr) 
 
Data for DLDL-16endr. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J = 8.0 Hz, 1H), 8.37 
(s, 1H), 8.10 (d, J = 8.3 Hz, 1H), 7.71 (br, 1H), 7.38 (br, 1H), 7.31-6.97 (br, 4H), 6.80 (br, 
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1H), 5.08 (d, J = 7.0 Hz, 1H), 4.66 (m, 1H), 4.35 (m, 1H), 4.29 (m, 1H), 4.22 (m, 1H), 
4.09 (m, 1H), 3.67 (m, 1H), 3.31 (m, 4H), 3.11 (m, 1H), 2.86 (dd, J = 15.5, 7.1 Hz, 1H), 
2.65 (m, 1H), 2.61-2.52 (m, 2H), 2.46-2.36 (m, 6H), 2.33 (m, 2H), 2.15 (m, 1H), 1.94 (m, 
1H), 1.73 (m, 2H), 1.61 (m, 1H), 1.50 (m, 2H) 
 
 
13C NMR (100 MHz, DMSO-d6) δ 175.6, 174.1, 174.0, 173.3, 171.9, 171.6, 170.4, 166.2, 
156.7, 155.7, 65.3, 63.3, 55.1, 51.7, 48.5, 47.8, 47.2, 44.9, 42.3, 40.1, 33.9, 30.9, 29.1, 
29.0, 28.1, 26.9, 24.7  
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HRMS (ESI) m/z calcd for C28H43N10O12+ 711.3056; found 711.3056 (M+H)+ 
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LC 
 
 
(S)-5-Guanidino-2-((S)-2-(4-((S)-2-((S)-4-methyl-2,5-dioxoimidazolidin-1-
yl)propanoyl)piperazin-1-yl)propanamido)-N-((S)-2-oxotetrahydrofuran-3-yl)pentanamide 
(LLLL-16aaar) 
 
Data for LLLL-16aaar. 1H NMR (400 MHz, DMSO-d6) δ 8.54 (d, J = 8.0 Hz, 1H), 8.28 (s, 
1H), 7.94 (d, J = 8.4 Hz, 1H), 7.56 (br, 1H), 6.52 (s, 2H), 4.80 (q, J = 7.1 Hz, 1H), 4.61 
(q, J = 9.3 Hz, 1H), 4.36 (t, J = 8.7 Hz, 1H), 4.31 (m, 1H), 4.23 (m, 1H), 4.09 (q, J = 7.0 
Current Chromatogram(s)
min2 4 6 8 10 12 14
mAU
0
200
400
600
800
1000
1200
1400
 DAD1 B, Sig=210,4 Ref=360,100 (D:\Burgess...roup\Jaru\data\dldl_endr_oldcolumn_003 2017-11-03 20-05-57.D)
2.
07
1
2.
64
8
3.
11
6
3.
54
2
3.
78
1
4.
46
6
4.
75
6
5.
77
9
6.
07
3
6.
54
3
6.
97
1
7.
10
5
7.
61
2
7.
90
3
8.
87
8
9.
51
5
9.
83
4
10
.0
51
10
.3
23
11
.1
95
Print of window 38: Current Chromatogram(s)
lcms 11/5/2017 8:46:10 PM SYSTEM Page 1 of 1
HN N
O
O
O
N
N
O
N
H O
H
N
O
O
NH
HN NH2
  
 
315 
Hz, 1H), 3.60-3.41 (m, 4H), 3.17 (m, 1H), 3.12 (m, 2H), 2.41 (m, 5H), 2.17 (m, 1H), 1.72 
(m, 1H), 1.59 (m, 1H), 1.48 (m, 2H), 1.42 (d, J = 7.1 Hz, 3H), 1.26 (d, J = 6.9 Hz, 3H), 
1.09 (d, J = 6.9 Hz, 3H) 
 
 
13C NMR (100 MHz, DMSO-d6) δ 175.0, 174.6, 172.0, 171.3, 167.0, 156.6, 155.7, 65.3, 
62.4, 51.6, 51.3, 49.1, 47.8, 46.5, 45.0, 42.1, 40.3, 29.5, 27.9, 24.8, 17.3, 14.8, 12.3 
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HRMS (ESI) m/z calcd for C24H40N9O7+ 566.3045; found 566.3042 (M+H)+ 
 
 
Solid-phase Syntheses and Characterizations of Compounds 17 and 18 
 
The derivatives of LDLL-16dlnr, compounds 17 and 18, were synthesized by solid-phase 
and solution-phase syntheses.  To synthesize the core structure, solid-phase synthesis 
was performed using 2-Cl-Trt resins loaded with Fmoc-b-Ala-OH.  The protocols were 
the same as the syntheses of compounds 12 in Appendix C to obtain the protected-form 
of compound 17.  The crude product after cleaving with 20% HFIP/CH2Cl2 was reacted 
with the photoaffinity fragment 19 (1.1 eq), HBTU (1.1 eq) and iPr2NEt (3 eq) in DMF.  
The reaction was stirred at room temperature for 12 h.  Solvent was completely 
removed, redissolved in CH2Cl2 and extracted with 10% citric acid, saturated NaHCO3 
and brine.  The organic solution was collected, dried and removed in vacuo.  Crude 
material was subsequently treated with TFA/Et3SiH/water (95:2.5:2.5 v/v) for 3 h, solvent 
was removed with N2 stream, and the crude material was purified by preparative 
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317 
reverse-phase HPLC (10% - 50% MeCN/H2O containing 0.05% TFA) to obtain 
compound 18 as white solids.  For compound 17, crude material after cleavage from 
beads was treated with TFA/Et3SiH/water cocktail and purified by preparative reverse-
phase HPLC (10% - 50% MeCN/water containing 0.05% TFA).  
 
3-((S)-2-((S)-4-Amino-2-(4-((R)-2-((S)-4-(carboxymethyl)-2,5-dioxoimidazolidin-1-yl)-4-
methylpentanoyl)piperazin-1-yl)-4-oxobutanamido)-5-guanidinopentanamido)propanoic 
acid (17) 
 
Data for Compound 17. 1H NMR (400 MHz, DMSO-d6) δ 8.49 (br, 1H), 8.34 (m, 1H), 
7.98 (m, 1H), 7.62 (br, 2H), 7.06 (br, 2H), 4.72 (m, 1H), 4.25 (m, 1H), 4.18 (m, 1H), 3.89 
(m, 1H), 3.65-3.33 (m, 4H), 3.26 (m, 2H), 3.10 (m, 2H), 2.86-2.70 (m, 4H), 2.70-2.60 (m, 
3H), 2.60-2.53 (m, 1H), 2.38 (t, J = 7.2 Hz, 2H), 2.07 (m, 1H), 1.76 (m, 1H), 1.62-1.40 
(m, 5H), 0.87 (m, 6H);  
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13C NMR (100 MHz, DMSO-d6) δ 173.2, 172.8, 172.7, 171.8, 170.9, 170.8, 166.7, 156.8, 
156.4, 63.2, 52.7, 52.4, 49.4, 49.1, 43.9, 41.1, 40.4, 36.6, 35.2, 34.9, 33.7, 33.5, 28.7, 
25.1, 24.0, 23.1, 21.3  
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HRMS (ESI) m/z calcd for C28H47N10O10+ 683.3471; found 683.3457 (M+H)+ 
 
LC 
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2-((S)-1-((R)-1-(4-((S)-4-Amino-1-(((S)-5-guanidino-1-oxo-1-((3-oxo-3-(4-(prop-2-yn-1-
yl(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)amino)piperidin-1-
yl)propyl)amino)pentan-2-yl)amino)-1,4-dioxobutan-2-yl)piperazin-1-yl)-4-methyl-1-
oxopentan-2-yl)-2,5-dioxoimidazolidin-4-yl)acetic acid (18) 
 
Data for Compound 18. 1H NMR (400 MHz, DMSO-d6) δ 8.49 (br, 1H), 8.34 (m, 1H), 
7.93 (br, 1H), 7.66-7.57 (br, 2H), 7.53 (d, J = 7.7 Hz, 2H), 7.30 (d, J = 7.9 Hz, 2H), 7.06 
(br, 2H), 4.72 (m, 1H), 4.40 (m, 1H), 4.25 (m, 1H), 4.19 (m, 1H), 3.99 (s, 2H), 3.85 (m, 
4H), 3.55-3.32 (m, 7H), 3.26 (m, 2H), 3.10 (m, 2H), 3.02 (m, 1H), 2.85-2.70 (m, 4H), 2.68 
(m, 2H), 2.63 (m, 2H), 2.47 (m, 2H), 2.07 (m, 1H), 1.97 (m, 2H), 1.78 (m, 1H), 1.61-1.38 
(m, 7H), 0.86 (m, 6H) 
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13C NMR (100 MHz, DMSO-d6) δ 173.3, 171.9, 170.9, 170.8, 168.6, 168.5, 166.7, 156.8, 
156.4, 130.1, 127.0, 126.6, 123.0, 120.9, 77.8, 63.3, 59.1, 52.7, 52.5, 52.4, 49.4, 49.1, 
43.9, 43.7, 41.1, 40.3, 38.7, 36.6, 35.4, 35.1, 33.4, 32.3, 28.7, 27.9, 25.1, 24.0, 23.1, 
21.3 
 
 
19F NMR spectrum 
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HRMS (ESI) m/z calcd for C45H64F3N14O9+ 1001.4927; found 1001.4897 (M+H)+
 
 
LC 
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Solution-phase Syntheses of LDLL-16dlnr 
 
Synthesis of L-homoserine lactone hydrobromide salt 
 
L-methionine (2.98 g, 20 mmol) and bromoacetic acid (3.06 g, 22 mmol) were dissolved 
in iPrOH, H2O and AcOH (5:5:2, 30 mL).  Mixture was stirred in the reflux condition for 
12 h, then solvent was completely removed under vacuum to obtain dark brown oil.  This 
crude was dissolved in 4:1 iPrOH:HBr in 33 % AcOH, and let it cool in the fridge to 
induce white precipitate.  Solid was filtered and washed with iPrOH.  The supernatant 
was concentrated in vacuo and reprecipitated again with the same condition.  
Precipitation was repeated until no further solid formed.  All crops of precipitate were 
combined to obtain the product as a hydrobromide salt (2.76 g, 75%). NMR spectra were 
identical to the reference.179 
 
Synthesis of dipeptide LD-7d’l  
 
L-Fmoc-Asp(tBu)-OH (1.94 g, 4.72 mmol), EDCI (1.00 g, 5.19 mmol) and HOBt (0.70 g, 
5.19 mmol) were stirred in 50 mL CH2Cl2 at 0 ºC under N2 atmosphere for 30 min.  
iPr2NEt (2.5 mL, 14.2 mmol) was added followed by D-Leu-OBn (1.04 g, 4.72 mmol).  
The reaction was allowed to stir at room temperature for 12 h, then was diluted with 100 
mL CH2Cl2 and extracted three times with 10% citric acid, three times with saturated 
NaHCO3 and brine.  Organic phase was dried with MgSO4 and evaporated in vacuo to 
obtain the product as a white solid (2.67 g, 92%), which was used in the next step 
without further purification.   
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Synthesis of hydantoin LD-8d’l  
 
Dipeptide LD-7d’l (0.62 g, 1.00 mmol) was stirred in Et2NH/CH2Cl2 solution (4 mL, 1:1 
v/v) for 3 h, solvent was removed in vacuo, and then the crude material was purified by 
flash column chromatography using 2-5% MeOH/CH2Cl2 with 0.1% Et3N to obtain 
product as a clear oil.  Purified NH2-dipeptide (0.40 g, 1.00 mmol) and NaHCO3 (0.25 g, 
3.03 mmol) were dissolved in 20 mL MeCN.  p-Nitrophenyl chloroformate (0.21 g, 1.1 
mmol) was added and the reaction was stirred at room temperature for 3 h under N2 
atmosphere.  Water (~ 10 mL) was added to produce bright yellow solution, which was 
stirred for additional 12 h at room temperature.  Organic solvent was removed in vacuo, 
then EtOAc (100 mL) was added into the aqueous solution.  The organic layer was 
separated, and extracted with 5% Na2CO3 five times to remove p-nitrophenol byproduct.  
The clear organic solution was further dried with brine and MgSO4.  The mixture was 
reduced in vacuo to obtain crude oil, which was purified by flash column chromatography 
using EtOAc:hexanes (1:4 v/v) to obtain product as a white solid (0.34 g, 80%)     
 
Benzyl ester deprotection (LD-20d’l) 
 
Hydantoin LD-8d’l (2.51 g, 6 mmol) and 10% Pd/C (620 mg, 0.6 mmol) were purged 
under N2 before adding 50 mL MeOH.  H2 balloon was purged for 10 min, and the 
reaction was stirred under H2 atmosphere for 12 h.  The mixture was filtered through 
celite and the clear solution was reduced in vacuo to obtain compound LD-20d’l  (1.99 g, 
100%) as clear oil. 
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Benzyl (R)-2-((S)-4-(2-(tert-butoxy)-2-oxoethyl)-2,5-dioxoimidazolidin-1-yl)-4-
methylpentanoate (LD-8d’l) 
 
Data for LD-8d’l.  1H NMR (400 MHz, CDCl3) δ 7.39-7.30 (m, 5H), 5.90 (br, 1H), 5.17 (d, 
J = 6.0 Hz, 2H), 4.77 (dd, J = 11.5, 4.4 Hz, 1H) 4.29 (m, 1H), 2.93 (dd, J = 17.4, 2.8 Hz, 
1H), 2.39-2.27 (m, 2H), 1.96-1.87 (m, 1H), 1.58-1.50 (m, 1H), 1.48 (s, 9H) 0.94 (dd, J = 
6.6, 3.6 Hz, 6H) 
 
HN
NO
O
CO2Bn
iPr
tBuO2C
[ppm] 7  6  5  4  3  2  1 
[re
l]
- 
0.
0 
 0
.5
 
 1
.0
 
 1
.5
 
 2
.0
 
 2
.5
 
LD_hydantoin_D(tBu)L_OBn  1  1  /Users/jaru/NMR_all/jtaechal
HN
NO
O
tBuO2C
O
O
Ph
1 
1 
1 
2 
2 
3 
3 
4 
4 
4 
5 
5 
5 
6 
6 
7 
7 
8 
8 
9 
9 
10 
10 
  
 
326 
13C NMR (100 MHz, CDCl3) δ 172.6, 169.8, 169.5, 156.2, 135.5, 128.8, 128.6, 128.4, 
82.6, 67.8, 53.7, 51.7, 37.8, 36.7, 28.3, 25.4, 23.3, 21.3 
 
 
HRMS (ESI) m/z calcd for C22H30N2NaO6Na+ 441.1996; found 441.1989 (M+Na)+
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General Procedure of Amide Coupling with HBTU 
  
N-protected amino acid (1 eq) was activated with HBTU (1.1 eq) and iPr2NEt (1 eq) in 
DMF (0.2 M) at 0 ºC for 10 min.  Then, amine compound (1 eq) was added followed by 
iPr2NEt (2.5 eq).  Reaction was stirred at ambient temperature for 12 h under N2 
atmosphere.  DMF was removed in vacuo, then crude material was redissolved in EtOAc 
and extracted with 10% citric acid, saturated NaHCO3 and brine.  After drying with 
MgSO4, the compound was purified by flash column chromatography using 5% 
MeOH/CH2Cl2 to obtain product.  
 
Nosyl deproection   
 
Compound LL-22n’r’ (0.80 g, 0.71 mmol) was dissolved in 7 mL DMF, then 
mercaptoethanol (0.10 mL, 1.43 mmol) and DBU (0.21 mmol, 1.43 mmol) were added 
subsequently, and the reaction was stirred for 2 h.  After the reaction completed, the 
mixture was diluted with EtOAc and extracted 3 times with saturated NaHCO3.  The 
organic phase was dried over Na2SO4 and removed in vacuo to obtain crude oil.  Small 
amount of CH2Cl2 was added to dissolve oil, then cold tert-butyl methyl ether was added 
to induce precipitation.  The solid was filtered, washed with ether to obtain product LL-
23n’r’ as a solid (0.64 g, 96%).   
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(9H-Fluoren-9-yl)methyl ((S)-1-oxo-1-(((S)-2-oxotetrahydrofuran-3-yl)amino)-5-(3-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2-
yl)carbamate (L-21r’) 
 
 
Data for L-21r’. 1H NMR (400 MHz, CDCl3) δ 8.02 (br, 1H), 7.74 (d, J = 7.7 Hz, 2H), 
7.58 (m, 2H), 7.36 (t, J = 7.4 Hz, 2H), 7.30-7.22 (m, 2H), 6.34 (br, 1H), 6.07 (br, 2H), 
4.76 (m, 1H), 4.49-4.37 (m, 2H), 4.37-4.29 (m, 2H), 4.27-4.12 (m, 2H), 3.43 (m, 1H), 
3.17 (m, 1H), 2.92 (s, 2H), 2.60 (s, 3H), 2.51 (m, 4H), 2.46-2.31 (m, 1H), 2.08 (s, 3H), 
1.98-1.88 (m, 1H), 1.80-1.68 (m, 1H), 1.68-1.58 (m, 2H), 1.44 (m, 7H) 
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13C NMR (100 MHz, CDCl3) δ 176.5, 173.4, 159.1, 156.9, 156.6, 144.1, 144.0, 141.5, 
138.6, 132.8, 132.5, 127.9, 127.3, 125.4, 124.9, 120.1, 117.8, 86.6, 67.3, 66.5, 54.2, 
48.9, 47.3, 43.4, 40.1, 30.3, 28.8, 28.5, 25.4, 19.5, 18.2, 12.7, 12.6 
 
 
HRMS (ESI) m/z calcd for C38H46N5O8S+ 732.3062; found 732.3047 (M+H)+
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(S)-2-(4-((4-Nitrophenyl)sulfonyl)piperazin-1-yl)-N1-((S)-1-oxo-1-(((S)-2-
oxotetrahydrofuran-3-yl)amino)-5-(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino)pentan-2-yl)-N4-tritylsuccinamide (LL-22n’r’) 
 
Data for LL-22n’r’.  1H NMR (400 MHz, CDCl3) δ 8.33 (d, J = 8.7 Hz, 2H), 7.89 (d, J = 
8.6 Hz, 2H), 7.08 (s, 15H), 5.96 (br, 2H), 4.27 (m, 2H), 4.01 (m, 2H), 3.74 (m, 1H), 3.16-
3.04 (m, 3H), 3.00 (m, 4H), 2.94 (m, 4H), 2.78-2.59 (m, 5H), 2.51 - 2.44 (m, 8H), 2.22-
2.10 (m, 2H), 2.08 (s, 3H), 1.79 (m, 2H), 1.56 (m, 2H), 1.45 (s, 6H) 
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13C NMR (100 MHz, CDCl3) δ 170.3, 170.1, 168.9, 168.4, 159.0, 156.6, 150.5, 144.4, 
142.0, 138.4, 133.1, 132.4, 129.2, 128.8, 128.0, 127.2, 124.9, 124.7, 117.7, 86.7, 70.7, 
63.8, 61.3, 55.1, 54.5, 52.7, 48.8, 46.5, 43.5, 43.2, 40.5, 36.2, 32.9, 31.3, 28.8, 24.9, 
19.5, 18.1, 12.7, 12.6 
 
 
 
HRMS (ESI) m/z calcd for C56H66N9O12S2+ 1120.4267; found 1120.4252 (M+H)+
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tert-Butyl 2-((S)-1-((R)-1-(4-((S)-1,4-dioxo-1-(((S)-1-oxo-1-(((S)-2-oxotetrahydrofuran-3-
yl)amino)-5-(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino)pentan-2-yl)amino)-4-(tritylamino)butan-2-yl)piperazin-1-yl)-4-
methyl-1-oxopentan-2-yl)-2,5-dioxoimidazolidin-4-yl)acetate (LDLL-16d’ln’r’) 
 
Data for LDLL-16d’ln’r’. 1H NMR (400 MHz, CDCl3) δ 8.15 (br, 1H), 7.75 (br, 2H), 7.20 
(m, 15H), 7.02 (m, 1H), 5.58 (m, 3H), 4.79 (m, 1H), 4.26 (m, 4H), 4.01 (m, 2H), 3.79-3.39 
(m, 4H), 3.14 (m, 5H), 2.96 (m, 4H), 2.84-2.69 (m, 2H), 2.55 (m, 1H), 2.50 (s, 3H), 2.43 
(s, 3H), 2.21 (m, 2H), 2.09 (m, 4H), 1.80 (m, 2H), 1.71-1.51 (m, 4H), 1.47 (m, 6H), 1.43 
(s, 9H) 0.92 (m, 6H);  
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13C NMR (100 MHz, CDCl3) δ 173.0, 169.1, 168.7, 168.6, 168.3, 167.8, 167.7, 161.8, 
161.5, 157.1, 143.9, 128.6, 127.9, 127.2, 82.2, 70.9, 63.4, 62.4, 54.2, 53.5, 52.3, 50.0, 
43.5, 43.3, 40.7, 37.0, 36.9, 34.6, 32.3, 30.4, 28.5, 28.0, 24.8, 22.9, 21.4, 19.1, 17.6, 
12.4  
 
 
HRMS (ESI) m/z calcd for C65H85N10O13S+ 1245.6013; found 1245.6013 (M+H)+ 
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APPENDIX E 
SUPPORTING INFORMATION FOR CHAPTER V 
 
Matching Analyses of Dipeptide Fragments on Ideal Secondary Structures 
 
All the mimics featured in Chapter V may be considered as modular, made up of 
dipeptide mimics connected to another fragment that projects a third amino acid.  We 
decided to compare common dipeptide fragments overlaid on ideal secondary 
structures.  To facilitate this, the algorithm at the heart of EKOS was modified to 
evaluate overlays on dipeptide mimics.  
 
All the mimics overlaid on all the secondary structures with an RMSD of <1.2 Å, except 
37 and 39 that did not match well with turns and b-strands.  Consequently, RMSD 
scores for the best overlays for each mimic (over all isomers) were averaged to give the 
data in Figure E.1a, but matches for 37 and 39 on turns and b-strands were not 
considered.  These data indicate 35 and 36 were the best dipeptide mimics in the series 
(Figure E.1).  Mimic 42 is interesting because it is the core of the so-called 
“triazolamers”, and the best dipeptide mimic for helical structures was 38.  Conversely, 
there could be clear reasons to anticipate other mimics in the series would not overlay 
well.  For instance, 44 has an inappropriate Ca - Ca separation, while mimic 45 is locked 
in a cis-amide bond conformation.  Consequently, henceforth the discussion of dipeptide 
mimics is restricted to 35, 36, 38, and 42.  
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Ketopiperazine 35 and hydantoin 36 were the most promising dipeptide mimics in 
general; both have a bias towards extended structures; they fit better than the 
triazolamers core in 42.  While 38 is an inferior universal mimic, its bias towards helical 
structures is notable, especially since nearly all the mimics A, 1, 2 and 24-29 prefer 
extended conformations.  Chemotypes 35 and 36 are reasonable helical mimics, with a 
bias towards looser, p-helical forms, while tightly wound, 310-helical, conformations are 
preferred by 38.  
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a 
 
b 
 
Figure E.1. (a) Average RMSD for overlays on all ideal secondary structures (except for 
17 and 19 on turns and b-strands). (b) and (c) Overlays for the best general dipeptide 
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mimics in the series, ie 35 and 36. (d) Overlays for the triazolamers core, 42. (e) 
Overlays for a good dipeptide to use in helical mimics, 38.  Overlays for all other 
dipeptide mimics (f – l) represent 37, 39, 40, 41, 43, 44, 45. 
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Figure E.1  Continued. 
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Figure E.1  Continued. 
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Figure E.1  Continued. 
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Figure E.1  Continued. 
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Figure E.1  Continued. 
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Table E.1  Number of conformers and clusters generated from QMD (< 3 kcal/mol from 
lowest energy). 
 
mimic configuration number of conformers number of clusters 
A 
LLL 469 6 
LLD 782 6 
LDL 577 7 
DLL 636 8 
LDD 647 9 
DLD 820 12 
DDL 505 3 
DDD 310 3 
1 
LLL 1500 8 
LLD 1500 9 
LDL 1500 8 
DLL 1500 8 
LDD 1500 9 
DLD 1500 8 
DDL 1500 9 
DDD 1500 8 
2 
L 1500 3 
D 1500 3 
24 
LLL 1180 17 
LLD 1178 19 
LDL 1229 17 
DLL 1227 15 
LDD 1230 18 
DLD 1285 35 
DDL 1202 16 
DDD 1275 18 
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Table E.1  Continued. 
25 
LL 1476 19 
DL 1483 18 
LD 1485 16 
DD 1478 18 
26 
LLL 1500 22 
LLD 1500 21 
LDL 1500 23 
DLL 1500 22 
LDD 1500 21 
DLD 1500 22 
DDL 1500 21 
DDD 1500 23 
27 
LLL 1500 11 
LLD 1500 19 
LDL 1499 21 
DLL 1500 19 
LDD 1500 17 
DLD 1498 20 
DDL 1499 16 
DDD 1500 19 
28 
LLL 1499 32 
LLD 1498 38 
LDL 1499 36 
DLL 1499 33 
LDD 1498 37 
DLD 1497 36 
DDL 1497 35 
DDD 1498 33 
29 
L 1500 2 
D 1500 3 
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Crystal Structure Determination of L-2fff  
 
 
 
 
Crystal Data for C27H24N4O (M =420.50): orthorhombic, space group P212121 (no. 19), 
a = 5.4354(6) Å, b = 12.4749(13) Å, c = 32.922(3) Å, V = 2232.3(4) Å3, Z = 4, T = 
110.0 K, μ(CuKα) = 0.616 mm-1, Dcalc = 1.251 g/mm3, 49719 reflections measured 
(5.368 ≤ 2Θ ≤ 128.728), 3669 unique (Rint = 0.0731, Rsigma = 0.0349) which were used in 
all calculations. The final R1 was 0.0423 (I > 2σ(I)) and wR2 was 0.1083 (all data).  
N
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APPENDIX F 
 
EXPERIMENTAL PROCEDURES FOR CHAPTER VI 
 
Matching Results of 30 On Ideal Secondary Structures And Crystal Structure 
 
Figure F.1.  Predicted mimicry of secondary structures for all diastereomers of 30aaa 
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Figure F.1.  Continued. 
c LDL-30aaa
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Figure F.1.  Continued. 
 
f DLD-30aaa
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X-Ray of LLL-30-fii   
 
 
Crystal Structure Determination Of LLL-30fii 
 
Crystal Data for C48H71N6O4 (M =796.10): monoclinic, space group P21 (no. 4), a = 
12.8948(11) Å, b = 9.7854(8) Å, c = 18.3889(16) Å, β = 94.667(6)°, V = 2312.6(3) Å3, Z = 
2, T = 110 K, μ(CuKα) = 0.572 mm-1, Dcalc = 1.143 g/mm3, 24722 reflections measured 
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(8.074 ≤ 2Θ ≤ 127.854), 7347 unique (Rint = 0.1116) which were used in all calculations. 
The final R1 was 0.0694 (I > 2σ(I)) and wR2 was 0.1819 (all data).  
 
Figure F.2.  Overlay of two different LLL-30fii conformers from crystal.  Conformer 1 and 
2 are shown in red and purple, respectively.  RMSD = 0.28 Å based on the 6 Ca and 
Cb coordinates. 
 
Figure F.3.  Predicted mimicry of secondary structures for conformer 1 and 2 from 
crystal.  
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Figure F.3.  Continued.  
General Procedure For The Preparation of C-terminal Dipeptide Amino Alcohol (31) 
 
 
Table F.1. Summary of dipeptide amino alcohol 31 
 PG R2 R3 Yield (%) 
L,D-31vv Fmoc L-Val D-Val 87 
L,L-31ii Fmoc L-Ile L-Ile 90 
L,D-31ff Cbz L-Phe D-Phe 92 
D,L-31t’d’ Fmoc D-Thr(Bn) L-Asp(tBu) 81 
D,L-31pv Fmoc D-Pro L-Val 93 
D,L-31pw Fmoc D-Pro L-Trp 80 
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Table F.1. Continued. 
L,L-31py’ Fmoc L-Pro L-Tyr(tBu) 91 
D,L-31d’k’ Fmoc D-Asp(tBu) L-Lys(Cbz) 87 
D,L-31y’s’ Fmoc D-Tyr( tBu) L-Ser(Bn) 82 
L,L-31ae’ Fmoc L-Ala L-Glu(tBu) 96 
L,D-31d’t’ Fmoc L-Asp(tBu) D-Thr(Bn) 71 
 
A representative synthesis of the L,D-31vv is described as follows: 
 
Unless the amino alcohols were commercially available, they are prepared from 
corresponding amino acids as previously described.197  A solution of Fmoc-L-valine (4.91 
g, 14.46 mmol) in dichloromethane (150 mL) was cooled to 0 ºC in an ice bath, D-valinol 
(1.79 g, 17.35 mmol), HOBt (2.93 g, 21.69 mmol) and EDCI (4.16 g, 21.69 mmol) were 
added in sequence.  The resulting solution was stirred at 0 ºC for 15 min, then N-methyl 
morpholine (2.70 mL, 24.58 mmol) was added.  The ice bath was removed and the 
reaction was stirred at ambient temperature for 4 – 5 h until the disappearance of 
starting material as monitored by TLC.  The resulting solution was washed successively 
with cold 5 % KHSO4 aqueous solution (3 × 50 mL), saturated NaHCO3 solution (3 × 50 
mL), and brine (75 mL).  The combined organic layer was dried over MgSO4 and filtered.  
The solvent was removed under vacuum and the resulting residue was crystallized using 
CH2Cl2-hexanes (1:4) to afford 5.35 g (87 %) of product as white solid.  The compound 
was used in next step without further purification.  
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General Procedure for the Preparation of N-protected Oxazoline (32) 
 
 
A representative synthesis of the L,D-32vv is described as follows: 
 
Compound L,D-31vv (0.25 g, 0.60 mmol) was dissolved in dry CH2Cl2 (40 mL) and 
cooled down using an ice bath. 4-Dimethylaminopyridine (7.33 mg, 0.06 mmol) and 
freshly distilled diisopropylethylamine (0.40 mL, 2.10 mmol) were added in sequence.  
The resulting clear solution was stirred at 0 ºC for 5min then a solution of 
methanesulfonyl chloride (0.06 mL, 0.72 mmol) in dry CH2Cl2 (50 mL) was added 
dropwise.  The ice bath was removed and the reaction mixture was stirred at 25 ºC for 1 
h until completion, as determined by TLC.  The reaction was quenched with saturated 
NH4Cl solution (50 mL) and the two phases were separated.  The aqueous phase was 
extracted with CH2Cl2 (3 × 50 mL) and the combined organic layers were washed with 
brine (75 mL), then dried over anhydrous Na2SO4.  Removing all the solvent gave crude 
product L,D-32vv which was chromatographed on silica gel with hexanes-EtOAc (6:4) 
then CH2Cl2-MeOH (98:2), affording the product (0.22 g, 92 %) as slightly yellow oil. 
 
(9H-Fluoren-9-yl)methyl (S)-1-((R)-4-iso-propyl-4,5-dihydrooxazol-2-yl)-2-
methylpropylcarbamate (L,D-32vv) 
 
O
N R
3
H
N
R2
32
PG
O
NFmocHN
  
 
353 
Data for L,D-32vv. 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 7.4 Hz, 2H), 7.58 (t, J = 6.9 
Hz, 2H), 7.34 (t, J = 7.3 Hz, 2H), 7.26 (t, J = 7.3 Hz, 2H), 5.66 (br, 1H), 4.36 (m, 3H), 
4.20 (d, J = 7.0 Hz, 2H), 3.91 (m, 2H), 2.11 (m, 1H), 1.72 (m, 1H), 1.02 – 0.79 (m, 12H).  
13C NMR (100 MHz, CDCl3) δ 166.2, 156.8, 155.9, 143.6, 141.0, 127.3, 126.7, 124.8, 
119.6, 71.5, 70.1, 66.6, 54.3, 47.0, 32.1, 31.2, 18.6, 17.9.  MS (ESI) m/z calcd for 
C25H31N2O3+ 407.2329; found 407.2060 (M+H)+. 
1H NMR spectrum: 
 
13C NMR spectrum: 
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(9H-Fluoren-9-yl)methyl (1S,2S)-1-((S)-4-((R)-sec-butyl)-4,5-dihydrooxazol-2-yl)-2-
methylbutylcarbamate (L,L-32ii) 
 
Data for L,L-32ii.  White solid, 1.83 g (91%).  1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 
7.5 Hz, 2H), 7.63 (d, J = 7.4 Hz, 2H), 7.45 – 7.37 (m, 2H), 7.32 (m, 2H), 5.62 (br, 1H), 
4.51 – 4.35 (m, 3H), 4.27 (m, 2H), 4.07 (br, 2H), 1.90 (br, 1H), 1.54 (m, 3H), 1.30 – 1.08 
(m, 2H), 0.94 (dd, J = 12.1, 6.7 Hz, 9H), 0.84 (d, J = 6.7 Hz, 3H).  13C NMR (100 MHz, 
CDCl3) δ 166.0, 156.0, 143.9, 141.3, 127.6, 127.0, 125.2, 119.9, 70.3, 70.1, 66.9, 53.8, 
47.3, 38.9, 38.3, 25.9, 24.9, 15.3, 14.4, 11.6, 11.5.  HRMS (ESI) m/z calcd for 
C27H35N2O3+ 435.2624; found 435.2651 (M+H)+.  
 
1H NMR spectrum: 
 
13C NMR spectrum: 
O
NFmocHN
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356 
Benzyl (S)-1-((S)-4-benzyl-4,5-dihydrooxazol-2-yl)-2-phenylethylcarbamate (L,D-32ff) 
 
Data for L,D-32ff.  White solid, 1.14 g (95%). 1H NMR (400 MHz, CDCl3) δ 7.39-7.17 (m, 
11H), 7.16-7.06 (m, 4H), 5.35 (br, 1H), 5.12 (m, 2H), 4.72 (br, 1H), 4.28 (m, 1H), 4.19 
(m, 1H), 4.00 (m, 1H), 3.17-3.07 (m, 1H), 3.07-2.91 (m, 2H), 2.56 (m, 1H). 13C NMR (100 
MHz, CDCl3) δ 166.2, 156.0, 137.7, 136.6, 136.2, 129.3, 129.2, 128.8, 128.7, 128.5, 
128.2, 128.0, 127.1, 72.0, 67.1, 66.9, 50.1, 41.3, 38.4. HRMS (ESI) m/z calcd for 
C26H27N2O3+ 415.2016; found 415.2031 (M+H)+.  
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
tert-Butyl 2-((S)-2-((1R,2R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(benzyloxy)propyl)-
4,5-dihydrooxazol-4-yl)acetate (D,L-32t’d’) 
 
Data for D,L-32t’d’.  White solid, 370 mg (81%). 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J 
= 7.5 Hz, 2H), 7.63 (m, 2H), 7.41 – 7.25 (m, 9H), 5.81 (d, J = 9.3 Hz, 1H), 4.60 (d, J = 
11.8 Hz, 1H), 4.52 (d, J = 9.1 Hz, 1H), 4.49 – 4.35 (m, 5H), 4.24 (t, J = 7.1 Hz, 1H), 4.09 
(m, 1H), 3.91 (t, J = 6.9 Hz, 1H), 2.82 (dd, J = 16.3, 3.5 Hz, 1H), 2.30 – 2.19 (m, 1H), 
1.46 (s, 9H), 1.29 – 1.22 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 170.1, 166.0, 156.3, 
143.6, 141.1, 137.9, 128.1, 127.6, 127.5, 127.4, 126.8, 125.0, 119.7, 80.7, 74.3, 73.3, 
72.0, 70.9, 66.9, 62.5, 53.9, 47.0, 41.3, 27.9, 14.0; MS (ESI) m/z calcd for C34H39N2O6+ 
571.2803; found 571.2800 (M+H)+.  
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
(R)-(9H-Fluoren-9-yl)methyl 2-((S)-4-iso-propyl-4,5-dihydrooxazol-2-yl)pyrrolidine-1-
carboxylate (D,L-32pv) 
 
Data for D,L-32pv.  Off-white crystal, 730 mg (54%) . 1H NMR (400 MHz, CDCl3) δ 7.70 
(d, J = 7.4 Hz, 2H), 7.59 (m, 2H), 7.35 (t, J = 7.3 Hz, 2H), 7.27 (m, 2H), 4.57 (d, J = 7.7 
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Hz, 1H), 4.46 (m, 1H), 4.35 (m, 1H), 4.21 (m, 2H), 3.98 – 3.81 (m, 2H), 3.69 – 3.57 (m, 
1H), 3.55 – 3.41 (m, 1H), 2.22 – 2.06 (m, 1H), 2.06 – 1.96 (m, 2H), 1.96 – 1.83 (m, 1H), 
1.83 – 1.63 (m, 1H), 0.95 – 0.86 (m, 3H), 0.82 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 
166.8, 154.4, 143.7, 141.1, 127.4, 126.8, 125.2, 125.0, 119.7, 71.9, 70.2, 70.0, 67.3, 
55.0, 54.8, 47.5, 47.1, 46.3, 31.8, 30.8, 24.0, 23.1, 18.5. MS (ESI) m/z calcd for 
C25H29N2O3+ 405.2173; found 405.2703 (M+H)+  
 
1H NMR spectrum: 
 
13C NMR spectrum: 
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(R)-(9H-Fluoren-9-yl)methyl 2-((S)-4-((1H-indol-3-yl)methyl)-4,5-dihydrooxazol-2-
yl)pyrrolidine-1-carboxylate (D,L-32pw) 
 
Data for D,L-32pw.  White solid, 1.41 g (69%). 1H NMR (400 MHz, CDCl3) δ 9.07 (s, 
1H), 7.74 (m, 2H), 7.69 – 7.50 (m, 3H), 7.38 (m, 2H), 7.34 – 7.23 (m, 3H), 7.14 (t, J = 7.3 
Hz, 1H), 7.07 (t, J = 7.3 Hz, 1H), 6.90 (s, 1H), 4.63 – 4.43 (m, 2H), 4.43 – 4.29 (m, 1H), 
4.25 – 4.16 (m, 2H), 4.01 (t, J = 7.8 Hz, 1H), 3.63 (m, 1H), 3.56 – 3.43 (m, 1H), 3.21 (dd, 
J = 14.5, 4.6 Hz, 1H), 2.81 (m, 1H), 2.09 (d, J = 13.0 Hz, 1H), 2.01 – 1.85 (m, 4H); 13C 
NMR (100 MHz, CDCl3) δ 170.8, 167.3, 154.5, 143.6, 140.9, 136.1, 127.3, 126.7, 124.9, 
124.7, 122.4, 121.4, 119.6, 118.4, 111.9, 110.0, 72.4, 67.1, 66.2, 65.6, 64.0, 60.0, 54.9, 
54.6, 47.1, 46.2, 33.2, 31.0, 20.7. HRMS (ESI) m/z calcd for C31H30N3O3+ 492.2282; 
found 492.2292 (M+H)+.  
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
(S)-(9H-Fluoren-9-yl)methyl 2-((S)-4-(4-tert-butoxybenzyl)-4,5-dihydrooxazol-2-
yl)pyrrolidine-1-carboxylate (L,L-32py’) 
 
Data for L,L-32py’.  White solid, 1.06 g (93%). 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 
7.5 Hz, 2H), 7.66 – 7.56 (m, 2H), 7.36 (t, J = 7.4 Hz, 2H), 7.28 (t, J = 6.2 Hz, 2H), 7.06-
6.96 (m, 3H), 6.87 (d, J = 8.3 Hz, 1H), 4.58 (d, J = 7.6 Hz, 1H), 4.46 – 3.91 (m, 6H), 3.58 
(m, 1H), 3.49 (m, 1H), 3.03 – 2.89 (m, 1H), 2.55 (m, 1H), 2.26 – 2.05 (m, 1H), 1.93 (m, 
3H), 1.29 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 167.6, 154.5, 153.8, 144.1, 141.2, 
132.4, 128.7, 128.4, 127.5, 126.9, 125.1, 119.8, 78.0, 71.8, 67.2, 66.9, 54.9, 54.7, 47.3, 
47.0, 46.8, 46.5, 40.5, 32.2, 30.2, 28.7, 24.4, 24.2, 23.2. HRMS (ESI) m/z calcd for 
C33H37N2O4+ 525.2748; found 525.2772 (M+H)+  
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
(R)-tert-Butyl 3-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-((S)-4-(4-
(benzyloxycarbonyl)butyl)-4,5-dihydrooxazol-2-yl)propanoate (D,L-32d’k’) 
 
Data for D,L-32d’k’.  Light yellow solid, 370 mg (80%). 1H NMR (400 MHz, CDCl3) δ 
7.71 (t, J = 7.5 Hz, 2H), 7.58 (t, J = 9.3 Hz, 2H), 7.36 (t, J = 7.4 Hz, 4H), 7.29 (dd, J = 
15.9, 5.8 Hz, 5H), 6.76 (d, J = 7.4 Hz, 1H), 6.01 (d, J = 6.2 Hz, 1H), 5.05 (s, 2H), 4.50 (s, 
1H), 4.37 (t, J = 7.9 Hz, 2H), 4.24 – 4.05 (m, 3H), 3.12 (d, J = 5.5 Hz, 2H), 2.94 (d, J = 
8.1 Hz, 2H), 2.79 (d, J = 11.2 Hz, 1H), 2.73 – 2.58 (m, 1H), 1.59 – 1.42 (m, 3H), 1.41 (s, 
O
NFmocHN
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9H), 1.36 – 1.19 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 170.6, 169.3, 156.4, 156.1, 
143.6, 141.1, 136.6, 128.3, 127.8, 127.5, 126.9, 125.0, 124.9, 119.9, 119.8, 81.6, 70.2, 
67.2, 66.3, 51.2, 48.3, 47.0, 40.4, 37.3, 30.0, 29.2, 22.5; MS (ESI) m/z calcd for 
C37H44N3O7+ 642.32; found 642.24 (M+H)+.  
 
1H NMR spectrum: 
 
13C NMR spectrum: 
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(9H-Fluoren-9-yl)methyl (R)-1-((S)-4-(benzyloxymethyl)-4,5-dihydrooxazol-2-yl)-2-(4-tert-
butoxyphenyl)ethylcarbamate (D,L-32y’s’) 
 
Data for D,L-32y’s’.  Yellow solid, 980 mg (98%). 1H NMR (400 MHz, CDCl3) δ 7.74 (t, J 
= 6.1 Hz, 2H), 7.53 (d, J = 7.4 Hz, 2H), 7.36 (q, J = 7.5 Hz, 2H), 7.34 – 7.25 (m, 6H), 
7.12 – 6.98 (m, 2H), 6.85 (d, J = 8.4 Hz, 2H), 6.47 (s, 1H), 5.64 (s, 1H), 4.47 – 4.34 (m, 
4H), 4.34 – 4.19 (m, 4H), 4.19 – 4.12 (m, 1H), 3.53 – 3.43 (m, 1H), 3.26 (s, 1H), 3.05 – 
2.97 (m, 2H), 1.30 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 170.9, 155.8, 154.3, 143.6, 
141.1, 137.6, 137.3, 130.9, 129.6, 128.3, 127.8, 127.6, 127.5, 127.0, 124.9, 124.0, 
123.8, 119.8, 78.2, 73.1, 67.4, 67.0, 56.3, 47.8, 37.0, 28.7; HRMS (ESI) m/z calcd for 
C38H41N2O5+ 605.3010; found 605.3020 (M+H)+. 
 
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
tert-Butyl 3-((R)-2-((S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)ethyl)-4,5-dihydrooxazol-4-
yl)propanoate (L,L-32ae’) 
 
Data for L,L-32ae’. Yellow solid, 540 mg (98%). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J 
= 7.3 Hz, 2H), 7.62 (t, J = 6.8 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 
5.56 (br, 1H), 4.48 (m, 1H), 4.40 (m, 3H), 4.15 (m, 1H), 3.96 (t, J = 8.1 Hz, 1H), 3.16 – 
2.95 (m, 1H), 2.37 (m, 2H), 1.85 (m, 2H), 1.45 (m, 12H); 13C NMR (100 MHz, CDCl3) δ 
172.7, 168.0, 155.7, 144.1, 141.5, 127.9, 127.2, 125.4, 120.2, 80.6, 73.4, 67.2, 65.5, 
47.4, 45.5, 32.0, 31.7, 31.1, 29.88, 28.3, 19.7. HRMS (ESI) m/z calcd for C27H33N2O5+ 
465.2384; found 465.2383 (M+H)+.  
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
(S)-tert-Butyl 3-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-((S)-4-((S)-1-(benzyloxy)ethyl)-
4,5-dihydrooxazol-2-yl)propanoate (L,D-32d’t’) 
 
Data for L,D-32d’t’.  Yellow solid, 380 mg (84%). 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J 
= 7.4 Hz, 2H), 7.60 (d, J = 7.7 Hz, 2H), 7.43 (t, J = 7.4 Hz, 2H), 7.36 – 7.24 (m, 7H), 6.88 
(br, 1H), 5.94, (br, 1H) 4.65-4.53 (m, 2H), 4.42 (d, J = 10.3 Hz, 2H), 4.28 – 4.17 (m, 3H), 
3.84 (m, 1H), 3.00-2.90 (m, 3H), 2.77-2.61 (m, 1H), 1.47 (s, 9H), 1.21 (d, J = 5.6 Hz, 
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3H). 13C NMR (100 MHz, CDCl3) δ 171.3, 156.3, 144.1, 143.9, 141.6, 141.5, 138.0, 
128.7, 128.1, 128.01, 127.9, 127.3, 125.3, 82.2, 71.5, 71.0, 67.6, 53.0, 47.4, 37.7, 29.9, 
28.3, 16.2. HRMS (ESI) m/z calcd for C34H38N2O6+ 571.2803; found 571.2816 (M+H)+.  
1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
General Procedure For The Preparation of Amino Oxazoline (33) 
 
A representative synthesis of the L,D-33vv is described as follows: 
To a solution of L,D-32vv  (301.5 mg, 0.742 mmol) in MeCN (20 mL), diethylamine (0.8 
mL, 7.42 mmol) was added in one portion at room temperature.  The reaction was stirred 
O
N R
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for 2 h and the solvent was removed under vacuum.  Residual Et2NH was azeotroped 3 
times with CH2Cl2 (3 × 20 mL).  The crude product was purified by flash chromatography 
(silica gel, hexane-EtOAc, 9:1 then dichloromethane-methanol, 20:1) to give the free 
amino-containing oxazoline compound L,D-33vv  as light yellow oil (110 mg, 81 %). 
 
(S)-1-((R)-4-iso-Propyl-4,5-dihydrooxazol-2-yl)-2-methylpropan-1-amine (L,D-33vv) 
 
Data for L,D-33vv.  1H NMR (400 MHz, CDCl3) δ 4.10 (dd, J = 8.9, 7.7 Hz, 1H), 3.85 – 
3.71 (m, 1H), 3.16 (d, J = 5.6 Hz, 1H), 1.86 – 1.75 (m, 1H), 1.67 – 1.54 (m, 1H), 1.47 (br, 
2H), 1.10 (br, 1H), 0.88 – 0.69 (m, 12H). 13C NMR (100 MHz, CDCl3) δ 169.4, 71.5, 69.8, 
55.2, 32.3, 31.8, 19.1, 18.6, 17.9, 17.2. HRMS (ESI) m/z calcd for C10H21N2O+ 185.1648; 
found 185.1661 (M+H)+.  
1H NMR spectrum: 
 
 
 
 
 
O
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13C NMR spectrum: 
 
 
(1S,2S)-1-((S)-4-((R)-sec-Butyl)-4,5-dihydrooxazol-2-yl)-2-methylbutan-1-amine (L,L-
33ii) 
 
Data for L,L-33ii.  Colorless oil, 390 mg (81%). 1H NMR (400 MHz, CDCl3) δ 4.17 (dt, J 
= 16.0, 7.9 Hz, 1H), 3.96 (m, 2H), 3.36 (d, J = 7.3 Hz, 1H), 1.94 (br, 2H), 1.65 (m, 1H), 
1.60 – 1.41 (m, 3H), 1.25 – 1.05 (m, 2H), 0.96 – 0.82 (m, 10H), 0.81 – 0.73 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 169.3, 70.3, 69.6, 54.6, 38.9, 26.0, 24.7, 15.6, 14.3, 11.5, 
11.4. HRMS (ESI) m/z calcd for C12H25N2O+ 213.1961; found 213.1971 (M+H)+.  
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1H NMR spectrum:
 
13C NMR spectrum: 
 
 
tert-Butyl 2-((S)-2-((1R,2R)-1-amino-2-(benzyloxy)propyl)-4,5-dihydrooxazol-4-yl)acetate 
(D,L-33t’d’) 
 
Data for D,L-33t’d’.  Light yellow oil, 180 mg (80%). 1H NMR (400 MHz, CDCl3) δ 7.35 – 
7.20 (m, 5H), 4.52-4.43 (dd, J = 11.5, 6.1 Hz, 2H), 4.29 – 4.18 (m, 1H), 4.18 – 4.09 (m, 
1H), 3.69 – 3.58 (m, 2H), 3.27 – 3.20 (m, 1H), 2.71 (br, 3H), 2.57 – 2.44 (m, 1H), 1.45 – 
1.38 (m, 9H), 1.26 – 1.18 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 173.3, 170.7, 138.3, 
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128.3, 127.7, 127.6, 81.1, 76.2, 75.1, 72.7, 71.3, 64.5, 55.0, 41.7, 28.0, 16.7. HRMS 
(ESI) m/z calcd for C19H29N2O4+ 349.2122; found 349.2156 (M+H)+.  
1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
 (S)-4-iso-Propyl-2-((R)-pyrrolidin-2-yl)-4,5-dihydrooxazole (D,L-33pv) 
 
Data for D,L-33pv.  Light yellow oil, 190 mg (68%). 1H NMR (400 MHz, CDCl3) δ 4.11 
(m, 1H), 3.85 (t, J = 8.0 Hz, 1H), 3.80 – 3.74 (m, 1H), 3.74 – 3.67 (m, 1H), 2.97 (m, 1H), 
2.81 – 2.73 (m, 1H), 2.50 (br, 1H), 1.98 – 1.88 (m, 1H), 1.77 – 1.68 (m, 1H), 1.68 – 1.56 
(m, 2H), 0.82 – 0.78 (d, J = 6.8 Hz, 3H), 0.73 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, 
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CDCl3) δ 168.8, 71.4, 70.1, 55.1, 46.7, 32.2, 30.1, 25.3, 18.4, 17.6. MS (ESI) m/z calcd 
for C10H19N2O+ 183.1492; found 183.1786 (M+H)+  
1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
3-(((S)-2-((R)-Pyrrolidin-2-yl)-4,5-dihydrooxazol-4-yl)methyl)-1H-indole (D,L-33pw) 
 
Data for D,L-33pw.  Yellow oil, 380 mg (59%). 1H NMR (400 MHz, CDCl3) δ 9.58 (br, 
1H), 7.58 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 6.6 Hz, 1H), 7.13 - 7.07 (m, 2H), 6.87 (s, 1H), 
4.47 (m, 1H), 4.16 (t, J = 8.9 Hz, 1H), 4.05 – 3.98 (m, 1H), 3.81 (m, 1H), 3.16 (m, 1H), 
3.08 – 2.99 (m, 1H), 2.91 – 2.75 (m, 2H), 2.56 (br, 1H), 2.05 – 1.93 (m, 1H), 1.88 – 1.64 
(m, 3H); 13C NMR (100 MHz, CDCl3) δ 169.2, 136.2, 127.4, 122.5, 121.3, 118.6, 118.5, 
118.4, 110.7, 72.2, 65.8, 55.0, 46.5, 30.9, 29.8, 25.3. HRMS (ESI) m/z calcd for 
C16H20N3O+ 270.1601; found 270.1614 (M+H)+.  
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
(S)-4-(4-tert-Butoxybenzyl)-2-((S)-pyrrolidin-2-yl)-4,5-dihydrooxazole (L,L-33py’) 
 
Data for L,L-33py’.  Light yellow oil, 1.45 g (70%). 1H NMR (400 MHz, CDCl3) δ 6.94 
(dd, J = 8.5, 2.0 Hz, 2H), 6.76 (d, J = 7.1 Hz, 2H), 4.26 – 4.16 (m, 1H), 4.07 (m, 1H), 
3.87 (dd, J = 8.3, 7.3 Hz, 1H), 3.72 – 3.63 (m, 1H), 2.92 (m, 2H), 2.81 – 2.63 (m, 2H), 
2.57 – 2.45 (m, 1H), 1.96 – 1.81 (m, 1H), 1.75 – 1.57 (m, 3H), 1.18 (d, J = 5.7 Hz, 9H). 
13C NMR (100 MHz, CDCl3) δ 169.4, 153.6, 132.5, 129.5, 129.4, 123.7, 77.9, 71.8, 66.5, 
55.0, 46.6, 40.5, 29.8, 28.5, 25.3. HRMS (ESI) m/z calcd for C18H27N2O2+ 303.2067; 
found 303.2062 (M+H)+.  
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
(R)-tert-Butyl 3-amino-3-((S)-4-(4-(benzyloxycarbonyl)butyl)-4,5-dihydrooxazol-2-
yl)propanoate (D,L-33d’k’) 
 
Data for D,L-33d’k’.  Light yellow oil, 1.55 g (77%). 1H NMR (400 MHz, CDCl3) δ 7.44 (d, 
J = 8.4 Hz, 1H), 7.34 – 7.25 (m, 5H), 5.13 – 5.05 (m, 2H), 3.84 (m, 1H), 3.60 (dd, J = 
11.2, 3.4 Hz, 2H), 3.45 (dd, J = 11.3, 5.8 Hz, 1H), 3.12 (br, 2H), 2.81 (br, 2H), 2.74 – 
2.58 (m, 2H), 1.58 –1.24 (m, 15H); 13C NMR (100 MHz, CDCl3) δ 173.8, 171.2, 156.5, 
136.6, 128.4, 127.9, 127.5, 81.4, 66.4, 64.8, 51.7, 51.4, 40.5, 40.2, 30.4, 29.5, 28.0, 
22.8; MS (ESI) m/z calcd for C22H34N3O5+ 420.2493; found 420.2800 (M+H)+. 
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1H NMR spectrum: 
 
 
13C NMR spectrum: 
 
 
(R)-1-((S)-4-(Benzyloxymethyl)-4,5-dihydrooxazol-2-yl)-2-(4-tert-
butoxyphenyl)ethanamine (D,L-33y’s’) 
 
Data for D,L-33y’s’.  Light yellow oil, 292 mg (62%). 1H NMR (400 MHz, CDCl3) δ 7.32 – 
7.19 (m, 5H), 7.03 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.4 Hz, 2H), 4.50 – 4.43 (m, 2H), 4.29 
– 4.18 (m, 3H), 4.09 (t, J = 6.5 Hz, 1H), 3.71 (dd, J = 7.5, 5.5 Hz, 1H), 3.58 – 3.39 (m, 
2H), 3.31 (dd, J = 9.3, 6.6 Hz, 1H), 2.97 (dd, J = 13.6, 5.2 Hz, 1H), 2.77 (dd, J = 13.6, 
O
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7.8 Hz, 1H), 1.26 (d, J = 7.4 Hz, 9H); 13C NMR (100 MHz, CDCl3) δ 170.7, 153.9, 137.8, 
131.9, 128.7, 128.2, 127.5, 123.8, 123.7, 77.9, 73.1, 71.9, 70.7, 65.5, 50.9, 40.5, 28.6. 
MS (ESI) m/z calcd for C23H30N2O3Li+ 389.2411; found 389.1712 (M+Li)+.  
\ 
1H NMR spectrum: 
13C NMR spectrum: 
 
 
tert-Butyl 3-((S)-2-((S)-1-aminoethyl)-4,5-dihydrooxazol-4-yl)propanoate (L,L-33ae’) 
 
Data for L,L-33ae’.  Yellow oil, 1.07 g (72%). 1H NMR (400 MHz, CDCl3) δ 4.26 – 4.12 
(m, 1H), 3.64 (ddd, J = 25.4, 11.2, 3.9 Hz, 2H), 3.51 (q, J = 6.9 Hz, 1H), 2.38 – 2.19 (m, 
2H), 1.98 – 1.85 (m, 2H), 1.81 (br, 2H), 1.45 (s, 9H), 1.35 (d, J = 8.2 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 175.6, 172.3, 80.7, 50.8, 48.7, 47.9, 31.9, 28.1, 27.0, 21.8. MS (ESI) 
m/z calcd for C12H23N2O3+ 243.1703; found 243.1986 (M+H)+.  
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
(S)-tert-Butyl 3-amino-3-((S)-4-((S)-1-(benzyloxy)ethyl)-4,5-dihydrooxazol-2-
yl)propanoate (L,D-33d’t’) 
 
Data for L,D-33d’t’.  Yellow oil, 120 mg (60%). 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.24 
(m, 5H), 4.63 (d, J = 11.7 Hz, 1H), 4.41 (d, J = 11.7 Hz, 1H), 3.97 – 3.88 (m, 1H), 3.82 
(m, 1H), 3.68 (m, 3H), 2.77 (dd, J = 16.6, 3.6 Hz, 1H), 2.60 (dd, J = 16.6, 7.5 Hz, 1H), 
2.35 (br, 2H), 1.43 (s, 9H), 1.20 (d, J = 6.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 174.4, 
171.2, 138.1, 128.4, 127.7, 127.6, 81.2, 73.9, 70.6, 63.7, 55.5, 52.0, 40.7, 28.0, 16.3. 
HRMS (ESI) m/z calcd for C19H29N2O4+ 349.2122; found 349.2127 (M+H)+.  
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
Procedures for the preparation of (S)-1-((S)-4-benzyl-4,5-dihydrooxazol-2-yl)-2-
phenylethanamine (L,D-33ff) 
 
 
To a solution of Cbz-containing oxazoline compound L,D-32ff (0.45 g, 1.09 mmol) in 
anhydrous methanol (10 mL) under nitrogen was added 10 wt % Pd/C (0.1 equiv Pd, 
109 mg). The reaction was placed under an atmosphere of hydrogen (1 atm, balloon) for 
12 h. After the completion of reaction (as monitored by TLC), the flask was purged with 
O
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N2. The reaction mixture was filtered over a celite pad and washed with portions of 
methanol (3 × 5 mL), the filtrate and washings were collected and concentrated under 
vacuum to afford the crude amine product L,D-33ff as colorless oil (570 mg, 90 %), 
which can be directly used for further reaction without any purification. 
 
General Procedure for the Preparation of N-Boc Amino Nitrile (46) 
 
 
 
N-Boc-protected amino alcohol was prepared from N-Boc-protected amino acid using 
known literature procedures.198  The crude N-protected amino nitrile compounds were 
synthesized on large scale from corresponding N-Boc-protected amino alcohols using 
the procedures from the literature.199 
 
General Procedure for the Preparation of N-Boc-b-Amino Acid (47) 
 
 
 
Typically, N-protected amino nitrile compounds 46 (20 mmol) was dissolved in EtOH (20 
mL) at room temperature and 2 M KOH aqueous solution (20 mL) was added in one 
BocHN
CN
R1
46
R1 =
a b c d
Ph
e f
OBn
g
BocHN
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46
2 M KOH, EtOH
90 ºC
BocHN
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portion.  The resulting mixture was stirred at 90 oC until the reaction was complete, as 
determined by TLC (usually 3 h was enough).  The resulting clear mixture was allowed 
to cool down to room temperature and EtOH was removed under vacuum.  The crude 
product was cooled to 0 oC and 1M HCl aqueous solution was slowly added until the pH 
of the solution reached about 1 - 2.  The solution was extracted with Et2O three times (3 
× 80 mL).  The combined Et2O solution was washed twice with water (2 × 100 mL) and 
brine (100 mL).  The ether phase was dried over anhydrous MgSO4 and concentrated 
under vacuum.  The resulting oily residue was used directly in the synthesis of 
compounds 34 without any purification. 
 
General Procedure for the Preparation of Piperidine-2,4-dione (34)191,192,200 
 
To a stirred solution of meldrum’s acid (476 mg, 3.3 mmol) and DMAP (550 mg, 4.5 
mmol) at 0 ºC in dichloromethane (15 mL) was added N-Boc-b-amino acid compounds 
47 (3.0 mmol) in one portion.  EDCI (978 mg, 5.1 mmol) was added in one portion and 
the reaction mixture was stirred at 25 ºC for 3 - 5 h.  The yellow reaction mixture was 
transferred to a separatory funnel, diluted with dichloromethane (80 mL) and washed 
with cold 5 % KHSO4 (3 × 75 mL) and brine (75 mL).  The organic layer was dried over 
MgSO4 and filtered.  The filtrate was concentrated under vacuum and 60 mL ethyl 
acetate was added.  After refluxing for 5 h under N2 atmosphere, the solution was 
dissolved in 1:1 TFA/dichloromethane to give 0.1 M concentration at 0 oC, and the 
reaction was stirred for 30 min at room temperature. Toluene (30 mL) was added and 
the solution was concentrated.  Residual TFA was azeotroped 3 times with toluene (3 × 
30 mL) and the residue was placed under high vacuum for 3 h to give the crude mixture.  
The crude product was dissolved in CH2Cl2 and a small portion of anhydrous K2CO3 was 
added. The solid was filtered and the filtrate was concentrated under reduced pressure.  
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The crude product was purified by flash chromatography (CH2Cl2–MeOH 98:2 to 95:5) to 
provide the desired product.55 
 
(R)-6-((S)-sec-Butyl)piperidine-2,4-dione (L-34i) 
 
Data for L-34i.  Pale yellow crystal, 60 mg (54%). 1H NMR (400 MHz, CDCl3) δ 7.82 (br, 
1H), 3.52 (m, 1H), 3.23 – 3.07 (m, 2H), 2.40 (dd, J = 16.1, 6.7 Hz, 1H), 2.30 (dd, J = 
16.1, 6.7 Hz, 1H), 1.62 – 1.50 (m, 1H), 1.38 (m, 2H), 1.19 (m, 2H), 0.89 – 0.79 (m, 6H); 
13C NMR (100 MHz, CDCl3) δ 203.7, 169.7, 52.5, 46.9, 40.2, 38.3, 25.2, 13.6, 11.2; 
HRMS (ESI) m/z calcd for C9H16NO2+ 170.1176; found 170.1177 (M+H)+. IR (film, cm-1) 
2924, 2859, 2361, 1728, 1667.  
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
 (R)-6-(Benzyloxymethyl)piperidine-2,4-dione (L-34s) 
 
Data for L-34s.  Pale yellow crystal, 1.05 g (65%). 1H NMR (400 MHz, CDCl3) δ 7.81 (s, 
1H), 7.26 (m, 5H), 4.45 (s, 2H), 3.82 – 3.75 (m, 1H), 3.55 – 3.37 (m, 2H), 3.22 – 3.15 
(dd, J = 36.4, 20.4 Hz, 2H), 2.57 (dd, J = 16.2, 5.8 Hz, 1H), 2.45 (dd, J = 16.2, 5.8 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 202.6, 169.7, 137.0, 128.1, 127.6, 127.3, 73.1, 72.2, 
48.4, 46.6, 40.7; MS (ESI) m/z calcd for C13H16NO3+ 234.1125; found 234.1138 (M+H)+; 
IR (film, cm-1) 3233, 2924, 2859, 1724, 1670.  
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
General Procedure for the Preparation of Scaffold 30. 
 
 R1 R2 R3 Yield% 
D,L,D-30vvv D-Val L-Val D-Val 63 (Method A) 
L,D,L-30fpv L-Phe D-Pro L-Val 40 (Method A) 
L,D,L-30lpw L-Leu D-Pro L-Trp 35 (Method B) 
L,L,L-30ipy’ L-Ile L-Pro L-Tyr(tBu) 
31 (Method A) 
65 (Method B) 
L,D,L-30s’y’s’ L-Ser(Bn) D-Tyr( tBu) L-Ser(Bn) 38 (Method A) 
L,L,L-30fii L-Phe L-Ile L-Ile 88 (Method B) 
 
A representative synthesis of the D,L,D-30vvv is described (method A) using a modified 
reported procedure.201,202  To a solution of compound L,D-33vv (0.110 g, 0.597 mmol) in 
dry isopropyl alcohol (4.5 mL) was added compound D-34v (0.102 g, 0.657 mmol), 
followed by acetic acid (0.1 mL).  The resulting solution was allowed to react at 55 ºC for 
15 min, and dried 3Å molecular sieve was added to the solution (the 3Å MS should be 
put in a 300 ºC muffle furnace for 24 h before using).  The reaction was stirred at 55 ºC 
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for another 45 min until completion, as monitored by TLC.  The solvent was removed 
under vacuum and the oily residue was purified by flash chromatography (silica gel, 
CH2Cl2-MeOH, gradually from 98:2 to 92:8) to afford the peptidomimetic compound 
D,L,D-30vvv as pale yellow oil (120 mg, 63 %). 
 
(S)-6-iso-Propyl-4-((S)-1-((R)-4-iso-propyl-4,5-dihydrooxazol-2-yl)-2-methylpropylamino)-
5,6-dihydropyridin-2(1H)-one (D,L,D-30vvv) 
 
Data for D,L,D-30vvv:  1H NMR (400 MHz, CDCl3) δ 5.65 (s, 1H), 5.07 (m, 1H), 4.61 (s, 
1H), 4.26 – 4.14 (m, 1H), 3.94 (m, 1H), 3.89 – 3.74 (m, 2H), 3.31 – 3.19 (m, 2H), 2.29 
(m, 1H), 2.22 – 2.14 (m, 1H), 2.15 – 2.02 (m, 1H), 1.76 – 1.59 (m, 1H), 0.99 – 0.75 (m, 
18H); 13C NMR (100 MHz, CDCl3) δ 175.4, 171.1, 166.0, 155.6, 86.7, 71.6, 70.4, 56.2, 
55.6, 32.4, 31.3, 31.0, 18.8, 18.6, 18.2, 18.0; HRMS (ESI) m/z calcd for C18H32N3O2+ 
322.2489; found 322.2300 (M+H)+.  IR (film, cm-1) 3271, 2963, 2932, 2874, 2361, 2338, 
1728, 1663, 1624.  
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1H NMR spectrum: 
 
 
13C NMR spectrum: 
 
 
(S)-6-Benzyl-4-((R)-2-((S)-4-iso-propyl-4,5-dihydrooxazol-2-yl)pyrrolidin-1-yl)-5,6-
dihydropyridin-2(1H)-one (L,D,L-30fpv) 
 
Data for L,D,L-30fpv:  Brown oil, 110 mg (40%). 1H NMR (400 MHz, CDCl3) δ 7.24- 7.11 
(m, 5H), 4.61 (s, 1H), 4.34 (m, 1H), 4.22 – 4.06 (m, 1H), 3.93 – 3.61 (m, 3H), 3.37 (m, 
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1H), 3.22 (m, 1H), 2.84 – 2.76 (m, 1H), 2.72 (m, 1H), 2.56 – 2.44 (m, 1H), 2.29 (m, 1H), 
2.17 – 1.98 (m, 3H), 1.98 – 1.87 (m, 2H), 1.75 – 1.64 (m, 1H), 0.93 – 0.74 (m, 6H); 13C 
NMR (100 MHz, CDCl3) δ 170.6, 166.4, 155.3, 136.8, 129.0, 128.6, 126.8, 126.7, 89.3, 
71.9, 70.3, 55.8, 53.3, 51.1, 48.2, 41.5, 32.2, 32.0, 30.8, 23.2, 18.7, 17.8; HRMS (ESI) 
m/z calcd for C22H30N3O2+ 368.2333; found 368.2334 (M+H)+. IR (film, cm-1) 3028, 3260, 
2959, 2874, 1667, 1632, 1574.  
 
1H NMR spectrum: 
 
13C NMR spectrum: 
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(S)-4-((R)-2-((S)-4-((1H-Indol-3-yl)methyl)-4,5-dihydrooxazol-2-yl)pyrrolidin-1-yl)-6-
isobutyl-5,6-dihydropyridin-2(1H)-one (L,D,L-30lpw) 
 
 
A representative synthesis of the L,D,L-30lpw using method B is as follows.  To a 
solution of compound D,L-33pw (25 mg, 0.093 mmol) in dry dicholoromethane (5 mL), 
compound L-34l (18.85 mg, 0.111 mmol) was added, followed by KHCO3 (93 mg, 0.928 
mmol), HOAt (25.3 mg, 0.186 mmol) and EDCI (35.6 mg, 0.186 mmol).  The resulting 
suspension was allowed to stir at 25 ºC for 14 h until completion, as monitored by TLC. 
The solvent was removed under vacuum and the residue was dissolved in 
dicholoromethane (15 mL), washed with saturated NaHCO3 solution (2 × 10 mL) and 
brine (10 mL).  The combined solvent was concentrated under vacuum and purified by 
flash chromatography (CH2Cl2-MeOH, gradually from 98:2 to 92:8) to afford the final 
peptidomimetic compound L,D,L-30lpw as yellow oil (22.5 mg, 35 %). 
 
Data for compound L,D,L-30lpw:  Yellow oil, 1H NMR (400 MHz, CDCl3) δ 8.93 (br, 
1H), 7.56 (d, J = 8.9 Hz, 1H), 7.39 – 7.32 (m, 1H), 7.15 (t, J = 7.5 Hz, 1H), 7.11 – 7.00 
(m, 2H), 5.11 – 5.00 (m, 1H), 4.64 (s, 1H), 4.56 – 4.45 (m, 1H), 4.37 (br, 1H), 4.16 (dd, J 
= 19.6, 10.4 Hz, 1H), 3.99 (t, J = 7.9 Hz, 1H), 3.64 – 3.51 (m, 1H), 3.44 (m, 1H), 3.33 – 
3.21 (m, 1H), 3.17 (dd, J = 14.6, 4.5 Hz, 1H), 2.84 (m, 1H), 2.47 (dd, J = 16.0, 4.7 Hz, 
1H), 2.17 (m, 2H), 2.11 – 1.97 (m, 2H), 1.93 (m, 1H), 1.64 (m, 1H), 1.53 – 1.42 (m, 1H), 
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1.27 (m, 1H), 0.90 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 170.9, 167.0, 155.9, 136.4, 
127.7, 123.1, 121.7, 119.1, 118.5, 118.3, 111.4, 111.3, 110.8, 89.4, 72.4, 66.5, 56.1, 
55.8, 48.3, 44.3, 33.2, 30.6, 24.3, 23.2, 22.0; HRMS (ESI) m/z calcd for C25H33N4O2+ 
421.2598; found 421.2534 (M+H)+.  IR (film, cm-1) 3213, 3051, 2955, 2924, 2870, 2361, 
1663, 1612, 1574.  
 
1H NMR spectrum: 
 
13C NMR spectrum: 
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(R)-4-((S)-2-((S)-4-(4-tert-Butoxybenzyl)-4,5-dihydrooxazol-2-yl)pyrrolidin-1-yl)-6-(2-
methylbutyl)-5,6-dihydropyridin-2(1H)-one (L,L,L-30ipy’) 
 
Data for L,L,L-30ipy’:  Isolated as dark brown oil, 34 mg (31%, method A); 540 mg 
(65%, method B). 1H NMR (400 MHz, CDCl3) δ 6.86 (dd, J = 8.3, 5.0 Hz, 2H), 6.69 (d, J 
= 8.4 Hz, 2H), 5.57 (m, 1H), 4.44 (m, 1H), 4.17 (m, 2H), 4.06 – 3.92 (m, 1H), 3.85 – 3.73 
(m, 1H), 3.33 – 3.15 (m, 2H), 3.10 (m, 1H), 2.77 (m, 1H), 2.46 – 2.13 (m, 3H), 1.92 (m, 
1H), 1.85 – 1.70 (m, 2H), 1.41 (m, 1H), 1.33 – 1.17 (m, 1H), 1.10 (d, J = 6.2 Hz, 9H), 
1.06 – 0.94 (m, 2H), 0.77 – 0.66 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 170.5, 166.8, 
155.2, 153.5, 131.7, 129.2, 129.1, 123.5, 89.1, 77.6, 71.6, 66.7, 55.0, 53.9, 47.8, 40.2, 
37.5, 30.3, 28.3, 27.8, 24.9, 22.8, 14.1, 11.0; HRMS (ESI) m/z calcd for C27H40N3O3+ 
454.3064; found 454.3069 (M+H)+.  IR (film, cm-1) 3264, 2970, 2928, 2874, 2361, 1736, 
1620, 1578, 1504.  
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
(R)-6-(Benzyloxymethyl)-4-((R)-1-((S)-4-(benzyloxymethyl)-4,5-dihydrooxazol-2-yl)-2-(4-
tert-butoxyphenyl)ethylamino)-5,6-dihydropyridin-2(1H)-one (L,D,L-30s’y’s’) 
 
Data for L,D,L-30s’y’s’:  Isolated as yellow oil, 22 mg (38%). 1H NMR (400 MHz, CDCl3) 
δ 7.46 (d, J = 8.0 Hz, 1H), 7.37 – 7.22 (m, 9H), 7.06 – 6.94 (m, 2H), 6.80 – 6.78 (m, 2H), 
5.70 – 5.60 (m, 1H), 5.24 (m, 1H), 4.76 (s, 1H), 4.52 – 4.41 (m, 4H), 4.20 (m, 1H), 4.11 
(m, 1H), 3.79 – 3.58 (m, 3H), 3.54 – 3.31 (m, 4H), 3.09 – 2.93 (m, 2H), 2.32 – 2.18 (m, 
2H), 1.34 – 1.25 (m, 9H); 13C NMR (100 MHz, CDCl3) δ 169.8, 167.1, 154.5, 153.1, 
137.8, 137.5, 131.6, 130.4, 130.2, 128.6, 128.4, 127.9, 127.8, 124.3, 124.0, 88.3, 78.4, 
73.4, 72.1, 71.9, 71.5, 65.6, 51.6, 49.6, 36.0, 30.9, 28.8; HRMS (ESI) m/z calcd for 
C36H44N3O5+ 598.3275; found 598.3265 (M+H)+.  IR (film, cm-1) 3271, 3063, 2974, 2928, 
2862, 2361, 1728, 1624, 1555, 1504.  
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1H NMR spectrum: 
 
13C NMR spectrum: 
 
 
(S)-6-Benzyl-4-((1S,2S)-1-((S)-4-((R)-sec-butyl)-4,5-dihydrooxazol-2-yl)-2-
methylbutylamino)-5,6-dihydropyridin-2(1H)-one (L,L,L-30fii) 
 
Data for L,L,L-30fii:  Yellow oil, 70 mg (88%).  1H NMR (400 MHz, CDCl3) δ 7.30 – 7.21 
(m, 3H), 7.20 – 7.14 (m, 2H), 5.29 (br, 1H), 4.94 (d, J = 7.8 Hz, 1H), 4.72 (s, 1H), 4.27 – 
4.18 (m, 1H), 4.06 – 3.99 (m, 1H), 3.95 (m, 1H), 3.81 – 3.70 (m, 1H), 2.89 – 2.74 (m, 
2H), 2.34 (d, J = 7.5 Hz, 2H), 2.29 (m, 1H), 1.94 – 1.83 (m, 1H), 1.64 – 1.44 (m, 2H), 
1.32 – 1.20 (m, 2H), 1.20 – 1.08 (m, 1H), 0.97 – 0.86 (m, 9H), 0.82 (d, J = 6.7 Hz, 3H); 
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13C NMR (100 MHz, CDCl3) δ 170.3, 165.6, 154.5, 136.9, 129.2, 128.8, 126.9, 87.6, 
70.1, 69.9, 55.1, 51.5, 41.4, 38.8, 37.4, 34.3, 25.9, 25.8, 14.9, 14.3, 11.6, 11.5; HRMS 
(ESI) m/z calcd for C24H36N3O2+ 398.2802; found 398.2804 (M+H)+. IR (film, cm-1) 3244, 
3028, 2963, 2928, 2878, 2361, 1667, 1620, 1555.  
 
1H NMR spectrum: 
 
 
13C NMR spectrum: 
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(R)-6-((R)-sec-butyl)-4-((S)-2-((S)-4-(4-hydroxybenzyl)-4,5-dihydrooxazol-2-yl)pyrrolidin-
1-yl)-5,6-dihydropyridin-2(1H)-one (L,L,L-30ipy) 
 
To a solution of compound L,L,L-30ipy in dichloromethane at 0 ºC, 5 eq of TMSOTf was 
added and stirred for 10 min.  Solvent was reduced by rotavap and purified by flash 
column chromatography (3% MeOH/CH2Cl2) to obtain product as colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 8.96 (br, 1H), 6.94 (t, J = 13.4 Hz, 2H), 6.75 (t, J = 13.4 Hz, 2H), 
5.19-5.09 (br, 1H), 4.68-4.65 (br, 1H), 4.45-4.22 (m, 2H), 4.20-4.08 (m, 1H), 4.06-3.94 
(m, 1H), 3.62-3.15 (m, 3H), 2.91 (dd, J = 16 Hz, 8 Hz, 1H), 2.55 (dd, J = 12 Hz, 8 Hz, 
1H), 2.47-2.24 (m, 2H), 2.24-1.83 (m, 5H) 1.21 (m, 1H), 0.92 (m, 8H); 13C NMR (100 
MHz, CDCl3) δ 171.4, 167.4, 156.3, 156.0, 130.2, 130.0, 127.8, 115.8, 115.7, 88.8, 72.4, 
67.3, 56.1, 54.4, 48.4, 40.6, 38.1, 30.8, 30.6, 29.7, 28.9, 28.5, 25.3, 23.4, 14.6, 11.4. 
HRMS (ESI) m/z calcd for C23H32N3O2+ 398.2438; found 398.2429 (M+H)+  
1H NMR spectrum: 
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13C NMR spectrum: 
 
 
pH Stability Assay 
 
Procedure: Stock solutions of trimer DLD-30vvv and triphenylphosphine oxide (internal 
standard) in phosphate buffer (pH 6.4, 7.4 and 8.4) were prepared and stored in 25 ºC.  
Samples (25 µL) were injected into RP-HPLC system (C-18 column) at regular intervals.  
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